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ABSTRACT 
Background: Levodopa is still thought of as the 'gold standard' symptomatic 
treatment for Parkinson’s disease. However, after four to five years of treatment, 
levodopa efficacy tends to decline even if there was a good initial therapeutic 
response. The ideal treatment of Parkinson’s disease is a much debated issue with a 
range of guidelines available. 
 
Objectives: This study was undertaken to analyse medication use and prescribing 
patterns as well as to determine the risk factors involved in causing dyskinesias in 
Parkinson’s sufferers. 
 
Methods: The study consisted of two parts, namely a drug utilisation review (DUR) 
and a questionnaire survey. There were 25 523 antiparkinsonian records consisting 
of 5 168 patients for the year 2010. The questionnaires were verbally administered to 
patients diagnosed with Parkinson’s disease. A total of 43 patients were interviewed.  
 
Results: The average age of the population was 70.74±10.37 years, with the oldest 
patient being 100 years. Females constituted 59.17% (5 168: n = 3 058) of the total 
number of patients. The most common antiparkinsonian products dispensed were 
combination drugs containing levodopa with a decarboxylase inhibitor and some with 
a COMT-inhibitor as well (46.5%; n = 11 875). Males represented 53.49% (43: n = 
23) of the patients included in the questionnaire survey. A review of the medical 
records showed that patients with dyskinesias were diagnosed with Parkinson’s 
disease at a younger age and had experienced longer disease duration.  
 
Conclusion: Parkinson’s disease is an under-recognised condition in South Africa. 
Treatment needs to be individualised and based on evidence-based guidelines. 
Further studies in South Africa, as well as SSA (sub-Saharan Africa), need to be 
conducted on both the prevalence as well as the treatment of Parkinson’s disease. 
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CHAPTER 1 
Introduction 
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1.1 Introduction 
 
‘This formidable opponent has left my movements slow and clumsy. But I am 
determined to fight back. I watch my family and friends watching me as I tread 
cautiously down stairs holding tightly onto the banister. They walk in front of me in 
case I should fall, concern evident in their furtive backward glances.’ 
(Ronald Rodrigues, Parkinson’s sufferer, 2011). 
 
Patients suffering from Parkinson’s disease end up living a life of frustration and lost 
independence. They suffer embarrassment due to a widespread lack of knowledge 
and understanding of Parkinson’s disease which has a negative effect on the social 
aspects of patients’ lives. Caregivers need to adjust their expectations of the patient 
and be supported by doctors and the community to cope with their mood swings, the 
debilitating adverse effects of medication and disease progression such as 
dyskinesias, as well as the immense emotional distress faced by Parkinson’s 
sufferers on a daily basis.  
 
This study was undertaken to determine the risk factors involved in causing 
dyskinesias in Parkinson’s sufferers as well as to analyse medication use and 
prescribing patterns. It consists of two parts, a drug utilisation review (DUR) and a 
questionnaire survey. The DUR portion involves the analysis of a prescription 
database requested from a national community pharmacy group, providing objective 
data. The questionnaire surveys provide objective data such as patient 
demographics and drug use; and subjective data such as the perceived benefit of 
the medication and severity of dyskinesias. 
 
1.2  Background to the study 
 
Parkinson’s disease is a progressive neurodegenerative disorder which affects one 
in every 100 people over the age of 65 years (Singh, Pillay and Choonara, 2007: 29). 
It is characterised by three hallmark symptoms: bradykinesia (slowed movement), 
tremor and muscle rigidity (Singh, et al., 2007: 29; Obeso, Olanow, and Nutt 2000: 
2). The underlying pathology of Parkinson’s disease is a loss of the dopamine 
3 
 
producing neurons in the substantia nigra of the brain (Foster and Hoffer, 2003: 
177). Therefore, it is logical that the aim of treatment would be to increase the levels 
of dopamine in the brain.   
  
The aetiology of idiopathic Parkinson’s disease remains largely unknown, but studies 
have shown there are genetic and even environmental links, often with an interplay 
between the two (Schapira and Jenner, 2011: 1 050). Some studies have indicated 
that the earlier in life that Parkinson’s disease presents, the more likely it is that there 
is a genetic link (Nelson, Berchou and LeWitt, 2005: 1 075; Warner and Schapira, 
2003: 16). This has been determined by twin and family studies in the hope of 
identifying the susceptible genes. The most important risk factor however is, simply, 
aging (Schapira and Jenner, 2011: 1 049). 
  
Patients are diagnosed with Parkinson’s disease after a series of neurological 
examinations and diagnostic tests. There is a risk of misdiagnosis, especially during 
the early stages of Parkinson’s disease). For example, the misdiagnosis rate in Italy 
ranged from approximately 10% by movement disorder specialists to 50% when the 
patient is seen in a primary health care facility (Alberio and Fasano, 2011: 326).   
 
There is little reported on the incidence and prevalence of Parkinson’s disease in 
Africa due to the lack of studies and the short life expectancy of the population 
(Okubadejo, Bower, Rocca and Maraganore, 2006: 2 050). It has been shown, 
however, that the population aged 60 years and older is expected to double in SSA 
by 2030 and double again by the year 2050 (Velkoff and Kowal, 2007: 4). In fact, the 
number of older people in SSA is growing faster than the rest of the world and will 
continue to do so in the future (Velkoff and Kowal, 2007: 5). As ageing is a risk factor 
in the development of Parkinson’s disease, it would be important to determine the 
incidence and prevalence of Parkinson’s disease in SSA in order to determine the 
future economic burden society may face. An article looking at Parkinson’s disease 
in Africa, with particular focus on Tanzania, reported that there was an overwhelming 
shortage of health workers and resources (Pearce and Wilson, 2007: 116). Infectious 
diseases like HIV and malaria tended to overshadow neurological disorders like 
Parkinson’s disease in these regions (Pearce and Wilson, 2007: 116). One study 
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(Dotchin, Msuya and Walker, 2007: 122) indicated that there is a low incidence of 
Parkinson’s disease in SSA, but noted that studies had only been conducted on 
small populations previously. Some reasons put forth for this low reported incidence 
include under diagnosis of Parkinson’s disease, differences in diagnostic criteria and 
early mortality in these populations due to other causes (Dotchin, et al., 2007:122).  
 
A South African study conducted in Durban aimed to determine the prevalence of 
Parkinson’s disease amongst black South Africans (Cosnett and Bill, 1988: 281). 
The records of all patients seen in a neurological consultation at three provincial 
hospitals in Durban for a period of seven years between 1978 and 1985 were 
summarised and amounted to a total of 2 638 records. The three hospitals included 
were King Edward VIII hospital which dealt mostly with black South Africans, R.K. 
Khan hospital, which dealt mostly with Indian patients and Addington hospital which 
dealt mostly with white patients (Cosnett and Bill, 1988: 282). The researchers also 
obtained data regarding the annual consumption of levodopa at the three hospitals 
under investigation. Of the total number of consultations, 1 984 were black South 
Africans, 395 were Indian and 259 were white South Africans. Of the black South 
Africans, the total number of Parkinson’s disease cases were three and the 
calculated rate per 1 000 patients amounted to 1.5, whereas, for white South 
Africans, the total number of Parkinson’s disease cases seen was six and the 
calculated rate per 1 000 patients was 23.1 (Cosnett and Bill, 1988: 282). The total 
amount of levodopa consumed at each of these hospitals was determined in relation 
to the total number of outpatients seen. It was shown that Addington hospital dealing 
mostly with white South Africans consumed on average six times more levodopa 
(24 530g) per year than King Edward VIII which dealt mostly with black South African 
patients (4 470g) (Cosnett and Bill, 1988: 282). The age group with the highest 
prevalence of Parkinson’s disease was found to be 50 years and younger (22.8%) in 
the case of black South Africans and decreasing with increasing age to just 1.8% of 
patients in the 70 year age group. These percentages were calculated according to 
the total number of consultations for each race group. White South Africans showed 
47.8% of patients with Parkinson’s disease in the age group 50 years and younger, 
decreasing to 14.3% in the 70 year age group which was still higher than that of the 
black South Africans. Indian South Africans held an intermediate position (Cosnett 
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and Bill, 1988: 283). The study concluded that the lower rate of Parkinson’s disease 
amongst black South Africans could be due to the lower life expectancy or failure of 
elderly patients to attend hospitals (Cosnett and Bill, 1988: 283). This study was 
conducted more than 20 years ago and the need for updated information in South 
Africa is important to determine the number of patients currently suffering from 
Parkinson’s disease and to project the number of patients expected to suffer from 
this condition in the future.    
 
In the more developed northern hemisphere, the prevalence is higher, since the life 
expectancy of the population is longer possibly due to various genetic and 
environmental factors. Approximately 100 000 people are living with Parkinson’s 
disease in America (Obeso, et al., 2000: 2) and in Europe there is an incidence of 
1.8% in people between the ages of 65 to 69 years with the incidence increasing to 
2.6% in people aged 85 to 89 years (De Rijk, Launer, Berger, Breteler, Dartigues, 
Baldereschi, Fratiglioni, Lobo, Martinez-Lage, Trenkwalder and Hofman, 2000: 21).  
In 2005, the number of individuals suffering from Parkinson’s disease in the 10 most 
populated countries in the world, was between 4.1 and 4.6 million and is expected to 
double by 2030 (Keus, Oude Nijhuis, Nijkrake, Bloem and Munneke, 2012: 1).  
 
1.3  Problem definition 
 
Levodopa is still thought of as the 'gold standard' symptomatic treatment for 
Parkinson’s disease. However, after four to five years of treatment, levodopa efficacy 
tends to decline even if there was a good initial therapeutic response (Singh, et al., 
2007: 30; Stern, 2001: 27; Garret, Rosas, Simões, Vieira and Costa, 1998: 99).  
 
Long-term treatment with levodopa results in the emergence of pharmacodynamic 
changes to the response of the drug. Patients tend to experience motor fluctuations 
and dyskinesias. Dyskinesias will occur in up to 80% of patients who have been on 
levodopa therapy for long periods of time and they tend to occur first on the side 
more severely affected by the Parkinson’s disease (Ha and Jankovic, 2011: 8). A 
major controversy in Parkinson’s disease therapy is whether to withhold levodopa as 
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the initial therapy in order to delay the onset of dyskinesias or to provide the patient 
with this ‘gold standard’ therapy in order to obtain maximum symptomatic control. 
Dyskinesias are loosely classified as either choreic or dystonic (Nadjar, Gerfen and 
Bezard, 2009: 2; Thanvi, Lo and Robinson, 2007: 385-386). The underlying 
molecular mechanism for the development of these dyskinesias is poorly 
understood. Several studies agree that young age of disease onset, disease severity 
and high doses of levodopa increase the risk for dyskinesias (Calabresi, Di Filippo, 
Ghiglieri, Tambasco and Picconi, 2010: 1 106; Voon, Fernagut, Wickens, Baunez, 
Rodriguez, Pavon, Juncos, Obeso and Bezard,  2009: 1 140; Encarnacion and 
Hauser, 2008: 58; Thanvi, et al., 2007: 384; Sossi, de la Fuente-Fernandez, 
Schulzer, Adams and Stoessl, 2006: 1 051). Recently, studies into the levodopa 
dose per kilogram have revealed this to be another important factor to consider when 
determining a patients’ risk for the development of dyskinesias (Sharma, Bachmann 
and Linazasoro, 2010: 492; Sharma, Ross, Rascol and Brooks, 2008: 495). 
 
This study will consider the patterns of prescribing for Parkinson’s disease in South 
Africa in order to identify the most commonly prescribed drugs and the economic 
burden these costs place on the patients. Patients will also be interviewed and their 
medical records retrospectively reviewed in order to determine whether the above 
risk factors do indeed play a role in the development of dyskinesias in patients with 
Parkinson’s disease. 
   
1.4 Research objectives 
 
The primary aim of the study is: 
To analyse the treatment of Parkinson’s disease in South Africa and investigate the 
risk factors involved in the onset of dyskinesias.   
 
The specific objectives of the DUR are to: 
 
 determine the gender and age distribution of patients diagnosed with 
Parkinson’s disease;  
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 analyse the prescribing patterns for Parkinson’s disease in the private sector 
on a national level; and 
 determine the average cost of medication per annum. 
 
The specific objectives of the questionnaire survey are to: 
 
 determine the age of onset of Parkinson’s disease; 
 establish when levodopa therapy was initiated, relative to the date of 
diagnosis;  
 determine if and when the emergence of dyskinesias occurred;  
 determine the severity of the dyskinesias; 
 assess the risk factors involved in the emergence of these dyskinesias. 
 
1.5  Division of chapters 
 
The final dissertation is divided as follows: 
 
 Chapter 1 - Introduction 
 Chapter 2 - An Overview of Parkinson’s Disease 
 Chapter 3 - Treatment of Parkinson’s Disease 
 Chapter 4 - Methodology  
 Chapter 5 - Results and Discussion of the Drug Utilisation Review 
 Chapter 6 - Results and Discussion of the Questionnaire Survey 
 Chapter 7 - Conclusion 
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CHAPTER 2 
An overview of Parkinson’s 
disease 
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2.1 Introduction 
 
In Parkinson’s disease, the disease process affects the darkly pigmented substantia 
nigra, an area which produces a large amount of dopamine. Damage to the 
substantia nigra will give rise to the hallmark symptoms of bradykinesia, tremor and 
rigidity. In Parkinson’s disease there is a decrease in the normally high levels of 
dopamine found in the basal ganglia, due to the death of the dopamine producing 
cells of the substantia nigra. Parkinson’s disease is a slowly progressive disease 
associated with increasing disability. The basis of treatment would therefore be to 
increase the levels of dopamine in the basal ganglia (Weicker, Kinscherf, Diserens, 
Deigner and Struder, 2001: 17). 
 
2.2 Etiology of Parkinson’s disease 
 
The aetiology of Parkinson’s disease is seen to be a combination of environmental 
and genetic factors, but genetic predisposition is increasingly seen as the main 
cause (Schapira and Jenner, 2011: 1 050). The earlier the onset of Parkinson’s 
disease, the more likely there is a genetic link (Nelson, et al., 2005: 1 075; Warner 
and Schapira, 2003: 16). 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a 
toxin that is relatively specific to the neurons causing Parkinson’s disease in animal 
models (Sian, Youdim, Riederer and Gerlach, 1999). MPTP is able to induce most of 
the biochemical, pathological and clinical features of Parkinson’s disease in 
nonhuman primates (Sian, et al., 1999).  
 
The mutated genes found in familial Parkinson’s disease include genes encoding for 
mitochondrial proteins such as Parkin, PTEN-induced putative kinase 1 (PINK-1), 
DJ-1, mitochondrial polymerase gamma 1 (POLG1) and genes coding for non-
mitochondrial proteins such as α-synuclein and leucine-rich repeat kinase 2 (LRRK2) 
(Aquilano, Baldelli, Rotilio and Ciriolo, 2008: 2 418; Zhang, Dawson and Dawson, 
2006: 37). The strongest risk factor for the development of Parkinson’s disease, 
however, is aging (Schapira and Jenner, 2011: 1 050). Unfortunately, little is known 
with respect to understanding what processes are involved in aging that make it such 
a prominent risk factor. A review in the United Kingdom reported that environmental 
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factors involved a range from general factors including industrialisation, well water, 
rural environments and plant-derived toxins, to more specific causes such as carbon 
monoxide, carbon disulfide and organic solvent exposure (Schapira and Jenner, 
2011: 1 050). 
 
With respect to environmental influences, a study was conducted which aimed to 
determine the effect of caffeine intake on the risk of Parkinson’s disease in males 
and females (Ascherio, Zhang, Hernán, Kawachi, Colditz, Speizer and Willett, 2001: 
56). Among men, there was a significant inverse relationship between coffee intake 
and Parkinson’s disease risk. With women there was a U-shaped relationship, with 
the lowest risk being amongst women consuming one to three cups of coffee on a 
daily basis (Ascherio, et al., 2001: 59). However, the association could be due to 
components of coffee other than caffeine. To address this, the study looked at the 
risk of Parkinson’s disease and the intake of caffeine from non-coffee sources. 
Among the men, there was a strong inverse relationship between the intake of 
caffeine from non-coffee sources and the risk of Parkinson’s disease and amongst 
women there were no significant associations found. The findings of this study were 
consistent with the results of similar studies conducted in Germany and Sweden 
(Ascherio, et al., 2001: 60). 
 
A six week randomised placebo controlled trial was done to determine the effect of 
caffeine in Parkinson’s disease (Postuma, Lang, Munhoz, Charland, Pelletier, 
Moscovich, Filla, Zanatta, Romenets, Altman, Chuang and Shah, 2012: 652). A total 
of 76 patients were screened and 61 were randomised to 100 to 200mg of caffeine 
twice daily compared to placebo. Patients were included in the study if they were 
conclusively diagnosed with idiopathic Parkinson’s disease and also suffered from 
excessive daytime sleepiness (Postuma, et al., 2012: 652). The results showed that 
there were decreases in Unified Parkinson’s Disease Rating Scale (UPDRS) scores, 
but not significantly. Also, there were no significant differences found in fluctuations 
and dyskinesias with caffeine compared to placebo nor was there any decrease in 
somnolence (Postuma, et al., 2012: 654, 655). However, there were decreases in 
bradykinesia and rigidity and the caffeine was not found to increase action tremors 
(Postuma, et al., 2012: 654). However, the study had many limitations and further 
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studies concerning caffeine in the future were suggested (Postuma, et al., 2012: 
657). 
 
2.2.1 Lewy bodies in Parkinson’s disease 
 
The Lewy body is a neuronal inclusion containing α-synuclein found in the substantia 
nigra and other regions which are associated with significant loss of neurons (Gibb 
and Lees, 1988: 745; Wakabayashi, Tanji, Odagiri, Miki, Mori and Takahashi, 2012: 
1). They are also present in many surviving cells of the substantia nigra in 
Parkinson’s disease patients and can therefore serve as a diagnostic marker (Gibb 
and Lees, 1988: 745). The actual mechanism of Lewy body neuroprotection or 
neurotoxicity is not well understood. The idea of neurodegeneration caused by Lewy 
bodies was based on the fact that there was neuronal loss in the areas of 
predilection for the Lewy bodies including the substantia nigra. The number of Lewy 
bodies in patients with mild to moderate neuronal loss in the substantia nigra is 
higher than in patients with severe neuronal depletion which suggests that Lewy 
bodies are found in dying neurons. Also, Lewy bodies may affect axonal transport 
and the cortical density of Lewy bodies could be a correlate of cognitive impairment 
in Parkinson’s disease (Wakayabashi, et al., 2012: 7).  
  
Lewy neurites are found to be present before Lewy bodies at most sites (Del Tredici 
and Braak, 2012: 597). They are likely derived from cytoskeletal elements and are 
associated with the disruption of axonal and cellular functioning. The resulting 
impaired neuronal transport leads to the formation of α-synuclein in the neuronal 
soma and contributes to the formation of Lewy bodies (Del Tredici and Braak, 2012: 
597). Incidental Lewy body disease in which incidental Lewy neurites and Lewy 
bodies are seen in neurologically asymptomatic patients is described in unaffected 
elderly patients, and may represent a preclinical phase of the disease (Del Tredici 
and Braak, 2012: 599).   
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2.3 Incidence and Prevalence of Parkinson’s disease 
 
There is an approximately 1.5 times higher risk of Parkinson’s disease for men than 
women (Burn, 2007: 78; Fargel, Grobe, Oesterle, Hastedt and Rupp, 2007: 208; 
Miller and Cronin-Golomb, 2010: 2 695). The incidence of a disease is the number of 
new cases identified over a period of time in a defined area, whereas the prevalence 
of a disease is the number of existing cases of a particular disease in a defined area.  
 
Overall there are not many incidence or prevalence studies available on Parkinson’s 
disease (Dorsey, Constantinescu, Thompson, Biglan, Holloway, Kieburtz, Marshall, 
Ravina, Schifitto, Siderowf and Tanner, 2007: 384-386). However, of those that have 
been conducted, there is a trend to the effect that there is a higher incidence of 
Parkinson’s disease in more developed countries where people have a longer life 
expectancy as opposed to developing countries where the life expectancy is shorter. 
However, the life span may not be the only confounding factor. Other influences 
such as environmental conditions and genetic differences also play a role.  
 
Studies in the United States show a prevalence of approximately 100 000 people 
with Parkinson’s disease with the average age of onset being 60 years (Obeso, et 
al., 2000: 2). European studies report an incidence of 1.8% in patients between the 
ages of 65 and 69 years, with an increase to 2.6% of patients between the ages of 
85 and 89 years (De Rijk, et al., 2000: 21).  
 
A Spanish study determined the prevalence of Parkinson’s disease and other 
parkinsonian disorders in three Spanish communities (Benito-León, Bermejo-Pareja, 
Rodríguez, Molina, Gabriel and Morales, 2003: 269). The study showed that 68% of 
the total 118 subjects were affected with Parkinson’s disease. The prevalence of 
Parkinson’s disease was also shown to increase with age, but decrease beyond the 
ages of 80 years for men and 85 years for women (Benito-León, et al., 2003: 269). 
The survey confirmed a higher prevalence in males than females. However, it did 
show a higher prevalence for women between the ages of 80 years to 84 years. 
Prevalence figures are influenced by disease duration and incidence and the higher 
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prevalence in this age group could be due to a difference in survival after the disease 
onset (Benito-León, et al., 2003: 273). 
 
African studies, however, have demonstrated a much lower incidence of Parkinson’s 
disease, but there is limited information regarding the prevalence of this disease in 
Africa (Okubadejo, et al., 2006: 2 050). The incidence of Parkinson’s disease 
increases with age from 1.7/10 000 person-years between the ages of 50 years and 
59 years to 9.3/ 10 000 person-years between the ages of 70 years to 79 years.  
 
2.4 Diagnosis of Parkinson’s disease 
 
Patients are diagnosed with Parkinson’s disease after a series of neurological 
examinations and diagnostic tests. Two of the three cardinal symptoms of 
Parkinson’s disease, bradykinesia, tremor and rigidity, need to be present before a 
diagnosis can be made, however, this is just a guideline (Berg and Poewe, 2012: 1; 
Marjama-Lyons and Koller, 2001: 24).  
 
Parkinson’s disease is characterised by the progressive loss of dopaminergic 
neurons in the substantia nigra of the brain, resulting in dopamine depletion (de la 
Fuente-Fernández, 2012: 696). Radiotracer neuroimagining such as dopamine 
transporter (DAT) SPECT (DaTSCAN) is being used as a diagnostic tool (de la 
Fuente-Fernández, 2012: 696). However, the clinical diagnosis of Parkinson’s 
disease has an accuracy of 84% in early disease. This means that use of the 
DaTSCAN may not be necessary on a large scale and may be reserved for 
challenging patients (de la Fuente-Fernández, 2012: 699). According to the NICE 
(National Institute for Health and Clinical Excellence) guideline, patients suspected of 
having Parkinson’s disease should be referred quickly, untreated, to a specialist for 
diagnosis and ongoing follow-up (Stewart, 2007: 240).  
 
A study of 253 patients who were not being treated with levodopa or dopamine 
agonists, with disease duration of 10 years or less, aimed to determine gender 
differences in disease onset and clinical presentation (Haaxma, Bloem, Borm, Oyen, 
Leenders, Eshuis, Booij, Dluzen and Horstink, 2007: 819). The study showed that 
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women were on average two years older (53.4 years) when diagnosed compared to 
men (51.3 years). A total of 67% of the women presented with tremor at symptom 
onset compared to men where only 48% presented with tremors regardless of age at 
onset (Haaxma, et al., 2007: 821). When bradykinesia or rigidity was the initial 
symptom, the age of onset tended to be three years younger in both genders 
(Haaxma, et al., 2007: 821, 823). The results of the study suggest that the later age 
at onset for women may demonstrate a slower development of clinical Parkinson’s 
disease, (Haaxma, et al., 2007: 821). There have also been gender differences 
identified with regards to dyskinesias. Women tend to experience dyskinesias more 
frequently and with more severity than men (Lyons, Hubble, Tröster, Pahwa and 
Koller, 1998: 118; Miller and Cronin-Golomb, 2010: 2 696).  
 
Determining the age of onset of the initial symptoms of Parkinson’s disease helps 
classify the patients as juvenile indicating onset before the age of 20 years, young 
onset, indicating onset between 21 years and 40 years, and late onset, which 
indicates onset over the age of 40 years (Reider, Halter, Castelluccio, Oakes, 
Nichols, Foroud, and the Parkinson Study Group, 2003: 275). A study was 
conducted to determine the reliability of the reported age of clinical onset of 
Parkinson’s disease (Reider, et al., 2003: 275). Medical records were consulted, self-
administered questionnaires were distributed to be completed at home by either the 
patient or a family member as well as a survey instrument completed during face-to-
face interviews conducted by the medical practitioner based on the responses given 
by the patient or family member (Reider, et al., 2003: 275). Upon analysing the data, 
it showed that there was little difference in the reliability when compared by gender, 
the initial symptom of Parkinson’s disease and the years of education. However, 
factors that did affect the reliability were age at the exam and the duration of the 
disease. Younger respondents were less reliable and those reporting the duration of 
clinical disease between five years to nine years had lower reliability (Reider, et al., 
2003: 277). The overall result showed that there was only a minor difference 
between the ages obtained from medical records and the reported age of onset 
obtained from the patients and family. This indicates that asking patients about their 
age of onset of the first symptom of Parkinson’s disease is likely to be accurate and 
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the researcher does not necessarily have to examine medical records (Reider, et al., 
2003: 278). 
 
2.5 Classification of Parkinson’s disease 
 
Parkinson’s disease is classified into stages according to the presentation of 
symptoms. One way of describing these stages is by using the Hoehn and Yahr 
scale (Hoehn and Yahr, 1967: 433). 
 
The Hoehn and Yahr scale breaks down the progression of Parkinson’s disease into 
different stages characterised by the symptoms exhibited by the patient and is 
summarised in Table 2.1. Progression from one stage to the next is thought to occur 
due to natural disease progression and in the absence of treatment. There are also 
different subtypes of Parkinson’s disease. These include those who are tremor-
dominant, akinetic-rigid and those with postural instability (Insight Medicine 
Information, 2011: 5). 
 
Table 2.1 Hoehn and Yahr classification of Parkinson’s disease 
 
Stage Symptom 
Stage 1 Unilateral symptoms, minimal or no functional impairment 
Stage 2 Bilateral symptoms, but no balance impairment 
Stage 3 Bilateral symptoms, mild to moderate disablity, but patient still 
physically independent 
Stage 4  Severe disability, but able to walk or stand unassisted 
Stage 5 Bed-ridden or confined to a wheelchair unless assisted  
(Source: Hoehn and Yahr, 1967: 433) 
 
The UPDRS is the major rating scale used to assess the severity of Parkinson’s 
disease (McNamara, 2009). The scale is divided into four sections and is 
summarised in Table 2.2. A neurologist would observe the patient’s performance 
when moving arms, legs or or bady. The performance is then scored on a scale of 
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zero to four, where zero is normal and four is severe. Therefore, the higher the 
overall score, the greater the severity of the condition (McNamara, 2009). 
 
Table 2.2 Unified Parkinson’s Disease Rating Scale divisions 
 
Division Explanation 
Part I Mentation, behaviour and mood 
Part II Activities of daily living 
Part III Motor  
Part IV Complications 
(Source: Goetz, Poewe, Rascol, Sampaio and Stebbins, 2003: 738) 
 
2.6 Dyskinesias 
 
Dyskinesias are defined as impaired voluntary movements which result in 
fragmented movement which only cease during sleep (Prashanth, Fox and Meissner, 
2011: 32). The incidence of dyskinesias varies widely, from 9% to 80%. This is due 
to the fact that there are many risk factors to take into account (Thanvi, et al., 2007: 
384). Such risk factors include age of disease onset, dose and duration of levodopa 
and even unknown genetic factors (Calabresi, et al., 2010: 1 106; Voon, et al., 2009: 
1 140; Thanvi, et al., 2007: 384). Up to 90% of patients tend to develop dyskinesias 
within 10 years of Parkinson’s disease onset. However, it is important to remember 
that not all patients on levodopa therapy will develop dyskinesias (Ha and Jankovic, 
2011: 8; Prashanth, et al., 2011: 31). Dyskinesias were recognised with the advent of 
levodopa and are therefore termed LIDs (levodopa-induced dyskinesias) and are a 
major limitation in the therapy of Parkinson’s disease (Prashanth, et al., 2011: 32). 
These involuntary movements can have a negative impact on the patients’ quality of 
life.  
 
2.6.1 Classification of dyskinesias 
 
Dyskinesias are classified as either choreic which involves a series of hyperkinetic, 
purposeless dance like movements or dystonic which involves abnormal, sustained 
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muscle contractions (Nadjar, et al., 2009: 2; Thanvi, et al., 2007: 385-386). Mild 
levodopa induced choreic movements tend to be non-disabling and are often not 
noticed by the patients themselves, but rather by family members (Ha and Jankovic, 
2011: 8). Dyskinesias are commonly seen affecting the muscles of the jaw, tongue, 
neck and face (Calabresi, et al., 2010: 1 106). Peak dose dyskinesias often involve 
the muscles of the neck, axial and upper limb (Ha and Jankovic, 2011: 8). The 
different types of LIDs are summarised in Table 2.3 below. 
 
Table 2.3 Different types of levodopa-induced dyskinesias 
 
Types of levodopa-induced 
dyskinesias 
Explanation 
Peak dose dyskinesia Most common form of LID 
Associated with peak plasma levels of levodopa 
Dose reduction may help attenuate them 
Diphasic dyskinesia Occur when the levels of levodopa are increasing 
or decreasing 
Do not occur at peak plasma levels Usually 
dystonic in nature 
Decreasing the dose of levodopa does not improve 
the condition 
Increased doses may be of more benefit 
Off state dystonia Occur when levodopa levels in the plasma are low 
Generally present as painful muscle contractions 
occurring in one foot 
Responds to levodopa therapy 
On state dystonia  Occur when the plasma levels of levodopa are high 
‘Yo-yo’ dyskinesia Occur at any time 
(Sources: Voon, et al., 2009: 1 141; Halkias, Haq, Huang and Fernandez, 2007: 268; 
Thanvi, et al., 2007: 385-386; Nutt, 2001: 103.) 
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2.6.2 Theories into the development of dyskinesias 
 
The pathophysiology and underlying molecular mechanism for the development of 
these dyskinesias is poorly understood. Several studies agree that young age of 
disease onset, disease severity and high doses of levodopa increase the risk for 
dyskinesias (Calabresi, et al., 2010: 1 106; Voon, et al., 2009: 1 140; Encarnacion 
and Hauser, 2008: 58; Thanvi, et al., 2007: 384; Sossi, et al., 2006: 1 051). Pulsatile 
stimulation of the dopamine receptors is also thought to play a role in the 
development of dyskinesia since it has been noted that the storage and clearance of 
striatal dopamine is dramatically reduced in the presence of severe nigrostriatal 
lesions. This has led to an effort to provide a more constant infusion of levodopa 
through the use of intraduodenal infusions (Calabresi, et al., 2010: 1 106-1 107; 
Thanvi, et al., 2007: 384).  
 
Studies into the levodopa dose per kilogram have revealed this to be another 
important factor to consider when determining a patients’ risk for the development of 
dyskinesias (Sharma, et al., 2008: 495; Sharma, et al., 2010: 492). Interest in these 
types of studies was sparked when it was observed that not all patients on similar 
levodopa doses develop dyskinesias as 60% of patients remain free of any 
dyskinesia after four to six years of therapy (Sharma, et al., 2010: 492). A possible 
explanation for this is the body weight of the patient (Sharma, et al., 2010: 492). This 
was also seen as the reason for women experiencing dyskinesias more frequently 
than men. Women weighed less and were receiving higher levodopa doses per 
kilogram (Miller and Cronin-Golomb, 2010: 2 696).  
 
A cohort study carried out by Sharma and colleagues (Sharma, McNamara, Hasoon, 
Vassallo and Ross, 2006: 499) in 2006 involved 220 patients suffering from 
Parkinson’s disease. The aim of the study was to identify new risk factors for the 
development of dyskinesia. At the second assessment, 29 new patients started 
exhibiting dyskinesia. It was noted that these patients had lost weight during the 
course of the study (72kg ± 15kg to 66kg ± 17kg). The patients exhibiting dyskinesia 
were receiving a significantly higher dose of levodopa per kilogram body weight 
(8.4mg/kg ± 3.5mg/kg as opposed to 6.0mg/kg ±3.9mg/kg).  
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Another study carried out (Sharma, et al., 2008: 493-496) manipulated data from two 
ropinirole versus levodopa studies (056 and REAL-PET) to calculate the levodopa 
dose per kilogram body weight. The study revealed that only the levodopa dose per 
kilogram body weight was a significant risk factor in the development of LID 
(Sharma, et al., 2008: 495). Other factors such as gender, the absolute levodopa 
dose, weight and the overall disease severity were not as significant (Sharma, et al., 
2008: 495).  
 
2.7 Non-motor symptoms  
 
In Parkinson’s disease there are also many non-motor symptoms (NMS), some of 
which have a greater negative impact on the patients’ quality of life than the motor 
symptoms. These NMS may appear before the motor symptoms are even 
recognised, (Park and Stacy, 2009: 293) and may also be present at more advanced 
stages of the disease (Chaudhuri and Schapira, 2009: 464). These NMS contribute 
to the immense complexity that is Parkinson’s disease and makes therapy 
challenging.  
 
It is well understood that there has been neuronal degeneration when patients 
present with early motor symptoms, but exactly when that degeneration began is a 
subject of much debate, and may vary between patients (Braak, et al., 2003: 197; 
Lang, 2011: 776). The early NMS of Parkinson’s disease may play an important role 
in the early diagnosis of the condition (Lang, 2011: 775).  
 
However, some of the early NMS, such as olfactory deficit and gastrointestinal 
disturbances, are not specific to Parkinson’s disease and are common amongst the 
general population. This creates difficulty in attributing them to preceding symptoms 
in the development of Parkinson’s disease.  
 
Other NMS experienced by Parkinson’s patients include disorders of mood and 
affect causing apathy, anhedonia, depression, cognitive dysfunction, hallucinations 
as well as complex behavioural disorders including impulse-control disorders 
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(Ceravolo, Rossi, Kiferle, and Bonuccelli, 2010; Poewe, 2008:14). Sensory 
dysfunction with pain is experienced by almost all patients. Sleep-wake cycle 
disturbances are also commonly experienced. Autonomic dysfunction resulting in 
orthostatic hypotension, urogenital dysfunction as well as constipation is also present 
in a large number of patients (Ceravolo, et al., 2010: 851; Poewe, 2008: 14).   
 
2.7.1 Olfactory deficit 
 
The first lesions occur in the olfactory structures (Braak, Del Trecidi, Rüb, de Vos, 
Jansen Steur and Braak, 2003: 208). However, there are other causes of olfactory 
dysfunction such as head injuries or smoking and since olfactory dysfunction 
appears in other neurological conditions such as Alzheimer’s disease and multiple 
system atrophy, it is not specific for Parkinson’s disease (Lang, 2011: 779).  
 
2.7.2 Neuropsychiatric symptoms 
 
Neuropsychiatric symptoms are seen in patients with Parkinson’s disease despite 
the common idea that the disease has no impact on sense and intellect (Poewe, 
2008: 16). Depression, anxiety, psychosis, cognitive dysfunction and dementia are 
the neuropsychiatric symptoms focused on in this section. 
 
2.7.2.1 Depression 
 
Depression has been found to affect up to 75% of patients with Parkinson’s disease 
(Poewe, 2008: 16; Chaudhuri, Healy and Schapira, 2006: 238; Cummings, 1992: 
444). The underlying biological mechanism involves a decreased level of 5-
hydroxyindolacetic acid, a metabolite of serotonin, in the cerebrospinal fluid as well 
as decreased 5-HT1A receptor binding (Chaudhuri, et al., 2006: 238). Even though it 
is common of Parkinson’s disease, depression is often not diagnosed and therefore 
may go untreated (Shulman, Taback, Rabinstein and Weiner, 2002: 193; Ceravolo, 
et al., 2010; Lyons and Pahwa, 2011: 310).  
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2.7.2.2 Anxiety 
 
Anxiety is closely related to the motor fluctuations associated with Parkinson’s 
disease. Patients experience more anxiety in the ‘off’ period which is a period of 
akinesia unrelated to the timing of the levodopa dose, and the anxiety may be 
improved by medication (Ceravolo, et al., 2010; Chaudhuri, et al., 2006: 238). In 
addition, patients may experience panic attacks, phobias and generalised anxiety 
disorder (Ceravolo, et al., 2010; Chaudhuri, et al., 2006: 238).  
 
2.7.2.3 Psychosis 
 
Psychosis and hallucinations are one of the most challenging NMS of Parkinson’s 
disease and sometimes require the patient to be placed in a nursing home. 
Hallucinations have a prevalence of up to 40% in patients suffering from Parkinson’s 
disease (Poewe, 2008: 17; Chaudhuri, et al., 2006: 238). They generally begin as a 
benign condition, but more problematic symptoms such as delirium, delusions and 
paranoid behaviour become increasingly common as the condition progresses 
(Chaudhuri, et al., 2006: 238). Psychotic symptoms may be triggered by all of the 
major classes of antiparkinsonian therapy, but it is more likely to occur with the 
dopamine agonists than with levodopa (Poewe, 2008: 17). Generally, interventions 
are aimed at decreasing the dose of the offending dopaminergic agent and adding 
an atypical antipsychotic if necessary. However, with this comes the risk of 
potentially worsening the motor symptoms (Ceravolo, et al., 2010). Clozapine is the 
only drug with proven antipsychotic effects which does not cause worsening of the 
motor symptoms (Ceravolo, et al., 2010; Poewe, 2008: 18).  
 
2.7.2.4 Cognitive dysfunction and dementia 
  
The risk of dementia is approximately six times higher in Parkinson’s disease than in 
a normal, healthy individual (Ceravolo, et al., 2010; Park and Stacy, 2009: 294; 
Chaudhuri, et al., 2006: 239). The underlying pathophysiology of dementia is likely 
related to the development of cortical Lewy bodies (Poewe, 2008: 17; Chaudhuri, et 
al., 2006: 239) and could even be due to genetic influences (Svenningsson, 
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Westman, Ballard and Aarsland, 2012: 698). A 15 year long study, originally directed 
at determining optimal early treatment for Parkinson’s disease, and which 
subsequently reported on the problems experienced by these patients over the 
duration of the study period (Hely, Morris, Reid and Trafficante, 2005: 190). Only one 
third of the original 149 patients survived the full duration of the study.  Cognitive 
impairment was present in 84% of patients and 48% of this group displayed the 
signs of dementia (Hely, et al., 2005: 194).).  
 
2.7.3 Sleep abnormalities 
 
Sleep disorders are a very common feature of Parkinson’s disease with a prevalence 
ranging from 75% to 98% (Ceravolo, et al., 2010; Poewe, 2008: 18). The problem 
includes difficulty falling asleep, frequent awakening during the night, muscle 
cramps, dystonia or nocturnal motor symptoms which involve difficulty turning in bed, 
motor restlessness or restless legs syndrome. Additional problems include bladder 
dysfunction, nocturnal confusion and excessive daytime sleepiness (Ceravolo, et al., 
2010; Poewe, 2008: 18). Features of the sleep disorders of Parkinson’s disease 
include a fragmented sleep pattern, reduced sleep efficiency, reduced slow-wave 
sleep, reduced rapid-eye movement sleep and rapid eye movement behaviour 
disorder (Poewe, 2008: 18).  
 
2.7.3.1 Rapid eye movement behaviour disorder 
 
Rapid eye movement behaviour disorder is characterised by a loss of rapid eye 
movement sleep muscle atonia. It is associated with a disruption of normal REM 
(rapid eye movement) sleep, as a result of which patients experience jerking and 
sometimes even violent movements of the limbs which may cause themselves or 
their partners injury (Ceravolo, et al., 2010; Poewe, 2008: 18).  
 
2.7.3.2 Excessive daytime sleepiness 
 
Excessive daytime sleepiness is also a common sleep disorder of Parkinson’s 
disease and affects up to 50% of the population (Ceravolo, et al., 2010). The severity 
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of the excessive daytime sleepiness has no relation to the patients’ nocturnal sleep 
disorders. Factors that contribute to excessive daytime sleepiness include motor 
disability, the impact of antiparkinsonian medication on alertness, the presence of 
depression or dementia and any concurrent mental illness (Ceravolo, et al., 2010). 
 
2.7.4 Autonomic dysfunction 
 
Dysautonomia is a common NMS of Parkinson’s disease. The cause of 
dysautonomia is degeneration of CNS neurons involved in the control of the 
autonomic nervous system as well as the peripheral postganglionic neurons 
(Ceravolo, et al., 2010). Dysautonomia generally presents with the symptoms of 
orthostatic hypotension, constipation and urinary and sexual dysfunction, all of which 
can have a negative impact on the patient’s quality of life (Ceravolo, et al., 2010; 
Poewe, 2008: 15).  
 
2.7.4.1 Orthostatic hypotension 
 
The prevalence of orthostatic hypotension varies widely in Parkinson’s disease with 
values ranging from 30% to 58% (Ceravolo, et al., 2010). Orthostatic hypotension 
usually develops late in the disease and may also be as a result of dopaminergic 
therapy (Ceravolo, et al., 2010; Chaudhuri, et al., 2006: 239).  
 
2.7.4.2 Constipation 
 
Lewy body pathology in the peripheral autonomic nervous system also affects the 
myenteric plexus which contributes to the development of constipation (Poewe, 
2008: 16). Constipation is a commonly reported problem of Parkinson’s disease and 
it frequently precedes development of the disease (Ceravolo, et al., 2010; Poewe, 
2008: 16; Chaudhuri, et al., 2006: 240).   
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2.7.4.3 Urogential dysfunction 
 
Urogenital dysfunction includes erectile and ejaculatory failure and is reported by 
about 60% of male patients (Ceravolo, et al., 2010; Poewe, 2008: 17). Sildenafil has 
proved to be safe and effective in the treatment of erectile dysfuntction in 
Parkinson’s disease (Ceravolo, et al., 2010). Patients also tend to develop detrusor 
muscle hyperactivity which leads to urinary urgency and frequency, nocturia, 
incomplete bladder emptying and urge incontinence (Ceravolo, et al., 2010; Poewe, 
2008: 17).  
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CHAPTER 3 
Treatment of Parkinson’s Disease 
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3.1 Introduction  
 
There are certain objectives to be achieved in order to provide Parkinson’s disease 
patients with effective treatment. These objectives are listed in Table 3.1. Guidelines 
published by the South African Medical Journal and the NICE for the treatment of 
Parkinson’s disease are referred to in this chapter.    
 
Table 3.1 Objectives of Parkinson’s disease therapy 
 
Objectives of Parkinson’s disease therapy 
Efficacy - decrease Parkinsonian symptoms while trying to reduce disease 
progression 
Safety - at least decrease the risk of adverse effects 
Costs – to as far as possible reduce costs associated with therapy 
(Source: Rascol, Payoux, Ory, Ferreira, Brefel-Courbon and Montastruc, 2003: 53).  
 
3.2 Treatment options  
 
There are many treatment options for the management of Parkinson’s disease, of 
which levodopa is only one. The different treatments available according to the 
SAMF (South African Medicines Formulary) 2012 are summarised in Table 3.2. 
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Table 3.2 Treatments available for Parkinson’s disease in South Africa 
 
Chemical Subgroup Chemical substance Tradename/s 
Dopa and dopa derivatives  Levodopa in 
combination with a 
dopamine 
decarboxylase 
inhibitor such as 
carbidopa or 
benserazide 
 Sinemet®/Carbilev® 
(levodopa/carbidopa) 
 
 Madopar® 
(levodopa/benserazide) 
 
 Levodopa in 
combination with a 
dopamine 
decarboxylase 
inhibitor and 
catechol-o-methyl-
transferase (COMT) 
inhibitor 
 Stalevo® 
Dopamine agonists Ergot derivatives 
 Bromocriptine  Parlodel® 
  
 Aspen Bromocriptine® 
 
Non-ergot derivatives 
 Ropinirole 
 
 Requip® 
 Requip XL® 
 Pramipexole 
 
 Pexola® 
Monoamine oxidase type B 
(MAO-B) inhibitors 
 Rasagiline  Azilect® 
 Selegiline  Parkilyne® 
COMT-inhibitors  Entacapone  Comtan® 
Anticholinergic agents  Biperiden  Akineton® 
 Trihexyphenidyl 
 Orphenadrine 
 Benzhexol® 
 Disipal® 
Amantadine derivatives  Amantadine  Symmetrel® 
(Source: ed. Rossiter, 2012: 458-464) 
 
Levodopa is able to alleviate all of the cardinal motor symptoms of Parkinson’s 
disease. Certain of the other agents may not be as effective as levodopa in treating 
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the bradykinesia, gait disturbances and other symptoms of advanced Parkinson’s 
disease, but they are useful when managing the mild disabilities that are associated 
with early Parkinson’s disease (Nelson, et al., 2005: 1 079). These agents are 
generally used as monotherapy to delay the initiation of levodopa therapy, or they 
are used in combination with levodopa in order to decrease the total levodopa 
requirement. These drugs complement levodopa therapy as they either increase 
dopamine activity in the brain or decrease the peripheral metabolism of levodopa to 
prolong its activity. Due to these factors, lower doses of levodopa can be used to 
achieve the same clinical effect as if it was used alone.  
 
3.2.1 Levodopa 
 
Dopamine cannot cross the blood brain barrier (BBB), thus levodopa is used instead. 
Levodopa is the immediate metabolic precursor of dopamine. It is decarboxylated in 
the brain by the enzyme dopamine decarboxylase to produce dopamine. When 
administered alone, only about one to three percent of the total levodopa dose 
crosses the BBB to enter the brain. This is since the rest of it is metabolised 
peripherally, by dopamine decarboxylase, to produce dopamine, which cannot cross 
the BBB. This means that when used alone, levodopa must be given in very large 
doses (Singh, et al., 2007: 32).  
 
In order to overcome this problem, levodopa is given in combination with a peripheral 
dopamine decarboxylase inhibitor, such as carbidopa or benserazide, which does 
not cross the BBB. As a result, the peripheral metabolism of levodopa is reduced 
and larger amounts are available to cross the BBB, where it is decarboxylated to 
produce dopamine (Aminoff, 2007: 443-444). The pharmacokinetics of levodopa 
differs when paired with carbidopa and benserazide (Goldstein, Gopinathan, 
Neophytides, Hiesiger, Walker and Nelson, 1984: 227). When combined with 
benserazide the peak dose of levodopa is higher and is achieved sooner, but also 
declines more rapidly. Generally, levodopa has a half-life of approximately 45 to 90 
minutes with the peak therapeutic response expected after two to three weeks of 
therapy (Halkias, et al., 2007: 262).  
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3.2.1.1 Benefits of levodopa 
 
Levodopa is able to alleviate all of the cardinal motor cardinal motor symptoms of 
Parkinson’s disease. It is especially effective in relieving bradykinesia (Aminoff, 
2007: 444).  It does not stop the progression of Parkinson’s disease, but it does 
lower the mortality rate. Many patients have reported an improvement in their quality 
of life with levodopa treatment (Aminoff, 2007: 444).  
 
3.2.1.2 Adverse effects of levodopa 
 
The onset, type and severity of side effects are some of the major disadvantages of 
levodopa treatment. The adverse effects of levodopa may be divided into the general 
adverse effects and the motor effects. Both these topics are discussed in this 
section. 
 
3.2.1.2.1 General adverse effects 
 
Levodopa can cause gastrointestinal disturbances such as nausea and vomiting. 
This occurs in 80% of patients when levodopa is administered alone, but in only 20% 
of patients when carbidopa is administered in combination with levodopa. There are 
cardiovascular effects such as arrhythmias, (Singh, et al., 2007: 32) although the 
incidence is low. The incidence of arrhythmia is further reduced when levodopa is 
taken in combination with carbidopa. The patient may experience behavioural effects 
such as depression, anxiety, insomnia, confusion, delusions, hallucinations, 
nightmares and euphoria (Aminoff, 2007: 444-446). These effects occur more often 
in patients receiving combination treatment because higher levels of levodopa enter 
the brain. Other effects include mydriasis (pupil dilation), acute glaucoma, blood 
dyscrasias, hot flushes and precipitation or aggravation of gout (Aminoff, 2007: 444-
446; Rezak, 2007: 216). 
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3.2.1.2.2 Motor effects 
 
Fluctuations in response to levodopa therapy will occur. Such fluctuations include 
dyskinesias and motor fluctuations. If the motor fluctuations are associated with the 
timing of the levodopa dose, it is referred to as the ‘wearing off’ phenomenon. These 
fluctuations are thought to occur because the patient is no longer able to store 
dopamine in the brain (Murata, 2009: 18). Dyskinesias are abnormal, involuntary 
movements ceased only by sleep (Prashanth, et al., 2011: 32). The incidence of 
dyskinesias varies widely, from 9% to 80% (Thanvi, et al., 2007: 384). Approximately 
50% of patients develop motor complications five years after the initiation of 
levodopa treatment, which increases to 70% after 15 years (Benbir, Özekmekçi, 
Apaydin, Delil and Erginöz, 2006: 732). 
 
3.2.1.3 Contraindications to levodopa 
 
Patients who suffer from closed-angle glaucoma may not receive levodopa as it may 
further increase intraocular pressure. Levodopa may exacerbate active peptic ulcer 
disease because levodopa has been known to cause gastric bleeding. Patients with 
a history of malignant melanoma or patients with suspicious undiagnosed skin 
lesions may not receive levodopa as it is a precursor of melanin and may activate 
malignant melanoma. Levodopa is also contraindicated in patients under the age of 
25 years (Aminoff, 2007: 446; Halkias, et al., 2007: 264, ed. Rossiter, 2012: 462). It 
is advised to avoid levodopa in pregnancy and lactation. Its use in porphyria is 
deemed safe (ed. Turner, 2010: 444). 
 
3.2.2 Dopamine agonists 
 
Dopamine agonists are divided into two groups, the ergot derivatives such as 
bromocriptine, and the newer generation non-ergot derivatives such as pramipexole 
and ropinirole. These agents can be used as initial treatment of Parkinson’s disease 
in the early stages to delay the onset of levodopa therapy. Dopamine agonists can 
also be used in combination with levodopa in order to decrease the overall dose of 
levodopa that is to be used by enhancing the antiparkinsonian effects of the drug 
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(Singh, et al., 2007: 33). Unlike levodopa, the dopamine agonists are not dependent 
on dopa-decarboxylase which is needed to convert levodopa into dopamine. Some 
common adverse effects associated with the use of pramipexole and ropinirole are 
confusion, insomnia, hallucinations, dizziness, dyskinesias, somnolence, nausea 
constipation, peripheral oedema and postural hypotension (ed. Rossiter, 2012: 459). 
These dopamine agonists are also associated with sudden sleep episodes. Patients 
may fall asleep without any prior warning which compromises their ability to operate 
machinery (ed. Rossiter, 2012: 458-459). Dopamine agonists do not compete with 
dietary amino acids for absorption, nor do they require further activation in the brain 
as is the case with levodopa (Stern, 2001: 29). These drugs have a longer half-life 
than levodopa and may provide longer periods of symptomatic relief (Stern, 2001: 
29). 
 
3.2.3 MAO-B inhibitors 
 
MAO-B inhibitors, such as rasagiline and selegiline, are useful agents in Parkinson’s 
disease management. These drugs act by irreversibly inhibiting the breakdown of 
dopamine by monoamine oxidase B, thus increasing its levels. Therefore, when used 
in combination with levodopa, they may allow the total dose of levodopa to be 
reduced (Singh, et al., 2007: 33). A few hours after these agents are orally 
administered, there is very little parent compound left, however, this is of little 
consequence due to the irreversible nature of the inhibition (LeWitt, 2009: 1 352).  
 
3.2.4 COMT-inhibitors 
 
COMT-inhibitors, such as entacapone, act to inhibit the peripheral metabolism of 
levodopa by the enzyme catechol-o-methyltransferase thus increasing the plasma 
levels of levodopa. COMT-inhibitors are used to extend the effects of levodopa and 
are generally used in combination with other antiparkinsonian drugs (Nelson, et al., 
2005: 1 079-1 085).  
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3.3 Guidelines for the treatment of Parkinson’s disease 
 
According to a guideline published in the South African Medical Journal, in the early, 
milder stages of the disease when the patient is not showing many symptoms, 
therapy with an anticholinergic, a dopamine agonist, amantadine or an MAO-B 
inhibitor may be useful as first line therapy (Carr, Kies and Fine, 2009: 756). As the 
patient progresses and the symptoms become more obvious, levodopa has a role to 
play. Neurologists may consider administering domperidone, a dopamine antagonist, 
concurrently with levodopa in order to reduce the incidence of peripheral side effects 
caused by the dopaminergic drug (Carr, et al., 2009: 756). The NICE guideline states 
that the treatment for Parkinson’s disease is open to interpretation as there are no 
definitive results for studies comparing the effectiveness of one drug class against 
the other (Stewart, 2007: 241). The guideline does, however, state that levodopa, 
dopamine agonists and MAO-B inhibitors have a role to play in the early stages of 
the disease. This is largely in agreement with the South African guideline, however, 
the NICE guideline does not promote the use of anticholinergic agents, especially in 
older patients due to the risk of neuropsychiatric effects (Stewart, 2007: 241).  
 
Once the patient has passed into the moderate to severe stage of Parkinson’s 
disease, they will be afflicted with motor fluctuations and an increasing burden of 
NMS (Carr, et al., 2009: 756). At this point, the problem may be the short half-life of 
levodopa as well as its narrow therapeutic window. Other agents such as the 
dopamine agonists, COMT-inhibitors or MAO-B inhibitors may be of benefit as 
adjunctive therapy to levodopa with dosage adjustments to obtain maximum 
symptom relief (Carr, et al., 2009: 756). The NICE guideline also recommends the 
use of these agents in the later stages of the disease and corresponds with the 
recommendations of the South African guideline (Stewart, 2007: 241).    
 
There are many available options for the management of Parkinson’s disease. 
However, the appropriate timing of implementation of particular agents has not been 
determined. This resulted in a lack of concrete guidelines for the management of this 
disease and means that neurologists need to rely on clinical experience. 
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3.4 Previous studies concerning dyskinesias 
 
There have been numerous studies into the therapies and development of 
dyskinesias in patients with Parkinson’s disease. There has not yet been an effective 
solution developed which has been able to eradicate the presence of dyskinesias. 
 
3.4.1 Risk factors concerning levodopa therapy  
 
Certain risk factors have been identified which are thought to cause dyskinesias. 
These include age of onset, gender, initial symptoms, evolution of the Hoehn and 
Yahr stage, severity of the nigrostriatal lesions, the year that levodopa was 
introduced relative to the date of diagnosis and the initial dose of levodopa (Thanvi, 
et al., 2007: 386-387; Benbir, et al., 2006: 726-732; Kumar, Van Gerpen, Bower and 
Ahlskog, 2005: 342; Kostić, Marinković, Svetel, Stefanova and Przedborski, 2002: 9; 
Garret, et al., 1998: 99-102).  
 
3.4.1.1 The ELLDOPA trial 
 
One of the most well-known studies in Parkinson’s disease history is the ELLDOPA 
study (Early versus Later Levodopa in Parkinson’s Disease) study. This placebo-
controlled, randomised, double-blind control trial aimed to determine whether or not 
levodopa slows down or hastens the progression of Parkinson’s disease (Fahn, 
1999: 532).  
 
A washout design was used to examine the effect of levodopa on disease 
progression. No other antiparkinsonian medication was allowed in the study to avoid 
any confounding influence of other drugs. Treatment naive patients with early 
Parkinson’s disease were randomised to receive either placebo or levodopa 150mg, 
300mg or 600mg daily for a 40 week period. This was to be followed by a two week 
washout period at which point any symptomatic benefit ought to have disappeared. 
The first evaluation was performed at baseline and the second after the two week 
washout period, which was 42 weeks after initiation of treatment. This means that 
both evaluations were performed in a drug-free state (Fahn, 1999: 532). As 
34 
 
predicted, levodopa had a clear superior symptomatic benefit compared with placebo 
in the first 40 weeks.  
 
Of the 361 patients enrolled in the study, 317 took the medication for the defined 
period of 40 weeks and 311 completed the additional two week washout period (The 
Parkinson Study Group, 2004: 2 502). At the end of the two week washout period, 
the UPDRS scores showed worsening in all groups except the arm of the levodopa 
group receiving 600mg daily (Henchcliffe and Severt, 2011: 609; The Parkinson 
Study Group, 2004: 2 502). During the two week washout period the UPDRS scores 
of the three levodopa groups worsened, but not as much as the placebo group and 
the patients in the 600mg arm performed the best. However, the adverse effects 
associated with levodopa such as nausea, dyskinesias, infection, hypertonia and 
headache were more pronounced in the group receiving 600mg daily (The Parkinson 
Study Group, 2004: 2 502).  
 
The overall conclusion of the study group was that there was no evidence found to 
suggest that levodopa accelerated the worsening of Parkinson’s disease over the full 
42 week period of observation (The Parkinson Study Group, 2004: 2 503). The 
continued benefit of levodopa after the washout period is consistent with disease 
modification but subsequent measurements have suggested that the washout period 
may have been insufficient to eliminate fully the effect of the medication on 
symptoms and that levodopa may have a longer term effect on parkinsonism than 
previously anticipated (Henchcliffe and Severt, 2011: 609; The Parkinson Study 
Group, 2004: 2 503).  
 
3.4.1.2 Continuous levodopa administration 
 
The idea of the continuous administration of levodopa to reduce dyskinesias 
associated with fluctuating levels of dopamine (Marin, Aguilar and Obeso, 2006: 647; 
Block, Liss, Reines, Irr, and Nibbelink, 1997: 23) has received much interest. Instead 
of levodopa, use has been made of a subcutaneous implant of apomorphine which is 
another potent dopaminergic agonist to reduce the incidence of dyskinesia in MPTP 
treated primates (Bibbiani, Costantini, Patel and Chase, 2005: 73-74). The implanted 
35 
 
animals remained stable for up to six months without demonstrating any dyskinesias 
(Bibbiani, et al., 2005: 75). However, the continuous delivery of a dopaminergic 
stimulant into the human striatum remains a problem as previous routes of 
administration were considered inconvenient. These methods of administration also 
caused side effects or possessed limited efficacy (Bibbiani, et al., 2005: 77).  
 
In humans, a study comparing a controlled-release preparation of levodopa to an 
immediate release formulation demonstrated that there was no difference in terms of 
dyskinesia but there was an improvement in the UPDRS scores with respect to the 
activities of daily living subscore. The controlled release group performed better than 
the immediate release group (Block, et al., 1997: 26). The controlled-release 
preparation showed a significant yearly improvement on the UPDRS activities of 
daily living scale (Bibbiani, et al., 1997: 25). 
 
3.4.1.3 Levodopa dose 
 
According to the World Health Organisation (WHO) the Defined Daily Dose (DDD) is 
the assumed average maintenance dose per day for a drug used for its primary 
indication in adults (WHO Collaborating Centre for Drug Statistics and Methodology, 
2009). When given in combination with a dopa-decarboxylase inhibitor like 
carbidopa, the DDD for levodopa is decreased to 600mg (WHO International 
Working Group for Drug Statistics Methodology).  
 
It has been seen that LIDs are more commonly associated with high daily doses of 
levodopa. These doses range from 400mg to 600mg daily (Benbir, et al., 2006: 732; 
Jankovic, 2005: 12; The Parkinson Study Group, 2004: 2 502; Schrag and Quinn, 
2000: 2 301).  
 
3.4.1.3 Age and disease severity 
 
With regards to age, it was found that younger patients tend to experience 
dyskinesias more frequently than older patients. One study (Garret, et al., 1998: 101) 
showed that of 50 patients with disease duration of 10 years and longer 56% 
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developed drug-induced dyskinesias within the first 10 years of the disease. The 
mean age of patients who developed these dyskinesias was 53.9±6.2 years. This is 
in accordance with a population-based study in Olmstead County, Minnesota in the 
United States of America (Kumar, et al., 2005: 343) which looked at patients with 
Parkinson’s disease incidence between the years 1976 to 1990. The study 
demonstrated that patients between the ages of 40 and 49 years and those between 
the ages of 50 and 59 years presented with 40% and 53% incidence respectively 
whereas patients between 60 and 69 years, 70 and 79 years and 80 and 89 years 
presented with 26%, 16% and 14% incidence, respectively. 
 
The earlier study (Garret, et al., 1998: 102) concluded that the onset of dyskinesias 
was also related to disease severity. This conclusion was supported by another 
prospective cohort study which followed a total of 40 patients who were at least 50 
years of age and did not present with LID at the start of the study (Kostić, et al., 
2002: 9-10; 13). Of the patients who had begun levodopa therapy at Hoehn and Yahr 
stage three, 90% developed dyskinesia. In the group of patients who had been 
started on levodopa at stage two of the disease, 54% developed dyskinesias and of 
the patients initiated on levodopa in stage one, a total of 70% developed 
dyskinesias. The study noted that patients beginning therapy in stage three 
developed LIDs significantly earlier than the other two groups (Kostić, et al., 2002: 
10).  The studies agree that the disease severity at the point of levodopa initiation 
plays a role in the development of dyskinesias.  
 
3.4.2 Ropinirole versus levodopa 
 
In order to delay the initiation of levodopa therapy and the incidence of LID, some 
neurologists prefer to begin therapy with a dopamine agonist such as ropinirole 
whose efficacy in Parkinson’s disease has been demonstrated (Rascol, Brooks, 
Korczyn, De Deyn, Clarke and Lang, 2000: 1 484). 
 
Two randomised double-blind studies (Hauser, Rascol, Korczyn, Jon Stoessl, Watts, 
Poewe, De Deyn and Lang, 2007: 2 409; Rascol, et al., 2000: 1 487) were 
conducted comparing ropinirole with levodopa as initial therapy in the onset of 
37 
 
dyskinesias. The earlier study (Rascol, et al., 2000: 1 484-1 491) compared the 
safety and efficacy of ropinirole with that of levodopa over a five year period in 268 
patients with early Parkinson’s disease. After the five year period it was found that 
the cumulative incidence of dyskinesia in the ropinirole group was 20% as opposed 
to the 45% incidence in the levodopa group (Rascol, et al., 2000: 1 487). The second 
study (Hauser, et al., 2007: 2 409) supported the previous findings. The results 
showed that patients randomised to the ropinirole exhibited lower incidence of 
dyskinesia and the average time to onset of dyskinesia was also significantly longer. 
However, in the later study, the UPDRS scores of patients randomised to the 
levodopa group showed greater improvement than the corresponding ropinirole 
scores (Hauser, et al., 2007: 2 410). 
 
3.4.3 Entacapone and levodopa  
 
Entacapone, a selective, potent and reversible peripherally acting COMT-inhibitor, 
will extend the half-life of levodopa by approximately 50% to 75% and decreases the 
fluctuation in levodopa blood levels, thus reducing the incidence of LID (Marin, et al., 
2006: 647; Smith, Jackson, Al-Barghouthy, Rose, Kuoppamaki, Olanow and Jenner, 
2005: 307). According to the WHO, the DDD for levodopa in combination with both a 
decarboxylase inhibitor and entacapone is further decreased to just 450mg. Initiating 
therapy with a combination of entacapone and levodopa as opposed to levodopa 
alone, has shown to reduce the induction and severity of dyskinesias in MPTP-
lesioned primates as opposed to those being treated with levodopa/carbidopa 
(Marin, et al., 2006: 647). 
 
A study was conducted which demonstrated that combination therapy with 
entacapone and levodopa could reduce the incidence and severity of LIDs (Marin, et 
al., 2006: 646). The study was conducted on male rats treated with either levodopa 
alone or levodopa in combination with entacapone. The end result showed that the 
rats receiving levodopa alone showed a gradual increase of AIMs (abnormal 
involuntary movements). The rats receiving the combination therapy also 
demonstrated such AIMs in the beginning but did not experience an increase over 
the period of therapy (Marin, et al., 2006: 648).   
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The findings of this study were prompted another study which considered the 
differences in dyskinesia incidence between MPTP-treated primates and patients 
with Parkinson’s disease when treated with entacapone as opposed to pulsatile 
levodopa therapy (Smith, et al., 2005: 307). The aim of this was to determine 
whether the concurrent administration of entacapone with levodopa would decrease 
the incidence of dyskinesias in MPTP-lesioned primates. The four times daily 
administration of enatacapone with levodopa showed significantly enhanced motor 
responses together with the reduced frequency and severity of dyskinesia (Smith, et 
al., 2005: 307). However, as the study was conducted on primates, the optimal 
dosage and therapy for humans would have to be determined (Smith, et al., 2005: 
313). 
 
3.4.4 Selegiline and levodopa 
 
The most important study involving selegiline is the DATATOP (deprenyl (selegiline) 
and tocopherol antioxidative treatment) study which showed that selegiline, with or 
without tocopherol, is ‘neuroprotective’ which means that it reduces the rate of 
progression of Parkinson’s disease (Olanow, et al., 2003: 1; Ward, 1994: 217). The 
study also found that the antiparkinsonian effects of selegiline continued for at least 
six weeks after its discontinuation (LeWitt, 2009: 1 352). This is due to the 
irreversible nature of the inhibition. It was shown that a full recovery of the inhibition 
required longer than four weeks (LeWitt, 2009: 1 352). A review of the effects of 
selegiline and rasagiline stated that one study showed there was no difference in 
effect between selegiline and placebo whilst others showed only a mild symptomatic 
benefit (LeWitt, 2009: 1 352). The same results were shown for rasagiline (LeWitt, 
2009: 1 353). Clinical experience has also shown that selegiline in combination with 
dopamine replacement therapy only offers limited benefits (LeWitt, 2009: 1 353).  
 
3.4.5 Rasagiline and levodopa 
 
A double blind, parallel group, randomised, delayed start clinical trial was conducted 
in order to determine the effect of early and later initiation of rasagiline on the 
progression of disability in Parkinson’s disease (Parkinson study group, 2004: 561). 
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Rasagiline is a selective irreversible inhibitor of monoamine oxidase type B. The 
group had, six months previously, conducted another study randomising patients to 
once daily rasagiline or placebo. In this second phase of that initial study, patients 
who were receiving 1mg or 2mg of rasagiline continued to receive that dosage and 
those who were previously receiving placebo were now given rasagiline 2mg 
(Parkinson Study Group, 2004: 561). This study aimed to determine if the patients 
with earlier initiation demonstrated better functional status at one year. The results 
showed that patients receiving rasagiline for one year demonstrated less symptom 
progression than those patients receiving rasagiline for just six months (Parkinson 
Study Group, 2004: 564).  
 
3.4.6 Levetiracetam for the management of LIDs 
 
Lately, the effect of the antiepileptic agent levetiracetam in reducing LID has been 
investigated. Levetiracetam is generally used as add-on therapy for the treatment of 
partial-onset seizures (Zesiewicz, Sullivan, Maldonado, Tatum and Hauser, 2005: 1 
206). The two studies discussed below agree that levetiracetam could be used to 
reduce the severity of LID experienced by Parkinson’s patients. 
 
One study (Zesiewicz, et al., 2005: 1 206) utilised nine patients suffering from 
Parkinson’s disease who were experiencing peak dose dyskinesia which was 
moderately disabling for at least 25% of the awake day. These patients were treated 
with levetiracetam of which the dose was titrated upward to reach a maximum of 
3000mg, given for up to 60 days (Zesiewicz, et al., 2005: 1205). The primary 
outcome measure of the study was the proportion of the awake day the patient spent 
in the ‘on’ phase without dyskinesia or without troublesome dyskinesia. The study 
group aimed to determine the tolerability and preliminary efficacy of levetiracetam in 
reducing LID in Parkinson’s disease patients (Zesiewicz, et al., 2005: 1206). Patients 
had to achieve at least a 70% concordance with the primary investigator for diary 
rating of ‘on’ and ‘off’ time. Of the three women and six men who were enrolled in the 
study, 56% dropped out before the end point. Two patients withdrew before 
completing their diaries and were not included in the final analysis. Two patients 
withdrew due to somnolence, one due to dizziness and confusion as well as another 
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patient due to obtundation which is defined as a greatly reduced state of 
consciousness without being comatose.  
 
At the end of the study, the mean dose of levetiracetam was 625mg daily with none 
of the four patients reaching the endpoint having received the maximum allowable 
dose of 3000mg per day (Zesiewicz, et al., 2005: 1207). Two of the patients 
achieved satisfactory dyskinesia control at 750mg and 1000mg respectively. Mean 
percent ‘on’ time without dyskinesia or troublesome dyskinesia increased from 43% 
at baseline to 61% at endpoint. There was no increase in ‘off’ time (Zesiewicz, et al., 
2005: 1207). Overall, the symptoms of Parkinson’s disease were much improved in 
two patients, unchanged in three, minimally worse in one patient and much worse in 
one patient.  
   
A further study was conducted to determine the safety and efficacy of levetiracetam 
for the management of LID (Stathis, Konitsiotis, Tagaris and Peterson, 2011: 267). 
The study involved a multicenter, double-blind, placebo-controlled, parallel group, 
crossover trial. The levodopa treated Parkinson’s patients received levetiracetam 
500mg per day and was titrated upward to 1000mg daily. The primary efficacy was 
determined by the percentage change in ‘on with LID’ time from patient diaries. The 
results of the studies showed a percentage change of ‘on with LID’ waking time 
decreased by 3.8% at 500mg per day and 7.8% at 1000mg daily (Stathis, et al., 
2011: 267). However, there was no decrease in ‘off’ time as shown by the 
abovementioned study as well. One patient withdrew due to adverse effects. The 
adverse effects, of which the most common included dizziness and somnolence, 
were more prominent in the 500mg per day group than the 1000mg per day. This 
indicates that it is possible for tolerance to be developed to the adverse effects 
associated with levetiracetam (Stathis, et al., 2011: 269). The study showed that a 
dose of 1000mg per day with slow titration can be useful in treating LID (Stathis, et 
al., 2011: 270).  
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3.5 Previous drug utilisation analyses 
 
Any previous drug utilisation studies found using the respective databases were 
included. These were then analysed and compared to the findings of the DUR. This 
section focuses on studies concerning the prescribing patterns of Parkinson’s 
disease as well as the cost of treatment. 
 
3.5.1 Prescribing patterns of antiparkinsonian medication 
 
A Singaporean study (Tan, Yeo, Tan, Pavanni and Wong, 2012: 511) aimed to 
determine the prescribing patterns of antiparkinsonian medication in Singapore. 
They also included a survey to determine which factors were considered by 
neurologists when prescribing these medications (Tan, et al., 2012: 511).  
 
The study population included 182 men and 124 women of the average age of 
64.4±9.9 years. The majority of patients were in Hoehn and Yahr stage three of the 
disease (Tan, et al., 2012: 512). Analysis showed that levodopa in combination with 
a decarboxylase inhibitor, such as carbidopa or benserazide, was the most 
commonly prescribed drug with 92.3% of the study population receiving one of these 
combinations. Interestingly, it was the levodopa/beneserazide combination which 
was more popular (Tan, et al., 2012: 513). Patients in later stages, such as Hoehn 
and Yahr stage three to five, of the disease were also using higher doses of 
levodopa compared to those in earlier stages (Tan, et al., 2012: 513). Dopamine 
agonists made up 26.8% of the total medications used, with the next being 
benzhexol and then selegiline. The COMT-inhibitors and amantadine use was less 
than 10%. The majority of the population was on monotherapy or a two drug 
combination therapy. Almost 40% of these patients were on monotherapy with 
levodopa. It also showed that patients on levodopa were in more advanced stages of 
the disease than those who were not, but no relationship was found between the use 
of dopamine agonists and disease severity (Tan, et al., 2012: 513). When asked, the 
neurologists claimed that factors that most influenced their decisions included stage 
of disease, cost of the drug, patient compliance and drug company sponsorship.  
 
42 
 
The group also found that 64.5% of the patients were also receiving medication 
unrelated to Parkinson’s disease which had the potential to interact with their 
antiparkinsonian medication (Tan, et al., 2012: 513). Other medication being used by 
12 of the patients included benzodiazepines such as alprazolam, clonazepam, 
diazepam and lorazepam (Tan, et al., 2012: 513).  
 
Another study in Italy demonstrated a similar result (Leoni, Martignoni, Cosentino, 
Michielotto, Calandrella, Zangaglia, Riboldazzi, Oria, Lecchini, Napp and Frigo, 
2002: 151). Levodopa was the most commonly prescribed drug (54%) followed by 
dopamine agonists and anticholinergic agents (Leoni, et al., 2002: 151). Some of the 
other medications prescribed unrelated to Parkinson’s disease included anxiolytics 
and sedative hypnotics (Leoni, et al., 2002: 153).  
 
3.5.2 Cost of treatment 
 
With the number of Parkinson’s sufferers increasing, the cost of care rises too. Due 
to the complicated nature of the symptoms and complications of Parkinson’s disease 
and its therapy, medical treatment alone is not enough. This means that caring for 
the patient can become quite expensive (Keus, et al., 2012: 1). As many as 18 
different disciplines can become involved in the care of a patient suffering from 
Parkinson’s disease (Keus, et al., 2012: 1).  
 
A study conducted in Germany aimed to determine the cost and trend of resource 
utilisation in patients with Parkinson’s disease over a period of four years (Winter, 
Balzer-Geldsetzer, von Campenhausen, Spottke, Eggert, Oertel and Dodel, 2010: 
18). The resource utilisation was recorded over a 12 month period. The study group 
made use of instruments such as patient diaries and questionnaire surveys (Winter, 
et al., 2010: 19). Two cohorts of patients were used, one from 2000 and the other 
from 2004. Disease severity was classified according to the Hoehn and Yahr stages.  
The total costs calculated were from the societal perspective and included both 
direct and indirect costs. The direct costs were made up of payments made by health 
insurance companies and patient co-payments. Health insurance spending included 
inpatient care, outpatient care, costs of additional services such as physiotherapy, 
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occupational therapy and speech therapy, costs for any special equipment required 
by the patient, home care including both formal and informal care. Formal care was 
that provided by health care professionals and informal care was that provided from 
family and friends. Drug costs were also included (Winter, et al., 2010: 19). The 
indirect costs involved included productivity losses due to premature retirement 
related to Parkinson’s disease or temporary sickness.  
 
In 2000 a total of 145 patients were included of which 97 were men and 48 women. 
The cohort of 2004 included 133 patients, but after a drop out of 13 patients, 120 
remained to participate in the study. Of these 120 patients, 82 were male and 38 
were female.  The number of patients in stages four and five were higher in the 
cohort from 2000 than 2004 (Winter, et al., 2010: 20), therefore costs were 
calculated for each Hoehn and Yahr stage separately. Depending on the stage, the 
total costs for 2004 were 25% to 31% higher than in 2000. The direct and indirect 
costs both increased with the Hoehn and Yahr stages. 
  
The overall resource utilisation increased by 25% to 31% over the total four year 
study period. This is due to the increasing prevalence of Parkinson’s disease. 
Changing trends in the utilisation of health care resources can lead to short term 
effects that can cause a dramatic increase or decrease costs (Winter, et al., 2010: 
21). The study also mentioned that there is an increase toward prescribing of 
dopamine agonists as opposed to levodopa (Winter, et al., 2010: 21). Due to the fact 
that these newer drugs are so expensive, it has elevated costs of Parkinson’s 
disease. The drug treatment constituted 12% to 32% of the total costs and consists 
61% to 73% of dopaminergic drugs.   
 
The study concluded that Parkinson’s disease places a significant burden on society 
and this burden is expected to increase in the coming years. The introduction of new 
healthcare programmes and technologies can produce rapid changes in the 
utilisation of health care resources (Winter, et al., 2010: 22). 
 
A study conducted in Ontario, Canada aimed to determine the burden of Parkinson’s 
disease (Guttman, Slaughter, Theriault, DeBoer and Naylor, 2003: 313). Databases 
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were used and the subjects were matched with controls. The study assessed the 
prevalence of Parkinsonism, physician and drug related costs, hospital admissions 
and utilisation for Parkinson’s patients compared with the controls. The study made 
use of a prevalence group which used databases from 1992/1993 to 1998/1999 and 
a cohort group utilising information from the fiscal year 1993/1994 (Guttman, et al., 
2003: 314).  
 
Results from the prevalence group showed a 25.8% increase in the number of 
patients from 1992 to 1998 (Guttman, et al., 2003: 315). There was also a 5.4% age-
adjusted prevalence for men over this time period and 9.8% for women. The 
proportion of patients under the age of 60 years was between 8.5% and 9.5% for 
men and 6.2% and 7.3% for women. The majority of patients were over the age of 
60 years (Guttman, et al., 2003: 315).  
 
Results from the cohort group showed that physician costs were 1.4 times higher for 
patients than for the controls (Guttman, et al., 2003: 315). Over the six years of the 
study, 68.4% of Parkinson’s patients were admitted to hospital compared to 56.9% of 
the control group. The total number of hospitalised cases of Parkinson’s disease 
decreased over the six years. Another finding of the study showed that the number 
of hospitalisations did not increase with age and severity of disease (Guttman, et al., 
2003: 315). The average cost of drugs for the study period was six times higher that 
than the controls. This is mostly due to the high cost of antiparkinsonian drugs 
(Guttman, et al., 2003: 316). The study concludes that the demonstrated increase in 
prevalence of Parkinson’s disease and the definitive economic burden that it places 
on society is reason enough to stimulate further investigation into the cause of 
Parkinson’s disease and development of preventative strategies (Guttman, et al., 
2003:318). 
 
A study conducted in Europe investigated the effect of dyskinesias in the Quality of 
Life (QoL) and economic cost of drug therapy (Péchevis, Clarke, Vieregge, 
Khoshnood, Deschaseaux-Voinet, Berdeaux and Ziegler, 2005: 956). Six patients 
were enrolled all of whom fell at different points on the disability scale to provide 
potentially varying QoL scores and health-economic outcomes. The QoL scores 
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were determined using a series of tests. These included the UPDRS, the 
Montgomery-Asberg Depression Rating Scale and their medical histories. Also used 
was the generic QoL questionnaire, the Short Form-36 and a Parkinson’s disease 
specific instrument, the Parkinson’s disease Quality of Life scale (Péchevis, et al., 
2005: 957). The Parkinson’s disease Quality of Life scale includes questions 
pertaining to daily activities and whether the patient is able to perform them without 
difficulty, as well as the emotional wellbeing of the patient such as the presence of 
depression, embarrassment to go out in public because of the disease or problems 
with personal relationships. The patients were required to keep a diary over a six 
month period and costs were calculated based on the items and activities recorded 
in the diary (Péchevis, et al., 2005: 957).  
 
The results showed that increasing dyskinesia scores were associated with a 
significant reduction in QoL scores (Péchevis, et al., 2005: 958). However, 
dyskinesias measured using the UPDRS did not have effects on activities of daily 
living scores after adjusting for fluctuation, disease and country. The study showed 
that there was a significant association between increasing dyskinesia severity and 
depression (Péchevis, et al., 2005: 959) which means that the decreased QoL could 
be due to the adverse effects on mood (Péchevis, et al., 2005: 961). Dyskinesias 
were also associated with a significant increase in health-related costs (Péchevis, et 
al., 2005: 960). It was shown that each unit increase in dyskinesia severity, when 
measured using the UPDRS, resulted in a total additional cost of €562 per patient 
over the six month period (Péchevis, et al., 2005: 960).   
 
In the Netherlands, a group of researchers examined how they could improve 
community healthcare for patients with Parkinson’s disease (Keus, et al., 2012: 1). 
The aim was to make the plan adaptable to other countries. An examination of the 
current therapy was evaluated then a regional expert centre for Parkinson’s patients 
was set up. This centre served as a tertiary referral centre for a large region. The 
centre was also responsible for initiating and conducting clinical trials and then 
distributing the newly acquired knowledge to the public at large (Keus, et al., 2012: 
1-2).  
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Evidence based guidelines were developed for allied health care professionals. 
These included physiotherapists particularly, as well as occupational therapists, 
speech and language therapists, dieticians, specialist nurses, psychologists, social 
workers, sex therapists and neurologists (Keus, et al., 2012: 2, 4). The NICE 
guidelines for Parkinson’s disease agree with this, stating that all Parkinson’s 
patients should have access to specialised nursing care, physiotherapy, 
occupational therapy as well as speech and language therapy (Stewart, 2007: 239). 
The researchers then developed a multifaceted implementation strategy called 
ParkinsonNet and a number of expert health care professionals interested in the 
project were selected and trained to work at each of them in the different regions. 
The training included measures to ensure that the professionals always 
communicated regularly and effectively with each other. Transparency and 
continuous education and exchange of knowledge were also encouraged (Keus, et 
al., 2012: 3). Figure 3.1 is a summary of the nine steps involved in the process of 
setting up this system. 
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Figure 3.1 Steps of the Dutch model to improve community health care for 
Parkinson’s disease* 
*(Source: Keus, et al., 2012: 2) 
 
When ParkinsonNet was evaluated it showed that the quality of care provided to 
Parkinson’s patients was improved and the volume of patients per therapist more 
than doubled while saving costs. It also showed that therapists treating more than 
nine Parkinson’s patients per year were more connected than those treating 10 or 
less and this connectedness was shown to influence clinical decisions concerning 
patients (Keus, et al., 2012: 4).  
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CHAPTER 4 
Methodology 
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4.1 Introduction 
 
This study consisted of two parts, namely a drug utilisation review and a 
questionnaire survey. The drug utilisation portion of the study involved the analysis of 
prescription records obtained from a national retail pharmacy group. The 
questionnaire survey portion was a semi-structured questionnaire which was verbally 
administered to patients by the researcher and a review of patient medical files was 
conducted at the hospitals of Groote Schuur (associated with the University of Cape 
Town) and Tygerberg (associated with Stellenbosch University) in the Western Cape 
Province and sourced from the Parkinson’s disease support group in the Eastern 
Cape Province. 
 
4.2 Ethical approval 
 
Before the study was initiated, approval had to be obtained from the Department of 
Pharmacy, the Faculty of Health Sciences Research, Technology and Innovation 
(FRTI) Committee and the Human Research Ethics Committee (REC-H) of the 
Nelson Mandela Metropolitan University (NMMU). Approval also had to be obtained 
from the Faculty of Health Sciences HREC at the University of Cape Town (UCT) as 
well as the Faculty of Health Sciences HREC at the University of Stellenbosch. See 
appendices A, B and C for the proof of ethical approval of these committees in order 
of mention.  
 
The World Medical Association has developed the Declaration of Helsinki as a 
statement of ethical principles for medical research involving human subjects, 
including research on identifiable human material and data (The World Medical 
Association, 2008: 1). This study utilises identifiable human data and thus the 
principles of the Declaration of Helsinki were consulted and adhered to in the 
formulation of the methodology. 
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4.3 Study Design 
 
Research design can be broadly categorised into two groups, namely exploratory 
and conclusive studies. Exploratory design provides insights and understanding to a 
particular phenomenon and the information that is required is only very loosely 
defined. The research process is flexible and unstructured and therefore subject to 
change during the study. The sample is usually quite small and not representative of 
the population as a whole. The analysis of the primary data is qualitative and the 
results obtained from these studies are only tentative. The results of exploratory 
studies are generally followed by further exploratory or conclusive studies (Malhotra, 
1999: 84). Conclusive studies are done to test for specific hypotheses. The 
information needed is clearly defined and the research process is formal and 
structured. The sample is large and representative of the population under study. 
The analysis of the primary data is quantitative and the results can be seen as 
conclusive. The results of such conclusive studies are generally used in decision 
making processes. (Malhotra, 1999: 84).  
 
This study consists of conclusive elements. The DUR is identified as conclusive 
since the information needed is clearly defined, the sample is large and the data 
analysis is quantitative. The questionnaire survey portion of the study is also 
conclusive as the method of analysis of the primary data is quantitative and the 
information required is clearly defined.  
 
The drug utilisation study was a cross-sectional study. A cross-sectional study is 
defined as one which focuses on a single sample from which data is obtained at a 
single point in time. Although the records included in the database span a period of 
one year, the information was obtained on only a single occasion (Malhotra, 1999: 
89). The data is retrospective in nature as the patients had already been entered into 
the database at the time of analysis and no new patients were added during the 
course of the study. 
 
The questionnaire survey is defined as an empirical, descriptive study. Empirical 
studies are those that provide evidence on the basis of actual observation or 
51 
 
experimentation (Merriam-Webster). A descriptive study involves the description of 
phenomena using statistical analysis (Mouton and Marais, 1988: 43). 
 
4.4 Literature Review 
 
An extensive literature review was conducted during the period February 2011 until 
July 2012. The literature review was performed to obtain knowledge about 
Parkinson’s disease, drug utilisation and the chosen methods of data collection. 
Appropriate books, internet websites and journal articles were consulted. Electronic 
information, including local and international journal articles was obtained through 
the use of PubMed®, ScienceDirect®, EBSCOHost® and library search engines of the 
universities included in the study.  
 
4.5 Drug utilisation study 
 
Drug utilisation was defined by the WHO in 1977 as ‘the marketing, distribution, 
prescription, and use of drugs in a society, with special emphasis on the resulting 
medical, social and economic consequences’ (WHO, 2003: 8). The main aim of drug 
utilisation research is to facilitate the rational use of drugs in a population. Drug 
utilisation research is conducted to determine the pattern of drug use, the quality of 
use, the determinants of use and the outcomes of drug use. Such studies also 
provide insight into the efficiency of drug use that is, determining whether a certain 
drug provides value for money (WHO, 2003: 8-9). The DUR was a structured 
process wherein a primary sample group was identified and analysed in terms of 
medicine usage, drug prescribing and drug dosage.  
 
4.5.1 Health Care System in South Africa 
 
South Africa has two health care sectors. The public health care sector provides 
health care facilities and services through government funding to members of the 
population who cannot afford the medical costs. The private health care sector 
provides health care facilities and services to those individuals able to pay for 
medical costs either from personal funds or private medical aid schemes. In 2004 
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only 18.5% of persons over the age of 20 years had access to medical benefits 
(Lehohla, 2004: 27). In 1999 over two thirds of the white population of South Africa 
had access to medical benefits whereas with the black population, only 8.9% had 
access. Between 1995 and 1998, public health care was the sector most commonly 
used and there has been an increase in its usage since (Lehohla, 2004: 31). It is 
shown that white South Africans are the group most likely to utilise private health 
care facilities while the black and coloured populations are most likely to utilise the 
public health services (Lehohla, 2004: 31). This study focuses on patients in the 
private health care sector with or without a medical aid.  
 
A national community pharmacy group provided a database containing all records for 
the time period of 1st January to 31st December of years 2008, 2009 and 2010. The 
database consists of all CNS prescription records for the above-mentioned time 
period. The data requested is from the whole of South Africa. 
 
4.5.2 Data Collection 
 
The information provided was anonymous and patient confidentiality was maintained 
at all times. Patients were identified only by a patient code. Geographical location 
was indicated by predetermined divisions of the provinces in the database. Data 
analysis makes use of the divisions provided by the database where some of the 
provinces were combined into one region. An extract of the database as well as a list 
of data fields provided is included as Appendix D. 
 
The data contained all records for CNS drug prescriptions in the year 2010. The only 
criteria for inclusion in the primary study sample were: 
 
 Use of medication which has been licensed by the Medicines Control Council 
of South Africa for the treatment of Parkinson’s disease;  and 
 being aged 50 years or older.   
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Data were obtained as text delineated files for each month. The data were then 
exported in Microsoft Access®. The data received was compatible with Microsoft 
Excel®. 
 
4.5.3 Data analysis 
 
There were 25 523 antiparkinsonian records for the year 2010. The extracted data 
contained information about patients receiving antiparkinsonian medication on a 
chronic basis.  
  
Demographic information, such as age and gender were missing from a number of 
records. A total of 3 954 records were excluded due to the exclusion criteria being 
patients under the age of 50 years. A further nine records were excluded due to the 
patients being over the age of 100 years and another 149 records due to there being 
no age recorded. A total of 218 records were excluded for unspecified gender. The 
letter ‘U’ and a blank area are indications of invalid entries identified. Records which 
indicated a zero ‘sales value’ or zero ‘units sold’ were excluded as this implies that 
the records were incorrectly captured or the items were not dispensed. So-called 
‘nonsensical’ sales values (those between R0.01 and R0.76) were also excluded. 
This brings it to a total 4 320 records excluded due these discrepancies. Certain 
patient profiles consisting of a total of 34 records were excluded as only half of the 
information pertinent to analysis was available. This brought the total analysed 
records to 25 523.  
 
There was no way to identify single patients within the database as more than one 
patient on the same medical aid was listed under the same profile number and 
differed only by the dependant number. To allow for identification of individual 
patients, a formula was derived to provide each patient with a unique numerical 
identifier. This was done by multiplying the profile number by 100 and adding the 
dependant number. 
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4.6  Questionnaire-based survey 
 
The purpose of this portion of the study was to determine the age of onset of 
Parkinson’s disease, establish when levodopa therapy was initiated relative to the 
date of diagnosis, determine the use of other medications even if not 
antiparkinsonian medication, determine if and when the emergence of dyskinesias 
occurred, determine the severity of the dyskinesia and assess the risk factors 
involved in the emergence of dyskinesia.  
 
At the public hospitals of Groote Schuur and Tygerberg, the specialised Parkinson’s 
disease clinic hours were used to source patients. The patient files were scanned in 
numerical order and patients were selected based on the inclusion criteria of the 
study. The medical records were available at the time of interview for review. A total 
of nine patients were obtained at Groote Schuur Hospital and 22 patients were 
obtained from Tygerberg Hospital.  
 
In Port Elizabeth, patients from the Parkinson’s disease support group were 
contacted and asked to participate in the study. Those who consented were visited 
at a time and place of his/her choice. Thereafter, the respective neurologists were 
contacted to request access to the patients’ medical records. A total of 12 patients 
were obtained from the support group. The questionnaire used is included as 
Appendix E and the request form sent to the neurologists as Appendix F.  The 
patient consent forms, both Engllish and Afrikaans are included as Appendix H and 
Appendix I, respectively. 
  
4.6.1 Advantages and disadvantages of questionnaires 
 
According to Mouton and Marias (1988: 50), the best research strategy for 
conducting a descriptive, general interest study is by making use of sample surveys. 
Closed-ended and open-ended questions may be asked; allowing for the provision of 
both facts and opinions and beliefs (Behr, 1983: 150-151). Questionnaires may be 
introspective or extrospective. They are considered introspective when the 
respondent is answering questions about him- or herself and extrospective when the 
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respondent is answering questions about someone else (Behr, 1983: 151). The 
questionnaire used in this study is introspective. 
 
The advantages of a questionnaire survey is that it is relatively simple to administer 
and distribute, there is reliable data collection as response options are generally 
limited and the coding, analysis and interpretation of the data is generally quite 
simple (Malhotra, 1999: 178). The advantage of verbal administration is that it allows 
the patient to ask questions if they do not understand what is required of them and 
also allows the researcher to question the patient further in order to obtain the 
necessary information. The advantage of the researcher administered questionnaire 
is a high response rate as the researcher personally conducted the interviews using 
English and Afrikaans as the acceptable languages. 
 
The disadvantage of verbally administering questionnaires is time restriction. It may 
result in the study population being decreased or inadequate information being 
obtained from patients due to time constraints. Another disadvantage would be bias 
in the answers resulting from prompting from the researcher if the patient 
misunderstands the questions. Also as humans, the patients will be aware that they 
are participating in research and react to the situation and this may result in possible 
bias as well. Inability to accurately recall information from the past may also reduce 
the reliability of the data (Malhotra, 1999: 178). However, despite these 
disadvantages, surveys are still a very commonly used form of data collection 
(Malhotra, 1999: 178).  
 
A review of patient medical records was also conducted. The researcher made use 
of a data collection sheet (Appendix G) which extracted information from the patient 
medical records concerning: the date of diagnosis; current disease severity; initial 
therapy prescribed; date of levodopa initiation; initial dose of levodopa; current 
levodopa regimen; other Parkinsonian medications the patient is receiving; incidence 
of dyskinesia and latency to onset of dyskinesia. Patient confidentiality was 
maintained at all times. The researcher ensured that no names or details that could 
be traced back to particular patients were present on documents. 
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4.6.2 Development of the questionnaire 
 
A questionnaire was developed pertaining to information found in the literature 
review. Ethics approval by the FRTI and the Human Ethics Committees of all three 
universities involved was obtained. 
 
After approval was obtained, a pilot study was conducted to determine how long it 
would take to administer the questionnaire and if the language used was clearly 
understood by the patients. The pilot study conducted at Groote Schuur Hospital 
showed that it would take approximately 15 minutes to verbally administer the 
questionnaire to the patient and minor changes were made to the questionnaire 
following the pilot study.  
 
4.6.3 Study site 
 
The study population was to consist of 50 patients from Groote Schuur Hospital in 
Cape Town who have been under the medical supervision of a well-known 
neurologist from January until June 2011. These patients had been conclusively 
diagnosed with Parkinson’s disease by this neurologist and were currently on 
levodopa therapy.  
 
Groote Schuur Hospital is a large academic training institution of the University of 
Cape Town with an extensive patient population. Many of the patients comprising the 
population of the researcher’s previous study (Gaida, Kubashe and Truter, 2010) 
visited the chosen neurologist for examinations and confirmation of diagnosis and 
disease severity. The attending neurologist was a respected professional and 
academic in his field. The patients’ medical records would be obtained from the 
hospital record department. Data were to be collected over a six month period 
(January to June 2011). Systematic random sampling was to be employed and the 
first 50 files, arranged in alphabetical order, of patients with Parkinson’s disease was 
selected, that is the first 25 male and the first 25 female patients who were willing to 
participate in the study. 
 
57 
 
 
The following patients were excluded from the study: 
  
 patients younger than 50 years as Parkinson’s disease is more common in 
patients this age and older (Goetz, et al., 2003: 743); and  
 patients who have been on levodopa therapy less than one year. The patient 
is unlikely to experience any side effects from levodopa therapy or any 
dyskinesias due to disease progression before this stage (Madden, Morris, 
Graham, Katekar and Wade, 1995: 48). 
 
The data collection began in May 2011. The neurology outpatient clinic at Groote 
Schuur hospital operated on Tuesday afternoons and Thursday mornings. The 
researcher would attend these clinic sessions and select the patient folders of those 
diagnosed with Parkinson’s disease in numerical order and proceed to interview the 
patients. This was the form of random sampling undertaken by the researcher as 
selecting patients in alphabetical order as previously desired was not possible. In 
August 2011 the researcher went on a six month international exchange programme, 
thus there was a break in the data collection until March 2012. During this period of 
time it was decided that the patient population at Groote Schuur may be too small to 
obtain the desired number of 50 patients. Tygerberg hospital was therefore 
approached for ethics approval which was granted to the researcher. Tygerberg 
hospital was chosen as it is another public sector hospital in Cape Town with a 
neurologist and runs a specialised Parkinson’s disease clinic every two weeks. The 
Parkinson’s disease support group in Port Elizabeth was also used as the 
specialised clinic at Tygerberg Hospital was not yielding as many patients as 
originally anticipated. The eventual number of patients interviewed was 43. 
 
4.6.4 Data analysis 
 
The questionnaires were coded and captured onto a purpose-designed spreadsheet 
using Microsoft Excel®. The results were analysed using descriptive and inferential 
statistics and compared with literature findings. 
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4.7 Confidentiality 
 
Confidentiality was maintained in both the DUR and questionnaire survey. The 
database analysed did not provide any identifiable reference to patients. The 
questionnaire survey maintained separation between the consent forms and the 
questionnaires to ensure confidentiality. The questionnaires of interviews conducted 
at the different hospitals were combined to ensure that patients could be identified at 
a particular site. The informed consent forms were reviewed separately as a means 
of record keeping. All of these documents were safely stored at the researcher’s 
home. The consent forms are attached as Appendices H and I. 
 
4.8 Limitations 
 
Limitations of both the DUR and questionnaire survey were identified and are 
described separately below. 
 
The most important limitations of the DUR were: 
 The database profiles may not be an accurate representation of the South African 
population. 
 The patient information was not linked for the different stores of the retail 
pharmacy group within the database. It is therefore possible that certain 
patients collected prescriptions from different stores in other regions where 
different profiles were used, thus the total number of individual patients may 
not be an accurate reflection of the actual number of patients due to the 
duplication of profiles.  
 Demographic information for the entire database population could not be 
accurately determined. 
 The age and/or gender fields were either empty, contained different entries for 
the same patient, or were stated as unknown for a large number of patients. 
 The exact dispensing date was not given. 
 It was not possible to determine an accurate time frame for drug utilisation as 
only the months were provided and not the individual dates for each 
dispensed prescription. 
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The most important limitations of the questionnaire based survey were: 
 Design of forms 
 The information sought in the forms was very specific and patients may not 
have been able to provide accurate records. This is particularly so since the 
majority of the patient population were elderly and impairment of memory may 
have played a role in the accuracy of information. 
 Study population 
 The questionnaires were limited to certain age groups which reduced the 
potential number of participants. 
 The interviews were conducted only in English and Afrikaans. For example, 
Xhosa is a language widely spoken in the Eastern Cape. Therefore patients 
speaking a language other than English or Afrikaans could not be interviewed, 
thus further reducing the number of participants.  
 As mentioned above, due to the age of the study population, memory 
impairment may have been a problem. 
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CHAPTER 5 
Results and Discussion of the 
Drug Utilisation Review 
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5.1 Introduction 
 
The following chapter focusses on describing and analysing the main findings of the 
DUR. The population analysed was provided by a national private community (retail) 
pharmacy group and consisted of all the records of antiparkinsonian drug 
prescriptions captured during the year 2010. The database was analysed at different 
levels with overall demographic statistics being provided for the complete dataset, as 
well as an overview of the drug classes and substances identified and distribution of 
prescriptions per month. The patient population was analysed to provide statistics on 
gender ratio, mean age of the population as well as the distribution of prescriptions 
and patients per region. The drug use and sales value was also investigated. In this 
chapter, patient statistics and regional statistics will be analysed and discussed. 
 
5.2 Overview of patient information 
 
Demographic information of the patients including age, gender and regional 
distribution was available. Of the 25 523 antiparkinsonian products dispensed, there 
were 5 168 patients identified with 3 058 (59.17%) being females and 2 110 
(40.83%) being males. This gives a female to male ratio of 1:0.68. The average 
number of prescriptions dispensed to male patients was 5.55±6.88 over the year 
whereas 4.51±5.44 was the average for females. The chi-squared test shows a 
statistical significant result (p <0.05) but this is due to the large sample. The practical 
significance, as indicated by Cramér's V (0.07), is small. 
 
Many studies have shown that Parkinson’s disease is more common in men than 
women (Fall, Axelson, Fredriksson, Hansson, Lindvall, Olsson and Granérus, 1996: 
638; Fargel, et al., 2007: 208; Miller and Cronin-Golomb, 2010: 2695; Shulman, 
2007: 12), but in this patient population it was shown that there were in fact more 
females than males. However, Japanese studies have shown a female prevalence in 
Parkinson’s disease (Kimura, Kurimura, Wada, Kawanami, Kurita, Suzuki, Katagiri, 
Daimon, Kayama and Kato, 2002: 296; Kusumi, Nakashima, Harada, Nakayama and 
Takahashi, 1996: 201). Another study conducted in France showed a prevalence 
ratio of Parkinson’s disease of 1.40% in patients over the age of 65 years with no 
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significant difference between males and females (Tison, Dartigues, Dubes, Zuber, 
Alperovitch and Henry, 1994: 113). According to the midyear population estimate of 
2010, 51% of the South African population was female (Statistics South Africa, 2010: 
3). This could partly explain why females were the dominant gender in the 
population. The result of this study was in keeping with another which analysed 
databases between the years 2005 to 2008. It was found that for each year female 
patients constituted 56% to 60% of the total population (van der Merwe, 2010: 96). 
The total population aged 50 years and older in South Africa according to the 
midyear population estimate of 2010 was 14.94% with 8.30% being female and 
6.64% being male (Statistics South Africa, 2010: 9).  
 
The average age of the population was 70.74±10.37 years, with the oldest patient 
being 100 years. It is important to keep in mind that only patients aged 50 years and 
older were included in the study. The Italian study (Leoni, et al., 2002: 151) included 
a cohort of 130 idiopathic Parkinson’s patients with a mean age of 68.6±9.9 years. 
The males were, on average, slightly older than the female patients. The age range 
was 38 years to 87 years (Leoni, et al., 2002: 151). A French study (Tison, et al., 
1994: 112) included only patients aged 65 years and older with an average age of 
74.9 years. 
 
For all tables and figures, denotation with a single ‘n’ will refer to either the number of 
patients or prescriptions within the sample or the total value in Rands. The age 
distribution according to gender is summarised in Table 5.1 and depicted in Figure 
5.1 according to 10 year intervals.  
 
Table 5.11 Age and gender of patients who were prescribed antiparkinsonian agents 
 
Gender Average Age ± SD Oldest patient(s) 
Female 70.37±10.66 years 100 years 
Male 71.17±9.88 years 95 years 
Both genders 70.74±10.37 years 100 years 
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Figure 5.1 Age and gender distribution of patients who were prescribed 
antiparkinsonian agents 
 
 
 
Figure 5.1 demonstrates that the highest prevalence of Parkinson’s disease was in 
the age category of 70 years to 79 years for both males and females. The reason for 
the decrease beyond this age could be due to mortality, or the general low life 
expectancy in South Africa, which is shown to be 53.3 years for males and 55.2 
years for females (Statistics South Africa, 2010: 3). Also, in South Africa, only 0.71% 
of the population is over the age of 80 years (Statistics South Africa, 2010: 9). A 
Spanish study showed that the prevalence of Parkinson’s disease increased with 
age, but decreased beyond the ages of 80 years for men and 85 years for women 
(Benito-León, et al., 2003: 269) which was in keeping with the results of the current 
study. 
 
5.3 Overview of antiparkinsonian drug prescriptions 
 
All antiparkinsonian drug prescriptions for the patient population selected across 
South Africa are represented in this section. Details such as the regional distribution 
of prescriptions across predefined areas of the country, the number of times the 
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prescription may be repeated, the drug classes identified and the sub-classes 
thereof are discussed. 
 
5.3.1 Antiparkinsonian products dispensed 
 
A total of 5 168 patients were dispensed 25 523 antiparkinsonian products 
throughout the year. This amounts to an average of 4.94±10.42 products per patient, 
indicating that patients were on combination therapies. The majority of these 
products were dispensed to females (54.05%). The age and gender distribution of 
patients is summarised in Figure 5.2. 
 
Figure 5.2 Percentage of antiparkinsonian products dispensed by age and gender  
 
 
 
Looking at the products dispensed according to age groups, it was seen that the 
majority of the products were dispensed to patients between the ages of 70 years to 
79 years for both genders. This age group constituted a total of 32.28% of the total 
study population and they were prescribed 35% of all antiparkinsonian products.  
Table 5.2 shows the average number of prescriptions received by gender and age. 
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Table 5.12 Average number of prescriptions received by gender and age  
 
Age categories Female Male 
50-59 years 3.44±2.70 4.10±4.34 
60-69 years 4.46±2.56 5.92±6.94 
70-79 years 4.99±3.92 5.78±3.63 
80-89 years 5.24±7.41 5.81±8.82 
≥90 years 4.27±5.82 5.58±5.70 
 
As can be seen, the average number of prescriptions for males was higher than 
females in each age category by at least one. The highest average number of 
prescriptions for females was in the age category 80 years to 89 years and for males 
this was 60 years to 69 years. This could mean that males could have experienced 
more severe disease than females. It was also seen that a total of 81.67% of 
prescriptions were repeats. 
 
According to the ATC (Anatomical-Therapeutic-Chemical) nomenclature, 
antiparkinsonian agents are N04 as a group and then further divided according to the 
various chemical groups. Figure 5.3 indicates the frequency of antiparkinsonian 
product prescribing, Figure 5.4 indicates the frequency of antiparkinsonian product 
prescribing according to gender and Table 5.3 summarises all the antiparkinsonian 
products dispensed in terms of chemical subgroups, tradenames and active 
ingredients.  
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Figure 5.3 Frequency of antiparkinsonian products dispensed according to active 
ingredients 
 
 
 
Figure 5.4 Frequency of antiparkinsonian active ingredients according to gender 
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Table 5.13 Antiparkinsonian products dispensed 
 
Chemical subgroup Chemical substance Tradename/s* 
 
Total 
Number % 
Dopa and dopa 
derivatives 
(N04BA) 
Levodopa in combination 
with a dopamine 
decarboxylase inhibitor such 
as carbidopa or benserazide 
Sinemet
®
 
Carbilev
® 
 
Tevo
® 
 carbidopa/levodopa 
levodopa/carbidopa 
 
Madopar
® 
levodopa/benserazide 
4 201 
6 385 
14 
 
 
 
728 
16.46%2 
5.01% 
0.05% 
 
 
 
2.86% 
 
Levodopa in combination 
with a dopamine 
decarboxylase inhibitor and 
COMT-inhibitor 
Stalevo
®
 
 
547 2.14% 
Dopamine agonists  
(N04BC) 
Ropinirole 
 
 
Pramipexole 
 
Reqip
®
 
Requip
® 
 XL 
 
Pexola
®
 
941 
941 
 
8 282 
3.70% 
3.69% 
 
32.44% 
MAO-B inhibitors  
(N04BD) 
Selegiline Parkilyne
®
 
Eldepryl
®
 
522 
20 
2.05% 
0.08% 
COMT-inhibitors 
(N04BX) 
Entacapone 
Tolcapone 
Comtan
®
 
Tasmar
®
 
120 
12 
0.47% 
0.05% 
Anticholinergic 
agents 
(N04A) 
Biperidin 
Orphenadrine 
Akineton
®
 
Disipal
®
 
1 409 
0 
5.53% 
0.00% 
Anticholinergic 
agents 
(N04A) 
Biperidin 
Orphenadrine 
Akineton
®
 
Disipal
®
 
1 409 
0 
5.53% 
0.00% 
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It was seen that the majority of antiparkinsonian products dispensed (46.5%) were 
combination drugs containing levodopa with a decarboxylase inhibitor and some with 
a COMT-inhibitor as well. Adding the values of these agents showed that a total of 
11 875 products dispensed contained levodopa. This was expected as levodopa is 
considered the gold standard treatment of Parkinson’s disease (Garret, et al., 1998: 
99; Stern, 2001: 27; Singh, et al., 2007: 30). The second most dispensed group of 
drugs were the dopamine agonists which include pramipexole and ropinirole. These 
made up a total of 10 164 of the products dispensed (39.80%). The levodopa-
containing products and dopamine agonists are both classified as dopaminergics. 
These were followed by the anticholinergic agents benzhexol and orphenadrine 
making up 2 352 of the total number of products dispensed (9.20%). The MAO-B 
inhibitor selegiline and the anti-viral agent amantadine only made up 2.12% and 
1.80% of the total products dispensed, respectively. These results are in keeping 
with other studies conducted (Leoni, et al., 2002: 149-157; Tan, et al., 2012: 511-
514). When examining the frequency of antiparkinsonian product prescribing by 
gender, it was seen that males were prescribed the levodopa-containing products 
whereas females were preferably prescribed the dopamine agonist pramipexole.  
 
The drug utilisation 90% (DU90%) represents the prescribed drugs which account for 
90% of the volume (Bergman, Popa, Tomson, Wettermark, Einarson, Åberg and 
Sjöqvist, 1998: 115). When calculating the DU90% it was seen that 22 970.70 
prescriptions would account for 90% of the total (n = 25 523). Figure 5.5 indicates 
the active ingredients identified by in order of prescribing frequency. 
 
The levodopa-containing products, dopamine agonists, pramipexole and ropinirole, 
as well as the anticholinergic agent biperidine, constitute 90% of the overall drug 
prescribing for Parkinson’s disease. As there are no definitive guidelines for the 
management and treatment of Parkinson’s disease, there can be no comparison. 
However, as levodopa is considered the gold standard of Parkinson’s disease 
treatment and is therefore expected to constitute a large proportion of the overall 
prescriptions.  
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Figure 5.5 Active ingredients of antiparkinsonian products ranked according to 
prescribing frequency  
 
 
  
The products bromocriptine, a dopamine agonist, trihexyphenidyl, an anticholinergic 
agent, and rasagiline, a monoamine oxidase B inhibitor are products recognised for 
the treatment of Parkinson’s disease in South Africa according to the SAMF (ed. 
Rossiter, 2012: 458, 462, 464) but were not prescribed throughout the year 2010. 
Bromocriptine is not the choice of dopamine agonist in the private sector as the 
neurologists and patients have access to both pramipexole and ropinirole. 
Bromocriptine is instead used for cessation of lactation. A guideline for the treatment 
of Parkinson’s disease published by the Scottish Intercollegiate Guidelines Network 
(2010: 19) does not recommend the use of ergot derived dopamine agonists such as 
bromocriptine for the first line treatment of Parkinson’s disease due to the risk of 
developing moderate to severe cardiac valvulopathy. According to the SAMF (ed. 
Rossiter, 2012: 458) trihexyphenidyl is a drug more commonly found in the public 
sector. The population analysed was private sector and would therefore not utilise 
this product. Rasagiline was launched recently in 2009 in South Africa with a retail 
price of R1 024.38 which would deter many patients from opting to use it. The 
following Table 5.4 represents the average age and standard deviation for patients 
grouped according to the prescribed drug. Age calculations were then further 
investigated through the isolation of male and female patients for each drug.  
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Table 5.4 Average ages of patients prescribed antiparkinsonian products 
 
 
Average 
age ±SD 
in years 
Active ingredients 
Amantadine Biperidine Entacapone Levodopa-
containing 
products 
Orphenadrine Pramipexole Ropinirole Selegiline Tolcapone 
Average 
patient 
age ±SD 
(both 
genders) 
68.07±0.00 
 
67.94±1.27 67.05±0.00 73.69±2.04 66.68±0.00 68.47±1.06 69.18±3.15 71.21±0.27  69.00±0.00 
Age range 
(in years) 
51-86 50-96 55-82 50-100 50-90 50-99 50-100 50-98 69 
Female 
patient 
average 
age ±SD 
(in years) 
68.87±0.00 67.53±3.16  66.68±0.00 73.69±2.42 67.07±0.00 67.27±0.24 69.15±3.89 70.93±1.08 None 
Male 
patient 
average 
age ±SD 
(in years) 
67.50±0.00 70.15±5.32 67.26±0.00 73.04±3.04 66.00±0.00 69.54±1.81 69.08±3.33 71.19±1.05 69.00±0.00 
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The levodopa-containing products were used by patients across the entire age range 
investigated. This was the case for almost all products with the exception of 
amantadine, entacapone and tolcapone. The average age of both males and 
females did not differ greatly amongst the products which showed that there were no 
preferred products for particular age groups. 
 
5.3.2 Area distribution of prescriptions 
 
The areas provided represented South Africa in seven predefined regions of the 
country. These regions include ‘Central Division’, ‘Eastern Cape’, ‘Free State 
Division’, ‘Kwa-Zulu Natal’, ‘Mpumalanga’, ‘Northern Division’, ‘North West Province 
Division’ and ‘Western Cape’. The ‘Central Division’ was made up of Gauteng and 
the ‘Northern Division’ represented the Northern Cape and Limpopo Province. The 
prescription distribution through the areas is demonstrated in Table 5.5. 
 
The average number of prescriptions per region was 3190.38±1 106.44 over the 
period of one year. The large standard deviation is due to patients travelling 
throughout the year and obtaining medication in different regions. The Western Cape 
held the highest proportion of prescriptions, 5 799±6.99 (22.72%) even though it did 
not possess the largest population in the country. The rest of the regions were 
similar in number of prescriptions. Gauteng houses the largest proportion of the 
country’s population, but had the third lowest proportion of prescriptions. Possible 
reasons for this distribution may be that the Western Cape has the largest number of 
the particular community pharmacy group in the country, other regions possessed 
larger rural areas without access to community pharmacies, or that the Western 
Cape holds a higher percentage of retired persons with access to medical aid. The 
Western Cape had the highest average number of prescriptions at 377.82±0.90 over 
the year. The regional distribution of patients is shown in Figure 5.6 below. 
 
 
 
 
 
72 
 
Table 5.5 Distribution of antiparkinsonian prescriptions per region 
 
Area Prescriptions Estimated South 
African population 
≥50 years 
percentage*  
Number % 
Gauteng 2 716 10.64% 3.62% 
Eastern Cape 3 064 12.00% 2.09% 
Free State 3 331 13.05% 0.90% 
Kwa-Zulu Natal  2 900 11.36% 1.64% 
Mpumalanga 2 292 8.98% 0.93% 
North West Province 2 986 11.70% 0.39% 
Northern Cape and Limpopo 2 435 9.54% 2.38% 
Western Cape 5 799 22.72% 1.79% 
Total 25 523 100.00%  
(*Source = Statistics South Africa, 2010: 14) 
 
Figure 5.6 Regional distribution of patients 
 
  
11.13% 
11.01% 
13.60% 
11.71% 
9.79% 
13.43% 
10.78% 
19.99% 
npatients = 5 168 
Gauteng
Eastern Cape
Free State
Kwa-Zulu Natal
Mpumalanga
Northern Cape and Limpopo
North West Province
Western Cape
73 
 
There were patients who had travelled throughout the year and obtained 
prescriptions in other regions. Figure 5.7 therefore, provides an approximation of the 
number of patients in each region.  
 
Figure 5.7 Frequency of dopaminergic prescriptions per region 
 
  
 
The average number of prescriptions for levodopa-containing products per region 
was 1 484.38±687.96 and the average number of dopamine agonist prescriptions 
was 1 270.50±313.21. The Western Cape held the highest volume of both levodopa-
containing products and dopamine agonists in terms of the total number of 
prescriptions as well as the overall volume of antiparkinsonian products dispensed. 
The total was 3 558 higher than the average and constituted 86.95% of the total 
antiparkinsonian prescriptions for the region. The Western Cape was followed by the 
Free State (n = 2 865) and the Eastern Cape (n = 2 824). This follows the pattern of 
the overall prescription distribution across South Africa which demonstrates the 
dominance of these two drug groups in prescribing. 
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5.3.3 Annual distribution of antiparkinsonian prescriptions 
 
The annual distribution of antiparkinsonian prescriptions provided information 
regarding the initial diagnosis and treatment and alteration of drug therapy. Figure 
5.8 illustrates the number of antiparkinsonian prescriptions dispensed per month and 
Figure 5.9 illustrates the patient distribution throughout the year. 
 
Figure 5.8 Number of antiparkinsonian products dispensed per calendar month 
 
 
 
The monthly dispensing of products remained largely unchanged throughout the 
year. This could indicate that patients were compliant in taking their medication. 
There was an increase from February to April and another gradual increase from 
September to December. The average number of prescriptions dispensed for the 
year was 72.86±58.07 which amounts to 6.07 products per month. Figure 5.9 below 
shows the number of patients per calendar month.  
 
Figure 5.9 clearly demonstrates that there were more female than male patients for 
each month. The month of December held the highest number of patients (n = 
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transferred their prescriptions from other pharmacies or pharmacy groups to the one 
under consideration in this study. The average number of prescriptions dispensed 
each month by gender are summarised below in Table 5.6. 
 
Figure 5.9 Number of patients receiving antiparkinsonian products per calendar 
month 
 
 
 
Table 5.6 Average number of prescriptions dispensed per month for the year 2010 
 
Months 
Average number of prescriptions ±SD 
Female Male 
January 1.23±0.56 1.37±0.81 
February 1.21±0.55 1.39±0.79 
March 1.21±0.55 1.38±0.76 
April 1.21±0.53 1.33±0.70 
May 1.23±0.57 1.35±0.66 
June 1.21±0.55 1.34±0.73 
July 1.21±0.57 1.34±0.70 
August 1.22±0.56 1.33±0.65 
September 1.22±0.57 1.34±0.67 
October 1.23±0.61 1.36±0.69 
November 1.22±0.57 1.37±0.72 
December 1.22±0.57 1.38±0.73 
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The above table indicates that males had a higher average number of prescriptions 
than females for each month. For females, the average number seemed to remain 
stable throughout the year ranging from 1.21 to 1.23 prescriptions per patient per 
month. For males, the range was 1.33 to 1.39 prescriptions per patient per month.  
 
5.3.4 Dopaminergic prescribing 
 
Figures 5.10 and 5.11 below indicate the number of prescriptions of levodopa-
containing products and dopamine agonists prescribed per month over the year. 
 
Figure 5.10 Individual number of prescriptions of levodopa-containing products 
dispensed per month 
 
 
 
The total number of prescriptions for levodopa-containing products throughout the 
year indicated an increase from March to April and then remained fairly constant for 
the rest of the year. The trendline showed that there was an overall increase in the 
number of prescriptions throughout the year.  
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Figure 5.11 Individual number of prescriptions of dopamine agonists dispensed per 
month 
 
 
 
If these curves are compared to the total annual distribution for all antiparkinsonian 
drugs to those for individual drug groups, the pattern shows to be similar as these 
two groups were dominant. The number of dopamine agonist prescriptions did not 
vary greatly over the year; there was a slight increase from February to March and 
again from October to November, but with a constant range of 700 to 900 
prescriptions per month throughout the year. Figures 5.12 to 5.15 show the 
distribution of levodopa-containing products and dopamine agonists as a function of 
age.  
 
Figure 5.12 Annual distribution of levodopa-containing product prescriptions per 
month for patients between 50 and 69 years of age 
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The age group 60 to 69 years held the higher proportion of prescriptions (n = 2 988). 
This group also constituted a higher proportion of the overall study population as 
compared to the age group 50 to 59 years. Also, patients aged 60 years or older 
may have had more severe symptoms than those in the 50 year age group and 
required higher doses to provide symptom relief. There was an overall increase in 
the number of prescriptions in the 60 year age group (n = 89). Patients in the 50 to 
59 years age group may have been recently diagnosed and were presenting with 
mild symptoms therefore not requiring high doses of levodopa. The age group 60 to 
69 years demonstrated an increase in the month of April then remained fairly 
constant for the rest of the year with the exception of a slight increase in October. 
The 50 year age group demonstrated a much more gradual increase throughout the 
year with an overall increase of only 31 prescriptions.  
 
Figure 5.13 Annual distribution of levodopa-containing product prescriptions per 
month for patients aged 70 years and older 
 
 
 
The age group 70 to 79 years held the highest number of prescriptions (n = 4 748). 
This group also constituted the largest proportion of the overall patient population. 
There is a sharp increase in the number of prescriptions from March to April and 
continues to increase throughout the year. The age group 60 to 69 years held the 
second highest proportion of prescriptions (n = 2 988) closely followed by the age 
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group 80 to 89 years (n = 2 938). This group also demonstrated an increase in the 
month of April and then remained fairly constant for the rest of the year. The age 
group 90 years and older demonstrated the lowest number of prescriptions as they 
constituted the lowest proportion of the overall population. There was an overall 
decrease in the number of prescriptions throughout the year which could be due to 
mortality in this group. 
 
When calculating the prescribed daily dose (PDD) of levodopa-containing products it 
was found that the majority of patients (n = 2 056) were receiving 300mg daily which 
is half the DDD for levodopa. There were 1 659 patients receiving 200mg of 
levodopa daily and 1 207 patients receiving 400mg as a total daily dose. Only 994 
patients were receiving the 600mg DDD. The overall average PDD of levodopa was 
calculated to be 1 183.01mg±3 809.31mg daily. This indicates the vast range of 
PDDs seen in the study population. The lowest PDD was found to be 3.33mg (n = 4) 
of levodopa while the largest PDD was seen to be 45 000mg (n = 2) of levodopa in 
the population.  There were 84 patients receiving 2 000mg of levodopa and more on 
a daily basis and 8 155 patients receiving daily doses of levodopa lower than 600mg. 
This shows that patients were receiving lower doses of levodopa than the stipulated 
DDD. This could mean that doctors in South Africa prefer prescribing lower doses of 
levodopa or that majority of patients in the population were not experiencing severe 
symptoms or were in the earlier stages of the disease. 
 
Figure 5.14 shows that the dopamine agonists pramipexole and ropinirole were 
prescribed more frequently in the younger patient categories. The age group 60 to 
69 years held the highest number of prescriptions (n = 3 277) and demonstrated an 
increase in the number of prescriptions throughout the year. This is in keeping with 
another study which stated that patients with early disease may be given dopamine 
agonists to delay the onset of levodopa therapy (Singh, et al., 2007: 33). Patients 
between the ages of 50 and 69 years may have been recently diagnosed or are still 
in the early stages of the disease. Dopamine agonists may be used as initial therapy 
to provide relief of milder symptoms. When comparing this to the levodopa-
containing products, it was seen that the 50 year age group received more dopamine 
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agonists (n = 2 169) than levodopa-containing products (n = 870) throughout the 
year. 
 
Figure 5.14 Annual distribution of dopamine agonist prescriptions per month for 
patients between 50 and 69 years of age 
 
 
 
Figure 5.15 Annual distribution of dopamine agonist prescriptions per month for 
patients aged 70 years and older 
 
 
 
Upon comparison, all three of the age groups shown in Figure 5.15 received more 
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greater symptom relief provided by levodopa as compared to pramipexole or 
ropinirole. Patients between the ages of 70 to 79 years received the highest number 
of dopamine agonists (n = 3 211). These patients received the largest proportion of 
antiparkinsonian prescriptions overall (n = 35%). This group may be experiencing 
more severe symptoms compared to the younger groups and require combination 
therapy for symptomatic relief. Mortality may be the reason for the decrease in 
patient numbers in the older age groups.  
 
When calculating the PDD of pramipexole, the average was seen to be 
1.21mg±1.82mg. The highest PDD was 12mg (n = 3) and the lowest was 0.0042mg 
(n = 2). The low PDDs were not repeat prescriptions. The high ODDs, however, were 
repeat prescriptions. The most commonly prescribed PDD for pramipexole was 
0.125mg (n = 2 861), the second most common 0.25mg (n = 2 088) and the third 
most common PDD was 0.5mg (n = 639). Only 22 patients were receiving 2.5mg 
which is the DDD for pramipexole. Looking at the average, it can be seen that most 
patients (n = 7 859) were receiving lower doses than the DDD.      
 
For ropinirole, the average PDD was seen to be 5.98mg±8.77mg. The majority of 
patients (n = 239) were receiving 3.73mg of ropinirole daily which is almost half that 
of the recommended WHO DDD. The second most commonly prescribed PDD was 
7.47mg (n = 216) and the third, 1.87mg (n = 138). The lowest PDD was 0.05mg (n = 
1) and the highest PDD was found to be 59.73mg (n = 1). The low PDD was not a 
repeat prescription and was the only prescription recorded for the patient throughout 
the year. The high PDDS were repeated prescriptions and patients were receiving 
them on a chronic basis. A total of 1 358 patients were receiving doses lower than 
the DDD of 6mg. 
  
5.3.5 Combined dopaminergic prescribing 
 
Dopaminergic products include levodopa-containing products and dopamine 
agonists. It was shown that 3 295 patients received a levodopa-containing product 
throughout the year while 3 166 patients received a dopamine agonist. This indicates 
that patients were prescribed combination therapies. Figure 5.16 shows the regional 
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distribution of prescriptions of patients receiving a combination of these 
dopaminergic products. 
 
Figure 5.16 Regional distribution of patients receiving dopaminergic prescriptions 
 
 
 
5.4 Cost of antiparkinsonian medication 
 
The total sales value of antiparkinsonian products for the year 2010 was  
R8 500 496.49. The total sales value includes patient as well as medical aid 
payments. Figure 5.17 indicates the total sales value by gender and Figure 5.18 
indicates the percentage of spending by age category. 
 
Figure 5.17 shows that although there were more females than males in the total 
population, more spending was attributed to male patients (55.46%), but females 
were dispensed more products throughout the year (54.04%). A reason for this could 
be that males experience more severe disease or side effects and therefore require 
more symptomatic treatment, or are more open about verbalising problems and 
concerns to medical practitioners.  
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Figure 5.17 Distribution of patient spending according to gender 
 
 
 
Figure 5.18 Percentage sales value of antiparkinsonian products according to age 
and gender 
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patients (32.27%) and received the highest number of products (35.00%). Patients in 
this age group are most likely to be in the more severe stages of the disease and 
therefore require higher doses and more supplementation in an attempt to effectively 
control symptoms of the disease and the side effects of the medications.  
The two individual products with the highest sales values were levodopa/carbidopa 
(45.67%) and pramipexole respectively (25.63%). Levodopa/carbidopa 100mg 
showed to be the product with the highest sales volume (number of prescriptions 
identified) (38.59%). The class of products with the highest percentage sales value 
were the dopamine replacement therapies containing levodopa, followed by the 
dopamine agonists pramipexole and ropinirole. The drug cost 90% (DC90%) 
indicates which products constituted 90% of the total cost of antiparkinsonian 
medication. Figure 5.20 shows the active ingredients identified ranked according to 
decreasing sales value. 
 
Figure 5.19 Percentage spending on antiparkinsonian active ingredients according to 
gender 
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Figure 5.20 Active ingredients ranked according to decreasing sales value 
 
 
 
The DC90% of the total cost of antiparkinsonian products for the year was calculated 
to be R7 650 446.84. The products which constituted the DC90% include the 
levodopa-containing products and the dopamine agonists pramipexole and 
ropinirole. When comparing this to the DU90%, it can be seen that fewer products 
constitute the DC90%. This could be due to the cost of the individual products.  
 
5.4.1 Levodopa-containing products 
 
Given that levodopa-containing agents are available in different strengths and 
combination formulas, the following section outlines the sales volume, the total sales 
value per item and the average cost per unit, where the unit is a tablet or capsule. 
The cost per unit may have varied throughout the year due to the increasing cost of 
medicines, the different prices set by medical aid schemes, the number of units 
dispensed and the pack size of the product selected.  
 
5.4.1.1 Levodopa/carbidopa 
 
This section focuses on the sales volume and value of levodopa/carbidopa 
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implemented in 2004 which regulated the maximum annual price increase without 
any allowance for discounts on medication. (Pretorius, 2011: 2; National Drug Policy 
for South Africa, 1996: 9). The aim of the SEP was to make medication more 
accessible to patients due to reduced prices. (Pretorius, 2011: 2). Figures 5.21 to 
5.24 provide information for all levodopa-containing antiparkinsonian products and 
Tables 5.7 and 5.8 indicate the average cost of the levodopa-containing products. 
 
Figure 5.21 Percentage sales volumes for individual levodopa/carbidopa 
antiparkinsonian tradename product strengths 
 
 
 
The highest sales volume for a formulation of levodopa/carbidopa was Carbilev® 
25/100mg tablets (44.94%), followed by Sinemet® 25/100mg tablets (20.91%) and 
Carbilev® 25/250mg tablets (15.28%). It follows that the highest sales value was 
Carbilev® 25/100mg (43.89%), with the second being Carbilev® 25/250mg (19.20%) 
and the third Sinemet® 25/100mg (18.79%). This could be due to the fact that the 
average price per unit of Carbilev® 25/250mg was R494.20 as opposed to Sinemet® 
25/100mg which was R348.66. Sinemet® CR 50/200mg has the fourth highest sales 
value. The total sales for Carbilev® as a tradename amounted to R2 448 829.10, 
whereas the Sinemet® total was R1 428 085.13, a difference of R1 020 743.97 which 
is 41.68% less than Carbilev®. Carbilev® 25/100mg had the highest cumulative sales 
value for the Carbilev® brand and Sinemet® 25/100mg for the Sinemet® brand. This 
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showed that doctors preferred prescribing the lower dose of the levodopa/carbidopa 
combination. Sinemet® CR 50/200mg is the only controlled release preparation of 
levodopa/carbidopa and had the third highest sales volume with the fourth highest 
cumulative sales value. The Madopar® brand is the only levodopa/benserazide 
combination. Madopar® 250mg tablets and Madopar® HBS (hydrodynamically 
balanced system) capsules which is a slow release preparation, are the only two 
products in the Madopar® brand. Together these two products made up a sales 
value of R344 024.46 with Madopar® 250mg tablets having the higher sales volume 
(n = 619; 85.03%) and value (n = R275 679.68; 80.13%). Madopar® is not the first 
choice of levodopa preparations. If the patient is not experiencing sufficient 
symptomatic relief, Madopar® is the alternative choice.  
 
Table 5.7 Average cost per pack for all levodopa/carbidopa preparations according 
to tradenames 
 
Tradename Average cost per pack Single exit price* 
Carbilev® 25/100mg tablets R354.32 R356.14 
Carbilev® 25/250mg tablets R494.20 R505.81 
Sinemet® 25/100mg tablets R348.66 R364.36 
Sinemet® 25/250mg tablets R463.84 R498.33 
Sinemet® CR 50/200mg 
tablets 
R505.91 R523.78 
Teva® Carbi-Levo 25/100mg 
tablets 
R334.73 Unavailable 
Teva® Carbi-Levo 25/250mg 
tablets 
R445.44 Unavailable 
(*Source: ed. Snyman, 2010: 1.7.1 – 42) 
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Figure 5.22 Percentage sales value of levodopa/carbidopa containing 
antiparkinsonian tradename products 
  
 
 
5.4.1.2 Levodopa/carbidopa/entacapone 
 
Levodopa in combination with the COMT-inhibitor enatacapone allows for lower 
doses of levodopa due to the decreased metabolism by entacapone. Figures 5.23 
and 5.24 indicate the sales volume and percentage sales value of the 
levodopa/carbidopa/entacapone combination product while Table 5.8 indicates the 
cost per unit and single exit prices of this product.  
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Figure 5.23 Sales volume of levodopa/carbidopa/entacapone containing 
antiparkinsonian tradename products 
 
 
 
Table 5.8 Average cost per unit for all levodopa/carbidopa/entacapone strengths 
according to tradenames 
 
Strength Average cost per unit Single exit price* 
Stalevo®  50/12.5mg FC 
tablets 
R896.09 R1 039.48 
Stalevo® 100/25mg FC 
tablets 
R914.31 R1 039.48 
Stalevo® 150/37.5mg FC 
tablets 
R914.17 R1 039.48 
(*Source: ed. Snyman, 2010: 1.7.1 – 43) 
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Figure 5.24 Percentage sales values for levodopa/carbidopa/entacapone containing 
antiparkinsonian tradename products 
 
 
 
For the Stalevo® brand, the highest sales volume (n = 273) and cumulative sales 
value (n = R308 028.66) is Stalevo® 150/37.5/200mg FC (film coated) tablet.  
 
5.4.2 Dopamine agonists 
 
The following section focuses on the sales volume and value of the dopamine 
agonists pramipexole and ropinirole. This group showed the second highest 
prescribing frequency.  
 
5.4.2.1 Pramipexole 
 
The following Figures 5.25 and 5.26 show the sales volume and percentage sales 
value of these products. Table 5.9 shows the cost per unit and corresponding single 
exit prices of these products. 
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Figure 5.25 Sales volume of pramipexole containing antiparkinsonian tradename 
products 
 
  
 
Table 5.9 Average cost per unit for all pramipexole tradename strengths 
 
Strength Average cost per unit Single exit price*  
Pexola® 0.125mg 
tablets 100 
R313.29 R298.36 
Pexola® 0.25mg tablets 
100 
R554.36 R591.99 
Pexola® 1mg tablets 
100 
R1 028.06 R1 117.37 
(*Source: ed. Snyman, 2010: 1.7.1 – 43) 
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Figure 5.26 Percentage sales value of pramipexole containing antiparkinsonian 
tradename products 
 
 
 
Although Pexola® 0.125mg had the highest sales volume, Pexola® 0.25mg had the 
highest cumulative sales value. This is due to the cost per unit. The price increases 
dramatically with increasing strength of the formulation. 
 
5.4.2.2 Ropinirole 
 
The following Figures 5.27 and 5.28 show the sales volume and percentage sales 
value of these products. Table 5.10 shows the cost per unit and corresponding single 
exit prices of these products. 
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Figure 5.27 Percentage sales volume of ropinirole containing antiparkinsonian 
tradename products 
 
 
 
Table 5.140 Average cost per unit for all ropinirole tradename strengths 
 
Strength Average cost per unit Single exit price* 
Requip® 0.25mg tablets 210 R272.07 Unavailable 
Requip® 0.25mg tablets 84 R115.38 R110.64 
Requip® 0.5mg tablets 84 R204.23 R205.26 
Requip® 1mg tablets 84 R255.62  R271.15 
Requip® 2mg tablets 84 R471.98 R522.15 
Requip® 5mg tablets 84 R759.09 R834.77 
Requip® XL 2mg starter pack 
tablets 42 
R298.13 R326.54 
Requip® XL 2mg tablets 28 R208.50 R217.57 
Requip® XL 4mg tablets 28 R263.34 R278.02 
Requip® XL 8mg tablets 28 R444.07 R495.72 
(*Source: ed. Snyman, 2010: 1.7.1 – 43) 
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Figure 5.28 Percentage sales value of ropinirole containing antiparkinsonian 
tradename products 
 
 
 
Of the immediate release formulations, Requip® 1mg tablets had the highest sales 
volume, but Requip® 2mg tablets had the highest cumulative sales value. This is due 
to the higher average cost price per unit of Requip® 2mg which was R603.20 
compared to that of Requip® 1mg which was R283.98. Looking at the extended 
release formulations, Requip® XL 8mg tablets had the highest cumulative sales 
value, but was only marginally higher in sales volume than Requip® XL 4mg tablets. 
 
5.5 Summary of major findings 
 
The major findings of the DUR were as follows: 
 
 There were more females (59.17%) than males; 
 The average number of prescriptions for the year was higher for males 
(5.55±6.88) than females (4.51±5.44); 
 The highest prevalence of Parkinson’s disease was in the age group 70 years 
to 79 years for both genders (32.28%); this group also received the highest 
number of products (35%) throughout the year; 
3.09% 
4.84% 
11.93% 
15.92% 
5.12% 2.24% 
9.80% 
15.10% 
31.96% 56.86% 
nR = R685 586.40 
 Requip® 0.25mg Tablets
Requip® 0.5mg Tablets
Requip® 1mg Tablets
Requip® 2mg Tablets
Requip® 5mg Tablets
Requip® XL 2mg Starter Pack
Requip® XL 2mg Tablets
Requip® XL 4mg Tablets
Requip® XL 8mg Tablets
95 
 
 An average of 4.94 products were dispensed to each patient throughout the 
year; 
 The majority of products were dispensed to females (54.05%); 
 The majority of antiparkinsonian products dispensed (46.5%) were 
combination drugs containing levodopa; 
 The second most dispensed group of drugs were the dopamine agonists 
(39.80%);  
 Levodopa-containing products, dopamine agonists, pramipexole and 
ropinirole, as well as the anticholinergic agent biperidine constituted the 
DU90%;  
 Males were prescribed the levodopa-containing products whereas females 
were preferably prescribed the dopamine agonist pramipexole; 
 The Western Cape held the highest volume of both levodopa-containing 
products and dopamine agonists in terms of the total number of prescriptions 
as well as the overall volume of antiparkinsonian products dispensed (3 558 ; 
86.95%); 
 There was an overall increase in the number of levodopa-containing product 
prescriptions throughout the year; 
 The age group 70 to 79 years held the highest number of levodopa-containing 
product prescriptions (n = 4 748); 
 The number of dopamine agonist prescriptions did not vary greatly over the 
year; 
 The dopamine agonists pramipexole and ropinirole were prescribed more 
frequently in the younger patient categories; 
 The most commonly PDD of levodopa was found to be 300mg with the 
average being 1 183.01mg±3 809.31mg daily; 
 The most commonly PDD of pramipexole was found to be 0.125mg with the 
average being 1.21mg±1.82mg; 
 The most commonly PDD of ropinirole was 3.73mg with the average being 
6.00mg±8.77mg; 
 Patients aged 70 years and older received more levodopa-containing 
products than dopamine agonists; 
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 There were 3 295 patients who received a levodopa-containing product 
throughout the year while 3 166 patients received a dopamine agonist; this 
indicates that patients were prescribed combination therapies; 
 The total sales value of antiparkinsonian products for the year was R 
8 500 496.49; 
 More spending was attributed to male patients (55.46%); 
 The majority (38.85%) of the cost was attributed to the age group 70 to 79 
years;  
 The products which constituted the DC90% include the levodopa-containing 
products and the dopamine agonists pramipexole and ropinirole; 
 The two individual products with the highest sales values were 
levodopa/carbidopa (45.67%) and pramipexole (25.63%); 
 The highest sales volume for a formulation of levodopa/carbidopa was 
Carbilev® 25/100mg tablets (44.94%); 
 The individual tradename product with the highest sales value was Carbilev® 
25/100mg (43.89%); and 
 The total sales for Carbilev® as a tradename amounted to R24 488 29.10, 
whereas Sinemet® totalled at 41.68% less than Carbilev®. 
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CHAPTER 6 
Results and Discussion of 
Questionnaire Survey 
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6.1 Introduction 
 
The results of both the patient questionnaires and the review of medical records will 
be discussed in this chapter. The patient questionnaires will be discussed in Section 
6.2. The results of the medical record reviews will be discussed in Section 6.3 and 
divided into eight subsections for each section of the questionnaire.  
  
6.2 Patient questionnaires 
 
A total of 43 completed questionnaires were analysed. Although the weight of the 
patient was requested in the questionnaire, not enough patients were able to provide 
this information to allow for meaningful analysis. The levodopa dose per kilogram 
weight was therefore not taken into account when considering the risk factors 
involved in causing dyskinesias. 
 
6.2.1 Demographics 
 
A total of 23 males (53.49%) were interviewed. It has been seen that there is an 
approximately 1.5 times higher risk of Parkinson’s disease for men than women 
(Burn, 2007: 78; Fargel, et al., 2007: 208; Miller and Cronin-Golomb, 2010: 2695). 
This study reported that Parkinson’s disease is more common in males than females 
with an approximate ratio of 1.15. Figure 6.1 demonstrates the ethnic distribution of 
patients. 
 
The majority of participants were coloured (n = 22; 51.16%) with the second highest 
ethnic group being white (n = 16; 37.21%). The coloured patients were identified in 
the public sector while the white group was made up mostly of private sector patients 
(68.75%). One patient was listed as ‘Other’ as the patient was both Indian and 
coloured. Further investigation is warranted in terms of the demographical 
distribution as these results may not be accurate representation of the ethnic division 
of Parkinson’s disease in the South African population. 
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Figure 6.1 Distribution of patients according to ethnic group  
 
 
 
14 patients were aged between 71 to 75 years (32.56%) and constituted the largest 
age group overall. The age group 66 to 70 years constituted the second largest 
group with seven patients identified (16.28%). The male patients were also found to 
be older than the females. Of the 23 male patients, 73.91% were aged 66 years or 
older as compared to females where only 11 (55%) of patients were found to be 66 
years or older. Figure 6.2 shows the distribution of patients as a function of gender 
and age. 
 
Figure 6.2 Distribution of patients as a function of gender and age  
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Figure 6.2 demonstrates that males were most prevalent in the age groups 71 to 75 
years and 66 to 70 years. Females were most prevalent in the age group 71 to 75 
years and 50 to 55 years. This shows that females were younger than male patients 
on average. An Italian study included 130 Parkinson’s patients with a mean age of 
68.6±9.9 years (Leoni, et al., 2002: 151). The study also showed that the male 
patients were slightly older than the female patients; which was in keeping with the 
results of this study.  
 
The majority of patients were diagnosed between five and 10 years before the onset 
of the study (n = 15; 34.88%) and 14 were diagnosed more than 10 years before the 
onset of the study (32.56%). Figure 6.3 shows the duration of disease of patients 
between the ages of 50 to 70 years. 
 
Figure 6.3 Disease duration in years of patients between the ages of 50 to 70 years  
 
 
  
There were eight patients up to the age of 70 years diagnosed less than five years 
before the onset of the study.  A total of six patients were diagnosed more than 10 
years before the onset of the study. This means that there were some patients who 
experienced early onset Parkinson’s disease, particularly the patients in the 50 to 55 
years age group. Figure 6.4 shows the disease duration of patients over the age of 
70 years. 
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Figure 6.4 Disease duration in years of patients aged 70 years and older    
 
 
 
Figure 6.4 shows that the older patients were mostly diagnosed more than 10 years 
ago (n = 6). There were very few patients in the older age groups and this was most 
likely due to a higher mortality rate in these age groups.  
 
There were three sites included in the study. Groote Schuur Hospital, Tygerberg 
Hospital in Cape Town and the Parkinson’s disease support group in Port Elizabeth.  
The majority of the patients were from Tygerberg Hospital (n = 22; 51.16%), with the 
support group in Port Elizabeth being the second largest pool of patients (n = 12; 
27.91%). 
 
6.2.2 Therapy 
 
All patients were diagnosed with Parkinson’s disease and on levodopa therapy with 
90.70% (n = 39) of patients reporting levodopa to be the first drug they were 
prescribed for Parkinson’s disease. Most patients (n = 15) were diagnosed between 
five and 10 years ago with 14 patients being diagnosed more than 10 years ago and 
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duration of levodopa therapy, it was found that 14 patients were using levodopa for 
two to four years and 12 were using levodopa for longer than 10 years. A total of 15 
patients were using levodopa for the entire duration of their diagnosis. Figure 6.5 
indicates the strengths of levodopa products used at the time of the study. 
 
Figure 6.5 Strengths of levodopa-containing products used   
 
  
 
The majority of patients were using levodopa/carbidopa 100/25mg. There were five 
patients found to be using a combination of two levodopa-containing products. These 
were a combination of a controlled release and standard release products or a 
higher strength levodopa/carbidopa 250/25mg in combination with a lower strength 
100/25mg. A total of 36 (83.72%) patients were also using other medications such as 
antihypertensives, hypoglycaemic agents, lipid lowering agents and antidepressants, 
which were unrelated to the motor symptoms of Parkinson’s disease. Figure 6.6 
indicates the PDDs of levodopa. 
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Figure 6.6 Prescribed daily doses of levodopa  
 
 
 
It can be seen from Figure 6.6 that the majority of patients were prescribed a daily 
dose of 300mg of levodopa (n = 7; 16.28%). The second largest group of patients 
received 600mg (n = 6; 13.95%) which is the DDD for levodopa. The average PDD 
was 750mg±452mg. There were two patients receiving a PDD of 2 000mg. There 
were 22 patients (51.16%) receiving doses higher than 600mg.  
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Figure 6.7 Prescribed daily doses of levodopa up to 600mg as a function of disease 
duration 
 
 
 
Figure 6.8 Prescribed daily doses of levodopa 700mg and higher as a function of 
disease duration 
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10 years ago. Of these patients, eight were receiving daily doses of 700mg and 
higher of levodopa. Both patients receiving 2 000mg of levodopa were diagnosed 
more than 10 years ago. Of the patients diagnosed between five and 10 years ago (n 
= 15), nine patients (60%) were receiving daily doses of 700mg or higher of 
levodopa. This shows that patients with longer disease duration were receiving 
higher daily doses of levodopa. 
 
6.2.3 Dyskinesias 
 
A positive incidence of dyskinesias was reported by 13 patients (30.23%). There 
were four patients unsure about the incidence while the rest of the 25 patients 
reported no experience of dyskinesias. Of those reporting a positive incidence, 
seven were males and six were females. Table 6.1 below indicates the observed 
frequencies of gender distribution of the patients reporting a positive incidence of 
dyskinesias. Figure 6.9 represents the age groups of patients with dyskinesias. 
 
Table 6.1 Gender distribution of patients reporting a positive incidence of dyskinesias 
 
Gender 
Dyskinesias 
Yes No/Unsure 
Female 6 14 
Male 7 16 
Total 13 30 
 
The table shows that there was no statistically significant difference in gender 
distribution of patients reporting a positive incidence of dyskinesias. The chi-square 
test also yielded a non-significant test result with a p-value of 0.9753.  
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Figure 6.9 Age groups of patients with reported incidence of dyskinesias   
 
 
 
Figure 6.9 shows that the majority of patients presenting with dyskinesias were in the 
age groups 56 to 60 years (n = 4) and 71 to 75 years (n = 4). When looking at this 
proportion in relation to the overall population it was seen that 66.67% of patients 
between the ages of 56 and 60 years developed dyskinesias while 28.57% of 
patients between the ages of 71 to 75 years reported a positive incidence. Previous 
studies found that younger patients tend to experience dyskinesia more frequently 
than older patients. One study (Garret, et al., 1998: 101) reported that the mean age 
of patients who developed dyskinesias was 53.9±6.2 years. This is in accordance 
with a study (Kumar, et al., 2005: 343) which demonstrated that patients between the 
ages of 40 and 49 years and those between the ages of 50 and 59 years presented 
with an incidence of 40% and 53%, respectively whereas patients between 60 and 
69 years, 70 and 79 years and 80 and 89 years had incidences of 26%, 16% and 
14% respectively. When dividing the patients in this study into the age groups used 
by another (Kumar, et al., 2005), it was seen that patients in the age groups 50 to 60 
years, 61 to 70 years and 71 to 80 years demonstrated an incidence of dyskinesias 
of 45.45%, 16.67% and 31.58% respectively. Figure 6.10 indicates the duration of 
illness of the patients indicating a positive incidence of dyskinesias. 
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Figure 6.10 Duration of illness of patients reporting positive incidence of dyskinesias 
  
 
 
Five patients were diagnosed more than 10 years ago (38.46%). Of the total number 
of patients in the study population diagnosed more than 10 years ago (n = 15), the 
proportion reporting a positive incidence of dyskinesias was 35.71%. Five were 
diagnosed between five and 10 years ago (38.46%). Of the 15 patients diagnosed 
between five and 10 years ago, 33.33% (n = 5) reported a positive incidence of 
dyskinesias. A total of three patients were diagnosed less than five years ago 
(23.08%). There was one patient who reported to be unsure about the date of 
diagnosis. Figure 6.11 indicates the subjective severity of the dyskinesias reported 
by patients. Table 6.2 indicates the observed frequencies of dyskinesias according to 
disease duration. 
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Table 6.2 Observed frequencies of dyskinesias in patients according to disease 
duration 
 
Disease duration as from date 
of diagnosis 
Dyskinesias 
Yes No/Unsure 
< 5 years 3 7 
5-10 years 4 11 
11+ years 5 9 
Not sure 1 3 
Total 13 30 
 
Only a very small difference was seen in dyskinesia frequency. The chi-square test 
yielded a non-significant result with a p-value of 0.9519.  
 
Figure 6.11 Severity of dyskinesias as reported by patients 
 
 
 
The dyskinesias were not considered disabling by four patients. They were still able 
to perform daily activities without much difficulty. Another four reported that the 
dyskinesias were severely disabling. They required assistance with the majority of 
activities attempted during the day. There were three patients who considered 
dyskinesias completely disabling. These patients were unable to perform any 
activities of daily life without assistance.  
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Figure 6.10 indicates the duration of levodopa therapy of patients with positive 
incidence of dyskinesias and Figure 6.12 indicates the relative strengths of levodopa 
therapies currently being used by patients with positive incidence of dyskinesias. 
Table 6.3 indicates the observed frequencies of dyskinesias according to the 
duration of levodopa therapy. 
 
Table 6.3 Observed frequency of dyskinesias in patients according to duration of 
levodopa therapy 
 
Levodopa duration 
Dyskinesias 
Yes No/Unsure 
2-4 years 5 9 
5-7 years 1 6 
8-10 years 3 3 
11+ years 4 8 
Not sure 0 4 
Total 13 30 
 
Statistical analysis showed that there were some differences. However, due to the 
small sample size, the chi-square test yielded a non-significant result with a p-value 
of 0.4138. 
 
Figure 6.12 Duration of levodopa therapy for patients with positive incidence of 
dyskinesia  
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Figure 6.12 shows that five patients were on levodopa therapy for just two to four 
years. Of these, three were diagnosed less than five years ago. However, these 
patients could have presented with more severe symptoms at diagnosis, or 
diagnosed at a later stage of the disease, therefore requiring higher initial doses of 
levodopa, which could explain the earlier onset of dyskinesias. A total of four patients 
were using levodopa for more than 10 years. A Turkish study stated that, in general, 
of all patients on levodopa therapy, 50% to 90% of them will develop motor 
complications after five to 10 years of treatment (Benbir, et al., 2006: 732). The 
results of this study show that less than 50% of patients developed dyskinesias after 
10 years of treatment with levodopa. The Turkish study (Benbir, et al., 2006: 729) 
also reported that the incidence of dyskinesias increased as the duration of levodopa 
usage increased. Another study stated that dyskinesias have been seen to occur 
within five years in 50% of patients on chronic levodopa therapy (Kessler and Rezak, 
2007: 223). An older study showed that of 50 patients with disease duration of 10 
years and longer, 56% developed drug-induced dyskinesias within the first 10 years 
of the disease (Garret, et al., 1998: 101). The current study showed that of the 25 
patients on chronic levodopa therapy for five years and longer, eight (32%) 
developed dyskinesias. A review stated that it was important to remember that not all 
patients on levodopa therapy would develop dyskinesias and that there could be 
certain genetic factors involved in determining its occurrence (Thanvi, et al., 2007: 
385). 
 
Figure 6.13 Strengths of levodopa therapies being used by patients with positive 
incidence of dyskinesias  
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The majority of patients with dyskinesias were using the 100/25mg strength and only 
one patient was on levodopa/carbidopa/entacapone. Table 6.4 indicates the initial 
and current total doses of levodopa for patients reported to experience dyskinesias. 
 
Table 6.4 Initial and current daily doses of levodopa for patients experiencing 
dyskinesias  
 
Patients Initial prescribed daily 
levodopa dose 
Current prescribed daily 
levodopa dose 
Difference between 
current and initial 
daily levodopa dose 
Patient 1 100mg 2 000mg 1 900mg 
Patient 2 500mg 1 000mg 500mg 
Patient 8 50mg 400mg 350mg 
Patient 11 Unsure 300mg _ 
Patient 16 200mg 600mg 400mg 
Patient 23 Unsure 400mg _ 
Patient 24 Unsure 1 300mg _ 
Patient 26 Unsure 800mg _ 
Patient 27 300mg 1 250mg 950mg 
Patient 30 Unsure 500mg _ 
Patient 34 Unsure 600mg _ 
Patient 36 300mg 450mg 150mg 
Patient 42 Unsure 1 000mg _ 
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When comparing the initial and current doses, there is a predictable difference in the 
values with most being twice as great, or more. Of the six patients who were able to 
provide both an initial and current dose of levodopa, only two were diagnosed less 
than five years ago. The patients all showed an increase in the total daily dose of 
levodopa with the exception of patient 36 who was diagnosed less than five years 
ago.   
 
Table 6.4 shows that many patients were unsure of the initial levodopa dose. This 
was expected due to ageing and memory loss. Inaccurate recollection was also 
expected. However, of the patients who answered, it was seen that most were 
receiving an initial dose of 200mg or more on a daily basis.  
 
A total of six patients were receiving doses higher than that of the DDD for levodopa. 
The single patient receiving a relatively low daily dose of 300mg of levodopa was 
using a combination of levodopa/carbidopa/entacapone. This means that although 
the levodopa dose was lower, since entacapone extends the half life of levodopa by 
50% to 75% (Marin, et al., 2006: 647; Smith, et al., 2005: 307), the potential for 
developing dyskinesias was greater. According to the WHO, the DDD for levodopa in 
combination with both a decarboxylase inhibitor and entacapone is decreased to 
450mg. 
 
6.3 Medical record review 
 
All 43 patient medical records were reviewed and analysed. According to these 
records, 44.19% of patients were diagnosed between five and 10 years ago (n = 19), 
23.26% were diagnosed fewer than five years before the onset of the study and 
27.91% have been diagnosed for more than 10 years.  
 
The medical records show that the majority of patients up to the age of 70 years 
were diagnosed between five and 10 years ago (n = 10; 23.26%). A total of seven 
patients were diagnosed fewer than five years before the onset of the study 
(16.28%) and four patients were diagnosed more than 10 years before the onset of 
the study (9.30%). When comparing these results to the patient interviews where the 
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majority of patients (n = 8) claimed to be diagnosed fewer than five years ago, it can 
be seen that memory impairment could have had an influence on their responses. 
The medical records provide a more accurate date of diagnosis, although the patient 
would only have presented to the neurologist when the symptoms became 
bothersome. Figure 6.14 indicates the duration of disease of patients between the 
ages of 50 to 70 years and Figure 6.15 indicates the disease duration of patients 
older than 70 years. 
 
Figure 6.14 Disease duration of patients between the ages of 50 to 70 years  
 
 
 
Figure 6.15 Disease duration of patients older than 70 years  
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The majority of patients in the age group 71 to 75 years were diagnosed between 
five and 10 years ago (n = 9; 20.93%). The rest of the patients aged 70 years and 
older were mostly diagnosed more than 10 years ago (n = 8; 18.60%). The patient 
interviews showed that patients over the age of 70 years claimed to be diagnosed 
more than 10 years ago. This shows that the patients may not be completely relied 
on when determining date of diagnosis. Figure 6.16 indicates the age at which 
patients were diagnosed.  
 
Most of the patients were diagnosed between the ages of 56 to 60 years (n = 9; 
20.93%) and 61 to 65 years (n = 9; 20.93%). This is in keeping with another study 
from Singapore, which reported an average age of 64.4±9.9 years. (Tan, et al., 2012: 
512). Furthermore, a study conducted in Cardiff in the United Kingdom showed 
5.40% and 31.20% of Parkinson’s disease patients had their disease onset before 
the ages of 50 and 65 years respectively (Wickremaratchi, Perera, O’Loghlen, 
Sastry, Morgan, Jones, Edwards, Robertson, Butler, Morris and Ben-Shlomo, 2009: 
806). This study also showed that the average onset for males was 67.7 years and 
the average onset for females was 69.7 years (Wickremaratchi, et al., 2009: 806). 
The majority of patients did not have a disease severity entered into the records. Of 
those that did (n = 6), five patients were described as having severe disease and one 
was described as having mild disease at the time of the study.   
 
Figure 6.16 Age at diagnosis 
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6.3.1 Treatment 
 
This section outlines the therapy being used by patients according to the medical 
records. The section focuses on the levodopa dosages and medication usage of 
levodopa, other antiparkinsonian medication and others of the entire study 
population as well as any co-morbidities with which they have been diagnosed. 
 
6.3.1.1 Levodopa 
 
All patients included in the study were on levodopa therapy. However, it was found 
that many patients were using other medication as well. Figure 6.17 indicates the 
current PDDs of levodopa prescribed to patients. 
 
Figure 6.17 Current prescribed daily doses of levodopa according to medical records  
 
 
 
Figure 6.17 shows that the majority of patients were using 300mg of levodopa daily 
(n = 7; 16.28%). The patient interviews also showed that the majority of patients 
received 300mg of levodopa daily (n = 7; 16.28%). According to the SAMF (ed. 
Rossiter, 2012: 457), the initial dose of levodopa in combination with carbidopa, is 
25/100mg three times daily which amount to a total daily dose of 300mg of levodopa. 
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The second largest group of patients were prescribed 750mg of levodopa daily (n = 
5; 11.63%). Only one patient was receiving a dose of 100mg which was also the 
lowest dose recorded. The lowest recorded dose from the patient interviews was 
200mg. A total of 25 patients (58.14%) were receiving doses higher than the DDD. 
There were three patients receiving doses of 2 000mg or more with the highest daily 
dose of levodopa recorded as 2 400mg (patient 33) which is four times that of the 
DDD. This patient was not experiencing dyskinesias. The maximum daily dose of 
levodopa according to the SAMF (ed. Rossiter, 2012: 457) is 2 000mg. However, 
minimum and maximum doses are only guidelines to dosing. If a patient requires 
higher doses, as long as the patient is able to tolerate the levodopa, a higher dose 
may be given. The average PDD was 809mg±514mg. This indicates a large range 
(100mg to 2 400mg) of doses prescribed. The average PDD obtained from the 
patient interviews was lower (750mg±452mg) than the prescribed dose. Some 
patients did admit to not adhering to the PDD and increasing or decreasing the 
dosage according to their preference. This could be a reason for the discrepancy 
noted between the two sources. Figures 6.18 and 6.19 indicate the total daily dose of 
levodopa prescribed as a function of disease duration. 
 
Figure 6.18 Prescribed daily doses of levodopa up to 600mg as a function of disease 
duration  
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Figure 6.18 shows that the majority of patients were diagnosed between five to 10 
years ago (n = 7) and were receiving doses of 300mg and above. A total of five 
patients were diagnosed fewer than 10 years ago and four patients were diagnosed 
more than 10 years ago. 
 
Figure 6.19 Prescribed daily doses of levodopa 700mg and higher as a function of 
disease duration  
 
 
 
As can be seen from Figure 6.19, the higher doses corresponded with longer 
disease duration. This is in keeping with Kitagawa and Tashiro (2005: 940). This is 
due to more severe disease and symptoms requiring higher doses to provide 
adequate relief. Patients diagnosed fewer than five years ago were receiving a 
maximum of 800mg of levodopa daily. However, patients diagnosed five years ago 
or longer, were receiving doses across the range of those identified. A Swedish 
study (Nyholm, Karlsson, Lundberg and Askmark, 2010: 260) acknowledged that 
there is no defined dose of levodopa denoting ‘high’ or ‘low’ although in their study a 
low dose was defined as 400mg or less and a high dose was defined as 1 200mg or 
more (Nyholm, et al., 2010: 261). The average dose of the population in this study 
falls in between these two values.  
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A Japanese study (Kitagawa and Tashiro, 2005: 940) showed that of a total of 92 
patients, the average daily dose of levodopa used by patients was 186.40mg.  This 
is a much lower dose compared to those found in this study. American and 
European guidelines stated that the recommended dose of levodopa/carbidopa be 
between 400mg to 600mg (VHA Pharmacy Benefits Management Services, Medical 
Advisory Panel and VISN Pharmacist Executives, 2012: 3). The PDDs according to 
gender are summarised in Figure 6.20. 
 
Figure 6.20 Prescribed daily doses of levodopa according to gender  
 
 
 
It can clearly be seen from Figure 6.20 that males were receiving higher levodopa 
doses than females. There were more male patients (n = 16; 37.21%) receiving 
higher doses than the DDD of 600mg with a mean dose of 858mg and median dose 
of 800mg. More females (n =  10; 23.26%) were receiving doses lower than 600mg 
with a mean dose of 642.50mg and a median dose of 525mg. This is in keeping with 
the Swedish study (Nyholm, et al., 2010: 261) which reported that males were 
receiving higher doses than females. In this study, males were receiving mean and 
median doses of 494mg and 465mg respectively and females receiving mean and 
median doses of 408mg and 395mg respectively (Nyholm, et al., 2010: 261).  
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6.3.1.2 Other antiparkinsonian medication 
 
The following section focuses on all other medication used for Parkinson’s disease 
such as dopamine agonists, anticholinergics, MAO-B inhibitors, COMT-inhibitors and 
others prescribed to patients by neurologists for the motor symptoms of Parkinson’s 
disease. 
 
6.3.1.2.1 Dopamine agonists 
 
The dopamine agonists included bromocriptine, pramipexole and ropinirole 
prescribed to Parkinson’s patients according to the medical records. A summary of 
the initial and current PDDs of bromocriptine, pramipexole and ropinirole as well as 
their duration of therapy is included as Appendix J. 
 
A total of 20 patients were prescribed a dopamine agonist (46.51%).  In the cases 
where ‘NA’ is stated in place of a current dose, it means that the patient is no longer 
on the therapy. Looking at each individual dopamine agonist, five patients (11.63%) 
were prescribed bromocriptine, six patients (13.95%) were prescribed pramipexole 
and 15 patients (34.88%) were prescribed ropinirole. There were also two patients 
(4.65%) prescribed pergolide, however both were discontinued after a period of six 
and nine years, respectively.  
 
For bromocriptine, there were two patients for whom the duration of therapy could 
not be determined, but in the other cases it can be seen that two patients had only 
been on bromocriptine for one year and less and one patient had been using the 
drug for eight years. Where the information was available it was noted that 
bromocriptine was initiated after levodopa therapy. The total daily doses of 
bromocriptine prescribed were varied, ranging from 2.5mg to 35mg daily. However, 
according to the WHO, the DDD for bromocriptine, when used in Parkinson’s 
disease, may be as high as 40mg daily. When looking at the location of each patient 
in this study, it was seen that four (80%) of the patients were located in the public 
sector which is the sector in which bromocriptine is more often used in South Africa. 
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It was stated that in patients who were no longer obtaining satisfactory results with 
levodopa, bromocriptine could be introduced (Lieberman and Goldstein, 1985: 218). 
Bromocriptine at low doses of 5mg to 30mg daily in combination with levodopa 
provided a modest antiparkinsonian effect. Higher doses of 31mg up to 100mg daily 
in combination with levodopa would result in more adverse reactions including 
dyskinesias. It was also noted that patients reacted differently to the different 
dopamine agonists with some improving and others not (Lieberman and Goldstein, 
1985: 225). An American study (Pfeiffer, Wilken, Glaeske, Agapito and Lorenzo, 
1985: 586) agreed with Lieberman and Goldstein by stating that there were modest 
but significant improvements in patients receiving bromocriptine at doses 7.5mg to 
15mg daily, but with a decline in efficacy seen at doses closer to 20mg. there were 
adverse effects noted, but they were mild in severity (Pfeiffer, et al., 1985: 588).  
 
However, a study conducted in Ecuador, investigated the benefit of combining 
bromocriptine with levodopa in early disease (Alarcόn, Cevallos and Lees, 1998: 
261). The study concluded that there was no statistically significant benefit of 
combining the two agents in early Parkinson’s disease, nor did it seem to affect the 
evolution of the disease in any way.  
 
When considering pramipexole it was seen that there were two cases where the 
duration of therapy could not be determined, but for those which could, three patients 
(50%) were using pramipexole for fewer than five years and only one patient 
(16.67%) for 10 years. According to the WHO, the DDD for pramipexole is 2.5mg 
daily. There were two patients receiving higher doses than this. Patient 12 was 
receiving 3mg daily and Patient 17 was receiving a total daily dose of 4mg. A review 
summarising studies done with pramipexole considered two studies using 
pramipexole only (Piedad and Cavanna, 2012). One study compared four different 
dosages of pramipexole and the other compared immediate release to extended 
release. Neither study detected any incidence of dyskinesias. In a study comparing 
pramipexole with bromocriptine, dyskinesias were found to be more prevalent with 
pramipexole (Mizuno, Yanagisawa, Kuno, Yamamoto, Hasegawa, Origasa, Kowa 
and The Japan Pramipexole Study Group, 2003: 1 154).  
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There were 10 patients using ropinirole for fewer than five years and two using 
ropinirole for between five and 10 years. Of the 15 patients, 10 are still continuing 
therapy with ropinirole. Comparing the number of patients using ropinirole to 
bromocriptine and pramipexole, it appears that ropinirole is the preferred choice of 
dopamine agonist by South African neurologists, most probably since it is the 
cheapest agent. There were three patients in whom ropinirole was started in the 
same year as levodopa or just one year later. According to the WHO, the DDD for 
ropinirole is 6mg. There were six patients receiving higher doses than this with the 
highest dose prescribed being 15mg daily.  
 
6.3.1.2.2 Anticholinergic agents 
 
This section focuses on the anticholinergic agents benzhexol (also known as 
trihexyphenidyl), biperidine and orphenadrine prescribed to Parkinson’s patients 
according to the medical records. A summary of the initial and current PDDs of 
benzhexol, biperidine and orphenadrine as well as their duration of therapy is 
included as Appendix K. 
 
There were 11 patients (25.81%) in the patient population prescribed an 
anticholinergic agent. Focusing on each individual agent, there were six patients 
(13.95%) prescribed benzhexol, two patients (4.65%) prescribed biperidine and five 
patients (11.63%) prescribed orphenadrine. Of the two patients prescribed biperidine 
neither were continued on the medication. 
 
In four of the six cases, benzhexol was discontinued. However, when examining the 
duration of therapy, it was seen that these drugs were used for several years before 
being discontinued. Analysis of the dates of when this drug was initiated in relation to 
levodopa, it was noted that in two cases benzhexol was initial therapy and in one 
case was initiated the same year as levodopa. It is likely that neurologists are using 
this drug to provide relief of symptoms of Parkinson’s disease in order to delay the 
introduction of levodopa. In the early, milder stages of the disease when the patient 
is not showing many symptoms, therapy with an anticholinergic may be warranted 
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(Carr, et al., 2009: 756). As the patient progresses and the symptoms become more 
obvious, levodopa has a role to play. 
 
Five patients were prescribed orphenadrine and three were still on the medication. 
The DDD for orphenadrine is 200mg. Only one patient was receiving a higher dose 
than this. In one instance, orphenadrine was initiated before levodopa and then 
discontinued. It was most likely that the symptoms were no longer effectively 
managed by orphenadrine and levodopa was required to provide symptomatic relief. 
 
6.3.1.2.3 MAO-B inhibitors 
 
This section focuses on the MAO-B inhibitors selegiline, also known as eldepryl, and 
rasagiline prescribed to Parkinson’s patients according to the medical records. A 
summary of the initial and current PDDs of selegiline and rasagiline as well as their 
duration of therapy is included as Appendix L.  
 
A total of four patients (9.30%) were prescribed MAO-B inhibitors. Of these, 
rasagiline was the more popular drug with three patients out of the four being 
prescribed as such. However, only one of these patients continued therapy of all 
MAO-B inhibitors prescribed.  
 
6.3.1.2.4 COMT-inhibitors 
 
This section focuses on the COMT-inhibitor entacapone prescribed to Parkinson’s 
patients according to the medical records. A summary of the initial and current PDDs 
of entacapone as well as the duration of therapy is included as Appendix M.  
 
Only two patients (4.65%) were prescribed entacapone. One patient discontinued 
the medication. However, it was not possible to compare the levodopa dose before 
and after the entacapone was introduced in Patient 21 as the initial dose of levodopa 
was not available. Theoretically, it should have been decreased.  
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6.3.1.2.5 Amantadine 
 
This section focuses on amantadine prescribed to Parkinson’s patients according to 
the medical records. A summary of the initial and current PDDs of amantadine as 
well as its duration of therapy is included as Appendix N.  
 
A total of eight patients (18.60%) were prescribed amantadine. The DDD of 
amantadine is 200mg but it can be seen that two patients were receiving higher 
doses than this.  
 
6.3.1.6 Other medication 
 
There were other agents that were prescribed to the Parkinson’s patients included in 
the study. Domperidone and metoclopramide were prescribed to two and one 
patient, respectively. Both these agents are dopamine antagonists used to increase 
gastric motility (ed. Rossiter, 2012: 43). However, in Parkinson’s disease 
neurologists may administer domperidone, concurrently with levodopa in order to 
reduce the incidence of peripheral side effects caused by the dopaminergic drug. 
Domperidone does not cross the blood brain barrier (Carr, et al., 2009:756). 
According to Daily Drug Use (ed. Turner, 2010: 446), metoclopramide reduces the 
effects of levodopa and concurrent use should be avoided. 
 
There were two patients receiving donepezil, an anticholinesterase, and one patient 
receiving memantine, an NMDA-receptor antagonist and a derivative of amantadine. 
The primary indication for these drugs in Parkinson’s disease is dementia (ed. 
Rossiter, 2012: 494). 
 
6.3.2 Co-morbid conditions  
 
The medical records were reviewed to determine any co-morbid conditions the 
patients may have been diagnosed with and the medication prescribed for these 
conditions and its impact on the antiparkinsonian medication. The most common 
conditions noted are summarised in Figure 6.21. 
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Figure 6.21 Common co-morbid diseases in Parkinson’s patients according to 
medical records 
 
 
 
Diagnoses were based on the primary indication of each drug. The group labelled 
‘Other’ consists of asthma, congestive heart failure, epilepsy, gout, hypothyroidism, 
ischaemic heart disease, osteoarthritis, postmenopausal (hot flushes, mood swings) 
and/or restless legs syndrome. As can be seen from Figure 6.21, many patients 
were diagnosed with hypertension (n = 18; 41.86%) and constipation (n = 14; 
32.56%). When looking at the metabolic conditions, the three most common were 
hypertension, hyperlipidaemia and diabetes. These conditions are all common 
diseases experienced by older patients. Considering what can be classified as the 
NMS of Parkinson’s disease the three most common found in this study include 
constipation, anxiety and depression (Ceravolo, et al., 2010; Poewe, 2008: 16; 
Chaudhuri, et al., 2006: 238, 240).  Figure 6.22 indicates the other medication used 
by Parkinson’s patients for co-morbid diseases unrelated to motor symptoms.  
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Figure 6.22 Medication used by Parkinson’s patients for co-morbid disease 
 
 
 
The drugs were grouped according to their primary indication. The group labelled 
‘Other’ consisted of allopurinol, donepezil, isosorbide mononitrate, levothyroxine, 
loratadine, promethazine and sodium valproate. One patient was prescribed 
donepezil.  
 
It can be seen that the most commonly prescribed class of drugs were the 
antihypertensives (n = 19; 44.19%). These included amlodipine, atenolol, carvedilol, 
enalapril, furosemide, hydrochlorothiazide, indapamide and perindopril. The second 
most commonly used class of drugs were the laxatives (n = 15; 34.88%). This group 
consisted of bisacodyl, lactulose, senna and sorbitol. This was not a surprising 
finding, as seen in Figure 6.21, constipation is a NMS experienced by many 
Parkinson’s patients.  
 
Three patients were found to be taking quetiapine. This is an atypical antipsychotic 
agent which acts through inhibition of dopamine receptors. Quetiapine has reduced 
propensity to cause extrapyramidal side effects (ed. Rossiter, 2012: 470). Psychosis 
is a documented NMS of Parkinson’s disease. The intervention is generally aimed at 
decreasing the dose of the offending dopaminergic agent and adding an atypical 
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antipsychotic if necessary (Ceravolo, et al., 2010). Psychosis is also more often seen 
with the dopamine agonists than with levodopa (Ceravolo, et al., 2010). It is 
interesting to note that of the three patients in this study receiving quetiapine, two 
were receiving the dopamine agonist ropinirole as ongoing therapy.  
 
The antidepressants prescribed included amitriptyline and fluoxetine (n = 9; 20.93%). 
These agents could have been used for their antidepressant effects or for their 
sedative effects, particularly in the case of amitriptyline. However, depression is also 
a known NMS of Parkinson’s disease and is seen to affect 10% to 45% of patients 
although some sources say it can be as many as 70% (Poewe, 2008: 16; Chaudhuri 
et al., 2006: 238; Cummings, 1992: 444). 
 
6.3.3 Non-dyskinetic patients 
 
This section focuses on non-dyskinetic patients, discussing the disease duration, 
duration of levodopa therapy as well as the initial and current doses of levodopa 
being used. Figure 6.23 indicates the disease duration of non-dyskinetic patients. 
 
Figure 6.23 Disease duration of non-dyskinetic patients 
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The majority of the patients were diagnosed between five and 10 years ago (n = 16; 
48.49%).  Table 6.5 indicates the initial and current doses of patients not diagnosed 
with dyskinesias.  
 
Table 6.5 Initial and current prescribed daily doses of levodopa in non-dyskinetic 
patients 
  
Patients Initial prescribed daily levodopa 
dose 
Current prescribed daily levodopa 
dose 
Patient 3 150mg 750mg 
Patient 4 300mg 300mg 
Patient 5 Information not available 900mg 
Patient 6 750mg 1 250mg 
Patient 7 300mg 1 250mg 
Patient 9 300mg 700mg 
Patient 10 Information not available 600mg 
Patient 12 150mg 300mg 
Patient 13 300mg 800mg 
Patient 14 Information not available 2 100mg 
Patient 15 675mg 300mg 
Patient 17 750mg 1 200mg 
Patient 18 Information not available 450mg 
Patient 19 150mg 800mg 
Patient 20 400mg 800mg 
Patient 21 Information not available 700mg 
Patient 22 Information not available  1 200mg 
Patient 24 Information not available 1 300mg 
Patient 25 300mg 750mg 
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Table 6.5 Initial and current prescribed daily doses of levodopa in non-dyskinetic 
patients (continued) 
 
Patients Initial prescribed daily levodopa 
dose 
Current prescribed daily levodopa 
dose 
Patient 28 300mg 450mg 
Patient 29 Information not available 300mg 
Patient 30 300mg 450mg 
Patient 31 300mg 300mg 
Patient 32  300mg 300mg 
Patient 33 Information not available 2 400mg 
Patient 34 600mg 300mg 
Patient 35 450mg 750mg 
Patient 37 Information not available 600mg 
Patient 38 Information not available 400mg 
Patient 39 600mg 750mg 
Patient 40 300mg 800mg 
Patient 41 300mg 750mg 
Patient 42 Information not available 1 000mg 
 
It can be seen that non-dyskinetic patients were receiving a wide range of levodopa 
doses (300mg to 2 400mg) with an average dose of 790.91mg±497.88mg. A total of 
11 patients were started on a dose of 100/25mg three times daily and increased from 
there. In almost all cases the total daily doses were increased. Only in two cases 
were there decreases in the total daily dose of levodopa. This could be due to 
excessive adverse effects experienced by the patient such as dyskinesias and the 
dose was decreased in order to provide relief from these effects. Figure 6.24 
indicates the age at diagnosis of Parkinson’s disease. 
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Figure 6.24 Age at diagnosis of Parkinson’s disease in non-dyskinetic patients 
 
 
 
Non-dyskinetic patients did not have an early diagnosis of disease with only seven 
patients being diagnosed under the age of 55 years. A risk factor for the incidence of 
dyskinesias is young age at Parkinson’s disease onset (Ha and Jankovic, 2011: 11; 
Kumar, et al., 2005: 343; Sharma, et al., 2010: 491; Thanvi, et al., 2007: 384). This 
explains the age of onset distribution of these patients. Figure 6.25 demonstrates the 
duration of levodopa therapy of non-dyskinetic patients. 
 
Figure 6.25 Duration of levodopa therapy for non-dyskinetic patients 
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Unfortunately there were many incidences where the information was not available 
due to patients being transferred from one institution to another or one practitioner to 
another. However, in the cases where the information was recorded, it can be seen 
that the majority of patients were diagnosed less than five years ago (n = 14; 
32.56%). This is in keeping with studies which indicate that a longer duration of 
levodopa therapy is a risk factor for the development of dyskinesias (Benbir, et al., 
2006: 729; Ha and Jankovic, 2011: 10; Schrag and Quinn, 2000: 2297; Thanvi, et al., 
2006: 385).  
 
6.3.4 Dyskinesias 
 
The medical records were reviewed for incidence of dyskinesias. It was found that 10 
patients (23.26%) were suffering from dyskinesias. It is important to remember that 
the review was cross-sectional and only the indication at the patients’ last visit was 
taken into consideration. The number of patients with dyskinesias as indicated by the 
medical records was less than the number of patients with self-reported dyskinesias 
(n = 13). A reason for this could be that patients did perhaps not fully understand 
what a dyskinesia was and answered positively. Of the 10 patients who were 
positively diagnosed with dyskinesias, 50% (n = 5) were males. The severity of the 
dyskinesias was not specified in five patients. Of the rest of patients, four were 
diagnosed as having mild dyskinesias (40%) and one was diagnosed as 
experiencing severe dyskinesias (10%). Figure 6.26 indicates the type of dyskinesias 
experienced by patients as diagnosed by the neurologists. 
 
Figure 6.26 shows that majority of patients experienced a combination of 
dyskinesias. A total of four patients did not have the information available in the 
medical records. In general, the most common type of dyskinesia is chorea, followed 
by dystonia and the two often coexist. The medical records reviewed did not state 
the types of dyskinesias these patients diagnosed with a combination were 
experiencing. The onset of levodopa induced dyskinesias is generally associated 
with maximal effect of levodopa therapy and is known as the peak dose dyskinesia 
which is most common. Less common is the diphasic dyskinesia (Chong and Lee, 
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2001; Tambasco, Simoni, Marsili, Sacchini, Murasecco, Cardaioli, Rossi and 
Calabresi, 2012: 2).  
 
Figure 6.26 Type of dyskinesias experienced by patients as diagnosed by 
neurologists 
 
 
 
When comparing the medical records to the patient interviews, four patients reported 
severely disabling dyskinesias, although only two of these patients were identified by 
the neurologist as experiencing dyskinesias. In both cases the severity was not 
specified. There were four patients in the interviews who reported that their 
dyskinesias were only mildly disabling. Of these four patients, three were diagnosed 
by a neurologist as having dyskinesias and were also all diagnosed with mild 
dyskinesias. This indicates that patients are relatively accurate when indicating the 
severity of dyskinesias, but not in identifying the incidence. Figure 6.27 demonstrates 
the age at diagnosis of patients experiencing dyskinesias according to medical 
records. 
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Figure 6.27 Age at diagnosis of patients with dyskinesias according to medical 
records 
 
 
 
Studies have shown that patients with a younger age at diagnosis are more likely to 
experience dyskinesias and more severe dyskinesias as well (Ha and Jankovic, 
2011: 11; Kumar, et al., 2005: 343; Sharma, et al., 2010: 491; Thanvi, et al., 2007: 
384). As seen in Figure 6.24, patients experiencing dyskinesias were diagnosed with 
Parkinson’s disease earlier than non-dyskinetic patients. One study reported that 
after five years of levodopa therapy, the incidence of dyskinesias for patients with 
onset age 40 to 49 years was 80%, decreasing to 26.70% for onset ages 50 to 59 
years, 22.70% for onset ages 60 to 69 years and 20% for onset ages 70 to 79 years 
(Ku and Glass, 2010: 1 179).  
 
Due to the small number of patients in these age groups, combining them into age 
groups 40 to 60 years, 61 to 70 years and 70 years and older (Kumar, et al., 2005: 
343), it was seen that five patients diagnosed between the ages of 40 to 60 years 
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other study as well (Kumar, et al., 2005: 343). The disease duration of patients 
positively diagnosed with dyskinesias is demonstrated in Figure 6.28 below.  
 
Figure 6.28 Disease duration of dyskinetic patients according to medical records 
 
 
 
It can be seen from Figure 6.28 that 50% of the patients positively diagnosed with 
dyskinesias were diagnosed more than 10 years ago. Comparing this result to non-
dyskinetic patients, the dyskinetic patients had longer disease duration. This is in 
keeping with the results of other studies which state that there is a positive 
relationship between disease duration and the risk of dyskinesias (Benbir, et al., 
2006: 728; Schrag and Quinn, 2000: 2297).   
 
Other risk factors in the development of dyskinesias are the dose of levodopa, initial 
and current as well as the duration of therapy (Jankovic, 2005: 12; Schrag and 
Quinn, 2000: 2297; Sharma, et al., 2010: 492). Table 6.6 indicates the initial and 
current prescribed daily doses of levodopa according to the medical records. 
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Table 6.6 Initial and current prescribed daily doses of levodopa according to medical 
records 
 
Patients Initial prescribed daily dose Current prescribed daily dose 
Patient 1 300mg 2 000mg 
Patient 2 Information not available 1 000mg 
Patient 8 600mg 1 000mg 
Patient 11 150mg 100mg 
Patient 16 750mg 600mg 
Patient 23 900mg 800mg 
Patient 26 600mg  1 500mg 
Patient 27 Information not available 250mg 
Patient 36 450mg 450mg 
Patient 43 Information not available 1 000mg 
 
In the instances where information was not available, patients had been referred 
from one institution to another and information was absent from the records. When 
comparing the initial and current doses, it was seen that the doses were increased in 
only three cases. In the instances where the dose has been decreased, it is normally 
done to provide control of dyskinesias. As mentioned above, the Turkish study 
(Benbir, et al., 2006: 729) showed that patients with an average initial dose of 
levodopa of 291mg daily resulted in dyskinesias. A total of six patients were 
receiving initial doses higher than 291mg. Dyskinesias were seen in patients 
receiving average levodopa doses of 338mg daily (Thanvi, et al., 2007: 384). The 
results of the current study show that eight patients were receiving daily doses 
higher than this. Six patients were receiving doses higher than the DDD of 600mg for 
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levodopa. Figure 6.29 indicates the duration of levodopa in patients positively 
diagnosed with dyskinesias according to the medical records. 
 
Figure 6.29 Duration of levodopa therapy in patients with dyskinesias according to 
medical records 
 
 
 
It was seen that the majority of patients with dyskinesias were on levodopa therapy 
for less than five years (n = 4; 40%). A total of four patients did not have the 
information available in the medical records. Even though the duration of levodopa 
therapy is considered a risk factor for the development of dyskinesias, the incidence 
is highly varied and dyskinesias have been seen as early as a few weeks after the 
initiation of levodopa therapy (Sharma, et al., 2010: 491; Thanvi, et al., 2006: 384). 
Figure 6.30 indicates the co-morbidities experienced by dyskinetic patients and 
Figure 6.31 shows the medications prescribed for these co-morbidities unrelated to 
motor symptoms of Parkinson’s disease. 
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Figure 6.30 Co-morbid conditions of patients with dyskinesias as diagnosed by a 
medical practitioner 
 
  
 
The majority of patients were suffering from hyperlipidaemia (n = 4; 40%) and 
constipation (n = 4; 40%). Constipation is a common NMS of Parkinson’s disease, as 
is depression and urinary incontinence which were both experienced by three 
patients (30%).   
 
Figure 6.31 Medication used by dyskinetic Parkinson’s patients for co-morbid 
conditions as prescribed by a medical practitioner 
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Many dyskinetic patients were receiving lipid lowering agents (atorvastatin, 
pravastatin and simvastatin) (n = 5; 50%), blood modifying agents (aspirin and 
warfarin) (n = 5; 50%) and laxatives (n = 4; 40%). There were two patients (20%) 
receiving the antipsychotic agent quetiapine. This is the one drug that could have a 
significant interaction with other antiparkinsonian medications as their mechanisms 
of action directly antagonise the other. Quetiapine is a dopamine antagonist and 
could worsen the effects of Parkinson’s disease. In spite of the interaction between 
antiparkinsonian medications and quetiapine, quetiapine is still used in the 
management of psychosis in patients with Parkinson’s disease and is, in practice, 
general well tolerated (Latoo, Mistry and Dunne, 2012: 8-9). Clozapine may also be 
used, however, the risk of agranulocytosis requires patient blood monitoring. The 
most promising option has been the cholinesterase inhibitor rivastigmine. 
Rivastigmine may be used alone or in combination with other antipsychotics (Latoo, 
et al., 2012: 9).  
 
6.4 Summary of major findings 
 
The major findings of both the patient interviews and the medical record review are 
summarised below. Table 6.7 provides a comparison of common facts obtained from 
both the patient interviews and medical record review. Table 6.8 compares the major 
findings of the patient interviews and medical record review in terms of dyskinesias. 
Patients were able to provide fairly accurate accounts of the disease duration. 
Patients were also aware of the levodopa dose they were prescribed and using at 
the time of the study. Patients diagnosed with dyskinesias according to the medical 
records were diagnosed with Parkinson’s disease earlier than non-dyskinetic 
patients. There were no proportional gender differences in the incidence of 
dyskinesias and 50% of the patients diagnosed with dyskinesias were diagnosed 
more than 10 years ago. The average PDD of patients with dyskinesias according to 
the medical records was 870mg. This was higher than the DDD of 600mg for 
levodopa.
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Table 6.7 Comparison of patient interviews and medical record review in terms of general findings 
 
Patient interviews Medical records 
General findings 
A total of 14 patients were found to be between the ages of 71 to 
75 years (32.56%) and constituted the largest age group overall 
 
There was a male to female ratio of 1.15:1  
The male patients were found to be older than the females  
34.88% (n = 15) patients were diagnosed between five and 10 
years before the study 
44.19% (n = 19) of patients were diagnosed between five and 10 
years ago 
The majority (n = 8; 18.60%) of patients up to the age of 70 years 
were diagnosed less than five years ago 
The majority (n = 10; 23.26%) of patients up to the age of 70 
years were diagnosed between five and 10 years ago  
90.70% (n = 39) of patients reported that levodopa was the first 
drug they were prescribed for Parkinson’s disease 
 
The average PDD of levodopa was 750mg±452mg The average PDD of levodopa was 809mg±514mg 
The range of PDDs of levodopa was 200mg to 2 000mg The range of PDDs of levodopa was 100mg to 2 000mg 
The majority (n = 7; 16.28%) of patients were prescribed a daily 
dose of 300mg of levodopa  
The majority (n = 7; 16.28%) of patients were using 300mg of 
levodopa daily  
There were 36 (83.72%) patients also using other medication 
such as antihypertensives, hypoglycaemic agents, lipid lowering 
agents and antidepressants, which were unrelated to the motor 
symptoms of Parkinson’s disease 
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Table 6.8 Comparison of patient interviews and medical record review in terms of dyskinesias 
 
Patient interviews Medical records 
Dyskinesias 
A positive incidence of dyskinesias was reported by 13 patients 
(30.23%) 
There were 10 patients (23.26%) suffering from dyskinesias 
53.85% (n = 7) were males and 46.15% (n = 6) were females 50% (n = 5) were males 
Fewer than 50% of patients developed dyskinesias after 10 
years of treatment with levodopa 
50% of the patients diagnosed with dyskinesias were diagnosed 
more than 10 years ago 
A total of four patients reporting a positive incidence of 
dyskinesias were using levodopa for more than 10 years 
The majority of patients with dyskinesias were on levodopa 
therapy for less than five years 
The average PDD of patients reporting a positive incidence of 
dyskinesias was 815.38mg  
The average PDD of levodopa prescribed to dyskinetic patients 
was 870mg 
Patients in the age groups 50 to 60 years, 61 to 70 years and 71 
to 80 years demonstrated an incidence of dyskinesias of 
45.45%, 16.67% and 31.58% respectively 
 
The majority of patients presenting with dyskinesias were in the 
age groups 56 to 60 years and 71 to 75 years 
 
Of the total number of patients diagnosed longer than 10 years 
ago, the proportion which reported the presence of dyskinesias 
was 35.71% 
 
Of the total number of patients diagnosed between five and 10 
years ago, 33.33% reported a presence of dyskinesias 
 
A total of four patients who reported the presence  of 
dyskinesias were using levodopa for more than 10 years 
 
 Patients experiencing dyskinesias were diagnosed with 
Parkinson’s disease earlier than non-dyskinetic patients 
 There were two patients (20%) receiving the antipsychotic agent 
quetiapine 
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CHAPTER 7 
Conclusion and 
Recommendations
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7.1 Study overview 
 
Parkinson’s disease is a progressive neurodegenerative disorder which affects one 
in every 100 people over the age of 65 years (Singh, et al., 2007: 29). The 
underlying pathology of Parkinson’s disease is a loss of the dopamine producing 
neurons in the substantia nigra of the brain (Foster and Hoffer, 2003: 177). 
 
There is an approximately 1.5 times higher risk of Parkinson’s disease for men than 
women (Burn, 2007: 78; Fargel, et al., 2007: 208; Miller and Cronin-Golomb, 2010: 2 
695). Studies have shown there are genetic and environmental links in the aetiology 
of Parkinson’s disease (Schapira and Jenner, 2011: 1 050; Nelson, et al., 2005: 1 
075; Warner and Schapira, 2003: 16).  
 
There is a low reported incidence and prevalence of Parkinson’s disease in Africa 
due to the lack of studies and the short life expectancy of the population (Okubadejo, 
et al., 2006: 2 050). It has been shown, however, that the population aged 60 years 
and older is expected to double in SSA by 2030 and double again by the year 2050 
(Velkoff and Kowal, 2007: 4). In America, approximately 100 000 people are living 
with Parkinson’s disease (Obeso, et al., 2000: 2) and there is an incidence of 1.8% in 
people between the ages of 65 to 69 years with the incidence increasing to 2.6% in 
people aged 85 to 89 years in Europe (De Rijk, et al., 2000: 21), showing that aging 
is indeed a risk factor to the development of Parkinson’s disease. It is therefore 
important to determine the incidence and prevalence of Parkinson’s disease in SSA 
and determine the economic burden it does and will place on society and health care 
resources in the future. 
 
Levodopa is still thought of as the 'gold standard' symptomatic treatment for 
Parkinson’s disease. However, after four to five years of treatment, levodopa efficacy 
tends to decline even if there was a good initial therapeutic response (Singh, et al., 
2007: 30; Stern, 2001: 27; Garret, et al., 1998: 99). Patients tend to experience 
motor fluctuations and dyskinesias. The major controversy in Parkinson’s disease 
therapy is whether to withhold levodopa as the initial therapy in order to delay the 
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onset of dyskinesias or to provide the patient with levodopa in order to obtain 
maximum symptomatic control. 
 
In the early, milder stages of the disease when the patient is not showing many 
symptoms, therapy with an anticholinergic, a dopamine agonist, amantadine or an 
MAO-B inhibitor may be useful as first line therapy (Carr, et al., 2009: 756). Once the 
patient has passed into the moderate to severe stage of Parkinson’s disease, other 
agents such as the dopamine agonists, COMT-inhibitors or MAO-B inhibitors may be 
of benefit as adjunctive therapy to levodopa with dosage adjustments to obtain 
maximum symptom relief (Carr, et al., 2009: 756). The NICE guideline also 
recommends the use of these agents in the later stages of the disease and 
corresponds with the recommendations of Carr and colleagues (Stewart, 2007: 241). 
The NICE guideline states that the treatment for Parkinson’s disease is open to 
interpretation as there are no definitive results for studies comparing the 
effectiveness of one drug class against the other (Stewart, 2007: 241). 
 
There have been numerous global studies into various aspects of Parkinson’s 
disease, but in South Africa, investigation into the treatment of the disease is limited. 
This study was therefore conducted with the aim of analysing the prescribed 
treatments for Parkinson’s disease in the private and public health care sector as 
well as the prevalence and risk factors for dyskinesias in the public health care 
sector. The methodology employed for the realisation of the study objectives 
included the undertaking of a literature review, the analysis of a prescription 
database, the administration of a questionnaire survey, and a review of medical 
records.   
 
The retrospective drug utilisation study was conducted through analysis of a 
prescription database containing records of prescriptions for antiparkinsonian 
products captured in a national retail pharmacy group across South Africa during the 
year 2010. The dataset was analysed to determine the overall demographic 
information pertaining to the distribution of prescriptions across South Africa, the 
monthly distribution of prescriptions and the frequencies of antiparkinsonian drugs 
dispensed. Within these prescriptions, only patients aged 50 years and older were 
143 
 
included in the analyses. Analysis of demographical information, prescribing in 
different age groups and most commonly identified dosages was conducted. 
 
The questionnaire surveys were verbally administered to patients conclusively 
diagnosed with Parkinson’s disease and fitted the inclusion criteria. The analysis of 
the questionnaires included the demographics of patients, the age at which the 
disease was diagnosed, the duration and dose of levodopa therapy, the use of 
medication other than levodopa as well as the presence, duration and severity of 
dyskinesias.  
 
The analysis of the medical record reviews included the date and age at which the 
disease was diagnosed, the disease severity, the presence, severity and type of 
dyskinesias, co-morbid conditions, any other medication the patients were using, the 
specific doses of levodopa and any other antiparkinsonian medication that was being 
used. In concluding the empirical analysis and achieving the stated research 
objectives, the following major findings are summarised. 
 
7.2 Summary of major findings 
 
As the study consisted of two parts, a DUR and a questionnaire-based survey, the 
major findings will be discussed separately. The summary will include a synopsis of 
the results of the analyses discussed in Chapters 5 and 6. 
 
7.2.1 Major findings of the drug utilisation review 
 
A total of 25 523 antiparkinsonian prescriptions were analysed. There were 5 168 
patients identified with 3 058 (59.17%) being female and 2 110 (40.83%) being male, 
a female to male ratio of 1:0.68.  
 
The average age of the population was 70.74±10.37 years, with the oldest patient 
being 100 years. Males were shown to be slightly older than females with the 
average age for males being 71.17±9.88 years and the average age for females 
being 70.37±10.66 years.  
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The highest prevalence of Parkinson’s disease was in the age category of 70 years 
to 79 years for both males and females. The reason for the decrease beyond this 
age is most likely due to increased mortality. 
 
An average of 4.94 products was dispensed to each patient throughout the year 
which indicates that patients were on combination therapies. The average number of 
prescriptions dispensed to male patients was 5.55±6.88 over the year whereas 
4.51±5.44 was the average for females. The Chi-squared test shows a statistical 
significant result (p<0.05) but this is unlikely to be of clinical significance.  
 
The majority of antiparkinsonian products were dispensed to females (54.05%). 
Patients between the ages of 70 years to 79 years received the highest number of 
antiparkinsonian products (35.00%) for both genders. This age group constituted a 
total of 32.28% of the total study population.  
 
It was seen that the majority of antiparkinsonian products dispensed (n = 11 875; 
46.50%) were combination drugs containing levodopa with a decarboxylase inhibitor, 
and some were combined with a COMT-inhibitor. This was expected as levodopa is 
considered the gold standard treatment of Parkinson’s disease. The second most 
dispensed group of drugs were the dopamine agonists which include pramipexole 
and ropinirole (n = 10 164; 39.80%). These were followed by the anticholinergic 
agents benzhexol and orphenadrine (n = 2 352; 9.20%). The MAO-B inhibitor 
selegiline and amantadine made up 2.12% and 1.80% of the total products 
dispensed, respectively. The average age of both males and females did not differ 
greatly amongst the products which showed that there were no preferred products 
for particular age groups. 
 
Dopaminergic products include levodopa-containing products and dopamine 
agonists. It was shown that 3 295 patients received a levodopa-containing product 
throughout the year while 3 166 patients received a dopamine agonist. This indicates 
that patients were prescribed combination therapies. It was seen that males were 
preferentially prescribed levodopa-containing products and females were 
preferentially prescribed pramipexole. 
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For the levodopa-containing products, patients in the age group 70 to 79 years held 
the highest number of prescriptions (n = 4 748) with the age group 60 to 69 years 
holding the second highest proportion of prescriptions (n = 2 988). The most 
commonly identified (n = 2 056) PDD was 300mg of levodopa which is half the DDD 
of 600mg.  
 
The dopamine agonists pramipexole and ropinirole were prescribed more frequently 
in the younger patient categories. The age group 60 to 69 years held the highest 
number of prescriptions (n = 3 277) and is likely to represent those patients who 
have been recently diagnosed or are in the early stages of the disease. The most 
commonly identified PDD of pramipexole was 0.125mg (n = 2 861) which is lower 
than the DDD of 2.5mg for pramipexole. The most commonly identified PDD for 
ropinirole was 3.73mg (n = 239) which was almost half of the DDD of 6mg for 
ropinirole.  
 
The monthly dispensing of products remained largely unchanged throughout the 
year. The average number of prescriptions dispensed for the year was 72.86±58.07 
which amounts to 6.07 products per month. There were more female than male 
patients for each month. However, the average number of prescriptions was higher 
for males than females for each month. The month of December held the highest 
number of patients (n = 1 876). The slight increase in patients throughout the year 
did not necessarily indicate an increased incidence of Parkinson’s disease, but could 
mean that patients transferred their prescriptions from other pharmacies or 
pharmacy groups to the one under consideration in this study. 
 
The average number of prescriptions per region was 3190.38±1 106.44 over the 
period of one year. The large standard deviation is due to patients travelling 
throughout the year and obtaining medication in different regions. The Western Cape 
held the highest proportion of prescriptions, 5 799±6.99 (22.72%). The rest of the 
regions were similar in number of prescriptions. The average number of prescriptions 
for levodopa-containing products per region was 1 484.38±687.96 and the average 
number of dopamine agonist prescriptions was 1 270.50±313.21.  
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7.2.2 Major findings of the questionnaire-based survey and medical record 
review 
 
The following section will be divided into two. The first will summarise the major 
findings of the questionnaire-based survey and the second part will summarise the 
major findings of the medical record review. 
 
7.2.2.1 Major findings of the questionnaire-based survey 
 
A total of 43 patients were interviewed. Twenty-three males (53.49%) were 
interviewed which showed an approximate ratio of males to females of 1.15:1 in this 
study. The majority of participants were coloured (n = 22; 51.16%) and white (n = 16; 
37.21%). The coloured patients were found in the public sector while white patients 
were made up mostly of private sector patients (68.75%). 
 
The majority of patients were in the age group 71 to 75 years (n = 14; 32.56%). This 
was a similar finding as that shown by the DUR. The male patients were also found 
to be older than the females; also a finding similar to that of the DUR. The majority of 
patients (n = 8) up to the age of 70 years were diagnosed less than five years ago. 
This indicates that some patients had early onset Parkinson’s disease. The patients 
over 70 years of age were mostly diagnosed more than 10 years ago (n = 6). There 
were very few patients in the older age groups and this was most likely due to a 
higher mortality rate in these age groups.  
 
There were 39 (90.70%) patients who reported that levodopa was the first drug they 
were prescribed for Parkinson’s disease. Fourteen patients were using levodopa for 
two to four years and 12 for longer than 10 years. A total of 15 patients were using 
levodopa for the entire duration of their illness.  
 
Most of the patients (90%) diagnosed less than five years ago were receiving doses 
of levodopa of 600mg or lower. Of the patients diagnosed more than 10 years ago, 
66.67% were receiving doses of levodopa higher than 700mg. The majority of 
patients were prescribed a daily dose of 300mg of levodopa (n = 7; 16.28%). The 
147 
 
second largest group of patients received 600mg (n = 6; 13.95%) which is the DDD 
for levodopa. The average PDD was 750mg±452mg. 
 
Dyskinesias were reported by 13 patients (30.23%). Of these, seven were males and 
six were females. 66.67% of patients between the ages of 56 and 60 years 
developed dyskinesias, as compared to only 28.57% of patients between the ages of 
71 to 75 years. Thus, younger patients experienced a higher incidence of 
dyskinesias (45.45%) compared to older patients (31.58%). A total of 35.71% of 
patients diagnosed more than 10 years before the study onset reported the presence 
of dyskinesias. Of the 13 patients with dyskinesias, four were diagnosed more than 
10 years ago. The results of this study show that 32% of patients on levodopa 
therapy for more than five years reported dyskinesias and fewer than 50% of 
patients reported dyskinesias after 10 years of treatment with levodopa.  
 
Most patients could not remember their initial dose of levodopa. This was to be 
expected due to ageing and memory loss. However, of the patients who answered, it 
was seen that most were receiving an initial dose of 200mg or more on a daily basis. 
A total of six patients were receiving doses higher than that of the DDD for levodopa 
which is 600mg daily.  
 
7.2.2.2 Major findings of the medical record review 
 
The medical records showed that 44.19% of patients were diagnosed between five 
and 10 years ago (n = 19), 23.26% were diagnosed less than five years ago and 
27.91% have been diagnosed for more than 10 years. The medical records provide a 
more accurate date of diagnosis, although the patient would only have presented to 
the neurologist when the symptoms became bothersome. 
 
Males were receiving higher PDDs of levodopa than females. The majority of 
patients were prescribed a daily dose of 300mg of levodopa (n = 7; 16.28%). The 
lowest recorded PDD was 100mg and the highest recorded PDD of levodopa was 
2 400mg. The average PDD was 809mg±514mg. This reflects the large range of 
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doses prescribed. It was seen that higher doses of levodopa corresponded with 
longer disease duration. 
 
A total of 20 patients were prescribed a dopamine agonist (46.51%) with five patients 
(11.63%) being prescribed bromocriptine, six patients (13.95%) prescribed 
pramipexole and 15 patients (34.88%) prescribed ropinirole. Eleven patients 
(25.81%) were prescribed an anticholinergic agent. Six patients (13.95%) were 
prescribed benzhexol, two patients (4.65%) prescribed biperidine and five patients 
(11.63%) prescribed orphenadrine. A total of four patients (9.30%) were prescribed 
MAO-B inhibitors. Only two patients (4.65%) were prescribed entacapone. A total of 
eight patients (18.60%) were prescribed amantadine.  
 
When comparing the private sector analysed in the DUR to the public sector which 
was the focus of the questionnaire-based survey, it was seen that patients in the 
private sector had access to a larger range of antiparkinsonian products, particularly 
auxiliary products usually given in combination with levodopa such as the COMT-
inhibitors and the MAO-B inhibitors. This could be due to constraints regarding 
funding of medication in the public health care sector. 
 
Domperidone and metoclopramide were prescribed to two and one patient, 
respectively. Domperidone is used in Parkinson’s disease to reduce the incidence of 
peripheral side effects caused by levodopa. Metoclopramide however, should not be 
used concurrently with levodopa. Two patients were receiving donepezil and one 
was receiving memantine for Parkinson’s disease dementia. Three patients were 
found to be taking quetiapine for psychosis. Two of these three patients were using 
ropinirole as ongoing therapy. Psychosis is more commonly associated with 
dopamine agonists than with levodopa. The antidepressants prescribed included 
amitriptyline and fluoxetine. 
 
Considering what can be classified as the NMSs of Parkinson’s disease the three 
most common include constipation, anxiety and depression. The most common co-
morbidities seen were hypertension, hyperlipidaemia and diabetes. The most 
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commonly used classes of drugs, other than those used for Parkinson’s disease, 
were antihypertensives, laxatives and blood modifying agents. 
 
The medical records showed that 10 patients (23.26%) were suffering from 
dyskinesias. Four patients were diagnosed as having mild dyskinesias (40%) and 
one was diagnosed as experiencing severe dyskinesias (10%). It is important to 
remember that the review was cross-sectional and only the indication of dyskinesia 
severity at the patients’ last visit was taken into consideration. This was lower than 
the number of patients self-reporting a positive incidence of dyskinesias. A reason 
for this could be that patients did perhaps not fully understand what a dyskinesia was 
and answered positively. 
 
Patients experiencing dyskinesias were diagnosed with Parkinson’s disease earlier 
than non-dyskinetic patients. It was seen that five patients diagnosed between the 
ages of 40 to 60 years experienced dyskinesias. This value then fell to two patients 
who were diagnosed between the ages of 61 to 70 years and one patient who was 
diagnosed over the age of 70 years. 
 
The majority (50%) of the patients diagnosed with dyskinesias were diagnosed more 
than 10 years ago. Comparing this result to non-dyskinetic patients, the dyskinetic 
patients had longer disease duration. After five years of being diagnosed with 
Parkinson’s disease, eight patients developed dyskinesias. This gives a rate of 
18.60% after five years of disease duration. It was seen that the majority of patients 
with dyskinesias were on levodopa therapy for less than five years (n = 4; 40%). 
Even though the duration of levodopa therapy is considered a risk factor for the 
development of dyskinesias, the incidence is highly varied. 
 
7.3 Recommendations 
 
Based on the major findings of the study, certain recommendations regarding the 
condition, in terms of treatment, can be made. Recommendations for future studies 
investigating aspects of Parkinson’s disease in both South Africa and internationally 
can also be made. 
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7.3.1 Recommendations regarding the study 
 
Parkinson’s disease places an economic burden on society and health care 
resources. This is a burden that is expected to increase as the population ages in 
South Africa. It is important that the full extent of the burden be calculated and 
understood in order to prepare for future incidence.  
 
Patients diagnosed with Parkinson’s disease need to be educated on the condition 
and what to expect. The medication prescribed to them needs to be explained and 
the patients need to be warned of any adverse effects they may experience. This will 
improve patient understanding and adherence to the prescribed regimen. 
 
Although there are guidelines outlining treatment for mild, moderate and severe 
Parkinson’s disease, specific doses of drugs are not available. This shows that 
guidelines are recommendations and that clinical experience and the patients’ ability 
to tolerate the drug have an influence on the prescribing of antiparkinsonian 
medication.  
 
In terms of dyskinesias, it was seen that patients diagnosed at a younger age and 
those using levodopa therapy for longer periods of time were most at risk for 
developing this complication. 
 
7.3.2 Recommendations regarding further research   
 
The results of this study indicate that there is a need for further research into various 
aspects of Parkinson’s disease in South Africa. Both branches of the study, being 
the DUR and the questionnaire-based survey, have further applications in research 
of this disorder. These include: 
 
 Analysis of prescriptions for antiparkinsonian products, especially levodopa-
containing products and dopamine agonists, dispensed across South Africa 
on an interlinked dispensing system, so as to analyse conclusively the 
prescribing trends in different patients and regions. 
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 The conducting of a questionnaire-based survey wherein the demographics of 
the country are reflected in the participants, so as to determine whether the 
incidence of Parkinson’s disease in South Africa differs between racial or 
cultural groups. 
 Taking into account weight-based dosing of levodopa and determining the 
effect it has on the incidence of dyskinesias, particularly in female patients.  
 The differences in the effectiveness of antiparkinsonian drug classes in terms 
of gender. 
 Further investigation into the effectiveness of the various drug classes used in 
the treatment of Parkinson’s disease and comparing these classes in order to 
establish more concrete treatment guidelines. 
 
7.3.3 Concluding statement 
 
There is a large amount of information regarding Parkinson’s disease from various 
resources. However, this information is largely derived from outside Africa. Given 
that Parkinson’s disease in South Africa is relatively common, it is important to 
ensure that research is undertaken so as to allow for better understanding and 
treatment of this condition. While this study was not a true representation of the 
incidence of Parkinson’s disease in South Africa, valuable information regarding the 
total cost of antiparkinsonian products, prescribing patterns and the incidence of 
dyskinesias was obtained from the DUR and questionnaire-based surveys.  
 
The ideal management of Parkinson’s disease is still a source of much debate. 
Based on the prescribing trends identified, it can be seen that levodopa is still the 
preferred first-line treatment for Parkinson’s disease. The value of the dopamine 
agonists, COMT-inhibitors and MAO-B inhibitors in the management of Parkinson’s 
disease may yet be realised through further research and gradual increases in 
prescribing. 
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APPENDIX A: ETHICAL APPROVAL - NELSON MANDELA METROPOLITAN 
UNIVERSITY 
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APPENDIX B: ETHICAL APPROVAL - UNIVERSITY OF CAPE TOWN 
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APPENDIX C: ETHICAL APPROVAL - TYGERBERG HOSPITAL 
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APPENDIX D: SAMPLE OF DATA ANALYSED 
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441 65 1 65001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
441 65 1 65001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
436 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
436 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
436 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
436 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
436 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ ANTI-CHOLINERGICS AKINETON 2MG TAB 50 
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3+ 
323 86 2 86002 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
448 94 1 94001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
448 94 1 94001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
448 94 1 94001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
448 94 1 94001 ETHICAL PRODUCTS SCH3+   CENTRAL NERVOUS SYSTEM 3+ ANTI-PARKINSONS 3+ 
ANTI-CHOLINERGICS 
3+ AKINETON 2MG TAB 50 
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The data fields included were: 
 pharmacy number (a number identifying the specific pharmacy in the national 
community pharmacy group, for example 253); 
 profile number (a number used to identify a specific group of patients, usually 
a family, for example 10); 
 dependant number (a number used to identify each individual person in a 
profile, for example 1 to 7); 
 dependant code (a number used to identify the main member and dependants 
belonging to a medical aid scheme, for example 001); 
 department (indicates whether the drug dispensed is a Schedule 3 or above 
or below); 
 sub-department (indicates which therapeutic class the drug belongs to in 
relation to its site of action, for example central nervous system); 
 class (indicates the type of drug dispensed in relation to its use, for example 
antiparkinsons); 
 sub-class (indicates which specific drug in each class, for example 
dopaminergics); 
 product description (indicates the trade name of the drug dispensed, for 
example Requip®); 
 NAPPI (National Pharmaceutical Product Interface) code (the unique number 
allocated to specific medicines which allows them to be deducted from 
medical aid benefits); 
 active 1 name (indicates the chemical name of the main active ingredient, for 
example ropinirole); 
 active 2 name (indicates the name of the second active ingredient in the case 
of combination preparations, for example carbidopa); 
 active 1 strength (indicates the strength of the primary active ingredient per 
dosage unit, for example mg); 
 active 2 strength (indicates the strength of the secondary active ingredient in 
the case of a combination preparation, for example 25mg); 
 schedule (the number which indicates the schedule of the drug dispensed, for 
example 4); 
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 dosage form (indicates the formulation of the drug, for example tablet); 
 dosage type (indicates if the formulation has been modified to prolong the 
release of the active ingredient from the dosage form, for example CR – 
controlled release); 
 script repeated (indicates whether the drug dispensed was authorised by the 
prescriber to be repeated on second or multiple subsequent occasions); 
 original number of repeats (a number which indicates how many times a drug 
is to be dispensed on a repeat basis, for example 5); 
 current repeat (the number indicating which repeat was being dispensed 
amongst the total possible number of repeats, for example 4); 
 drug schedule (as for schedule); 
 units sold (a number indicating the exact number of dosage units dispensed to 
the patient, for example 30, where 30 would mean tablet or capsules); 
 quantity sold (the number indicating the number of pre-packed dosage 
containers dispensed to the patient, for example 1. If the pack was broken, 
the quantity sold would be indicated as 0.); 
 sales value (a currency value indicating the cost of the drugs sold in South 
African Rands, for example R153.46); 
 gender (indicates whether the patient is male (M) or female (F)); 
 age category (a number range to group together patients of different ages in 
years, for example +65); 
 relation (a number indicating the relationship of the patient to the primary 
profile member where ‘2’ indicates spouse, ‘3’ indicates a child and ‘4’ 
indicates an unspecified relationship); 
 age (a number representing the actual age of the patient in years, for example 
70); 
 area description (geographically determined, identifying the region in which 
the prescription was dispensed, for example Eastern Cape); and 
 calendar month (a number representing which month the prescription was 
dispensed, for example 9 is September). 
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APPENDIX E: PATIENT QUESTIONNAIRE 
 
PATIENT QUESTIONNAIRE 
 
Demographic information: 
 
1. Gender 
      
              Male 
 
              Female 
 
 
2. Ethnic group 
 
White 
 
Coloured 
 
Black 
 
Indian 
 
Other 
 
 
3. Patient age  
  
 
  50-55 years 
  
            56-60 years 
 
            61-65 years 
 
            66-70 years 
 
            71-75 years 
 
            76-80 years 
 
            81-85 years 
 
            Over 85 years 
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4. What is your current body mass? 
 
__________________________________ 
 
 
Clinical Information: 
 
5. When were you diagnosed with Parkinson’s disease? 
 
 
 
6. How long have you been on levodopa therapy?  
 
 
 
7. What was your initial daily dose of levodopa? 
 
 
 
 
 
 
8. What is your current daily dose of levodopa?  
 
 
 
 
 
 
 
9. Was levodopa the first drug you were treated with? If no, which were you 
started on? 
 
Yes 
 
  No, initial treatment was ________________________________________ 
 
 
10. What other medication are you currently using? 
 
 
 
 
 
Less than 5 years ago Between 5 and 10 years 
ago 
More than 10 years ago 
Two to four years Five to seven years Eight to ten years Longer than 10 
years 
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Dyskinesias 
 
11. Do you currently experience dyskinesias? If yes, when did they start? 
 
Yes _________________________________________________________ 
 
 No 
 
 Unsure    
 
 
12. How disabling are these dyskinesias?  
 
Not disabling Mildly disabling Moderately 
disabling 
Severely 
disabling 
Completely 
disabling 
 
          
General: 
 
13. Any other comments regarding medication and its influence on your well-
being? 
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APPENDIX F: LETTER SENT TO NEUROLOGISTS 
 
 
 
 
 
Faculty of Health Sciences, School of Pharmacy 
Tel. +2776335589  
      razia.gaida@live.nmmu.ac.za 
Date:__________________ 
Contact person: Razia Gaida 
Dear Doctor 
 
I am a postgraduate Pharmacy student at NMMU conducting a research project in fulfilment of my MPharm. 
 
The topic of my research is “Treatment of Parkinson’s disease in South Africa and investigation of risk factors 
causing dyskinesia”.  The aim of this study is to explore the onset of dyskinesias in patients with Parkinson’s 
disease who are currently on levodopa and analyse the risk factors involved with the onset. Patient confidentiality 
will be maintained at all times. 
 
I have obtained consent from the following patients to allow me to review their files and obtain the date of 
diagnosis, the date of initiation with levodopa treatment, other medication being used, the presence and severity 
of dyskinesias and any other benefit or side effect the patient experiences: 
 
_____________________ 
_____________________ 
_____________________                 Patients’ names here 
_____________________ 
_____________________ 
 
I would very much appreciate your co-operation and assistance.  If you have any queries please feel free to 
contact me at the above details. 
 
 
___________________ 
Yours sincerely, 
Razia Gaida 
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APPENDIX G: MEDICAL DATA RECORD SHEET 
 
Drug Initial dose Incremental dose 
increases 
Current dose Date started Date stopped 
Levodopa/Carbidopa      
Levodopa/Carbidopa/Entacapone      
Levodopa/Benserazide      
Bromocriptine      
Pramipexole      
Ropinirole      
Entacapone      
Pergolide      
Lisuride      
Pregabalin      
Clonazepam      
Other 
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Date of diagnosis 
___________________ 
Age of patient at diagnosis 
______________________ 
Disease severity 
       Mild (early) 
       Moderate 
       Severe 
Presence of dyskinesias  
        Yes 
        No 
Severity of dyskinesia 
      Mild 
      Moderate 
      Severe 
Type of dyskinesia 
      Peak dose dyskinesia 
      Diphasic dyskinesias 
      Off state dystonia 
      On state dystonia 
      ‘Yo-yo’ dyskinesia 
 
Co-morbid conditions and medication 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________ 
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APPENDIX H: PATIENT CONSENT LETTER - ENGLISH 
      
 
 
 
 
 
  Faculty of Health Sciences, Department of Pharmacy 
Tel. (+27) 76 633 5589 
      razia.gaida@live.nmmu.ac.za 
Date:________________ 
Contact person: Razia Gaida 
NMMU REC-H Ref: H11-HEA-PHA-001 
UCT HREC Ref: 154/2011 
TYGERBERG REC-H Ref: H11-HEA-PHA-001 
 
Dear Sir/Madam 
 
You are being asked to participate in a research study. The title of the study is ‘Treatment of 
Parkinson’s disease in South Africa and investigation of the risk factors causing dyskinesia’. The 
study aims to determine the way the medicine is prescribed to patients suffering from Parkinson’s 
disease and to determine the risk factors which are involved in the onset of dyskinesias.  
  
In order to participate, you are required to provide written consent that must include: 
 Your name and surname 
 The date 
 Your signature 
 
Your participation will involve the following: the researcher will extract data from your medical file; and 
you will be asked to answer a questionnaire. It is important that you understand that participation in 
this study is completely voluntary; if you choose not to participate, this will not affect your present or 
future medical care in any way and there will be no penalty to you. 
 
If you agree to participate, you are free to withdraw at any time during the study without any penalty 
incurred to you. Withdrawing from the study will not affect your current or future medical care in any 
way. If you wish to withdraw please notify the researcher so that your participation may be ended in 
an orderly manner.  
 
It is important to remember that participation in this study will not benefit you in any way nor will it 
cause you any harm. There will not be any experiments conducted on you and your current 
medication will not be changed in any way. No changes to your medical records will be made. 
Participation in this study will not incur any additional costs to you as the participant.  
 
This research may be presented at scientific conferences or in scientific publications, but your identity 
will remain confidential at all times. No information will be able to be tracked back to you.  
This study has been approved by the Research Ethics Committee (Human) of the Nelson Mandela 
Metropolitan University in Port Elizabeth as well as the Faculty of Health Sciences Research Ethics 
Committee of the University of Cape Town. 
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If you have any questions, please feel free to contact the researcher using the following details: 
Telephone: 076 633 5589 
E-mail: razia.gaida@live.nmmu.ac.za  
 
If you have any questions regarding your rights and welfare as a participant, please feel free to 
contact the Chairperson of the Human Research Ethics Committee of the University of Cape Town, 
Professor Mark Blockman using the following details: 
Telephone: (021) 406 63388 
Or Dr Blanche Pretorius, Chairperson of the Human Research Ethics Committee of NMMU, using the 
following details: 
Telephone: (041) 504 2538 
 
This informed consent statement has been prepared in compliance with current statutory guidelines. 
If you understand and accept the conditions and are willing to participate please sign your name and 
initials below. 
 
 
 
________________________________   ___________________________ 
Participant’s name and surname   Participant’s signature 
 
 
Yours sincerely, 
 
 
 
______________________ 
Razia Gaida 
Researcher     
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APPENDIX I: PATIENT INFORMED CONSENT LETTER - AFRIKAANS 
 
 
      
 
Fakulteit Gesondheidswetenskappe, Departement Farmasie 
Razia Gaida 
Selfoon: (+27) 76 633 5589 
      razia.gaida@live.nmmu.ac.za 
        Datum:________________________ 
 
Hoofnavorser: Razia Gaida 
NMMU REC-H Verwysingsnommer: H11-HEA-PHA-001 
UCT HREC Verwysingsnommer: 154/2011 
TYGERBERG REC-H Verwysingsnommer: H11-HEA-PHA-001 
 
Geagte Meneer / Mevrou / Mejuffrou 
 
U word genooi om deel te neem aan ’n navorsingsprojek. Die titel van die studie is 'Behandeling van 
Parkinson se siekte in Suid-Afrika en ‘n ondersoek na die risikofaktore van diskinesias’. Die studie het 
ten doel om die wyse waarop die medisyne wat voorgeskryf word aan pasiënte wat aan Parkinson se 
siekte ly en die risikofaktore wat betrokke is by die aanvang van dyskinesias te bepaal.  
 
Om deel te neem, moet u asseblief skriftelike toestemming gee wat insluit:  
• U naam en voorletters 
• Die datum 
• U handtekening  
 
U deelname sal die volgende behels: die navorser sal ‘n uittreksel uit u mediese lêer aanvra, en u sal 
gevra word om ‘n vraelys te voltooi (mondelings). U deelname is volkome vrywillig en dit staan u vry 
om deelname te weier. U sal op geen wyse hoegenaamd negatief beïnvloed word indien u sou weier 
om deel te neem nie. U mag ook te eniger tyd aan die navorsingsprojek onttrek, selfs al het u 
ingestem om deel te neem.  
 
U ontrekking uit die studie sal geen invloed op u huidige of toekomstige mediese sorg op enige wyse 
hê nie. As u wil ontrek, moet u asseblief die navorser in kennis stel sodat u deelname beëindig kan 
word. 
 
U sal nie enige direkte voordeel trek uit die studie nie, en ook nie enige skade berokken word nie. 
Daar sal geen eksperimente op u uitgevoer word nie en u huidige medikasie sal nie verander word 
nie. Geen veranderinge sal ook in u mediese rekords aangebringword nie. Deelname aan hierdie 
studie sal ook nie enige bykomende koste vir u inhou nie. 
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Hierdie navorsing mag in die toekoms (na voltooing) aangebied word by wetenskaplike konferensies 
of gepubliseer word in wetenskaplike publikasies, maar u identiteit sal te alle tye vertroulik bly. Geen 
inligting sal bekend gemaak word wat enige persoon in staat sal stel om u op te spoor of te kontak 
nie. Hierdie studie is deur die Etiek Komitee (Menslik) van die Nelson Mandela Metropolitaanse 
Universiteit in Port Elizabeth goedgekeur, sowel as deur die Navorsingsetiekkomitee van die Fakulteit 
Gesondheidswetenskappe aan die Universiteit van Kaapstad. 
 
As u enige vrae het, is u welkom om die navorser te kontak by:  
Selfoon: 076 633 5589  
E-pos: razia.gaida@live.nmmu.ac.za  
 
As u enige vrae oor u regte as 'n deelnemer het, is u welkom om die Voorsitter van die 
Navorsingsetiekkomitee van die Universiteit van Kaapstad te kontak, Professor Mark Blockman by:  
Telefoonnommer: (021) 406 63388  
OF Dr Blanche Pretorius, Voorsitter van die Navorsingsetiekkomitee van die NMMU, by: 
Telefoonnommer: (041) 504 2538 
 
Hierdie verklaring is opgestel in ooreenstemming met huidige statutêre riglyne. As u die inhoud 
verstaan en die voorwaardes aanvaar, en bereid is om deel te neem, teken asseblief u naam en 
voorletters hieronder.  
 
 
_________________________                                                    _________________________ 
Naam en voorletters                                                                       Handtekening  
 
 
 
Die uwe,  
 
 
 
____________________________ 
Razia Gaida  
Navorser 
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APPENDIX J: INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF BROMOCRIPTINE, PRAMIPEXOLE AND 
ROPINIROLE AND DURATION OF THERAPY AS PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS 
 
Patients Bromocriptine Pramipexole Ropinirole 
Initial  Current  Duration  Initial  Current  Duration  Initial  Current  Duration  
Patient 1 2.5mg NA* 1 year _ _ _ 3mg NA 1 year 
Patient 2 _ _ _ _ _ _ INA** 12mg INA 
Patient 9 _ _ _ _ _ _ 1.5mg 7.4mg 4 years 
Patient 10 7.5mg 7.5mg 8 years 0.25mg NA 1 year _ _ _ 
Patient 12 _ _ _ 0.75mg 3mg 10 years _ _ _ 
Patient 13 _ _ _ 0.5mg NA 1 year 6mg 6mg 1 year 
Patient 14 _ _ _ _ _ _ 15mg 8mg 8 years 
Patient 15 _ _ _ _ _ _ 15mg 8mg 8 years 
Patient 16 _ _ _ _ _ _ INA 8mg 1 year 
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INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF BROMOCRIPTINE, PRAMIPEXOLE AND ROPINIROLE AND 
DURATION OF THERAPY AS PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS (CONTINUED) 
 
Patient 17 _ _ _ 4mg 4mg 2 years 3mg NA 4 years 
Patient 19 _ _ _ _ _ _ 3mg 4mg 6 years 
Patient 20 _ _ _ _ _ _ INA 15mg INA 
Patient 21 _ _ _ INA 1.5mg INA _ _ _ 
Patient 23 35mg 20mg INA 0.125mg NA INA 6mg NA 1 year 
Patient 24 INA 7.5mg INA _ _ _ _ _ _ 
Patient 27 15mg 15mg <1 year _ _ _ _ _ _ 
Patient 33 _ _ _ _ _ _ 3mg 3mg 1 year 
Patient 41 _ _ _ _ _ _ 3mg NA 1 year 
Patient 42 _ _ _ _ _ _ 2.25mg 1.5mg 2 years 
Patient 43 _ _ _ _ _ _ 4.5mg 3.75mg 4 years 
(*NA – Not applicable; **INA – Information not available) 
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APPENDIX K: INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF BENZHEXOL, BIPERIDINE AND ORPHENADRINE 
AND DURATION OF THERAPY AS PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS 
 
Patients Benzhexol Biperidine Orphenadrine 
Initial  Current  Duration  Initial  Current  Duration Initial Current  Duration 
Patient 1 6mg NA* 5 years - - - - - - 
Patient 3 - - - 2mg NA 2 years 100mg 150mg 2 years 
Patient 6 3mg 3mg 5 years - - - - - - 
Patient 7 2mg NA 3 years - - - - - - 
Patient 11 - - - - - - 100mg 100mg 1 year 
Patient 17 6mg NA 1 year - - - - - - 
Patient 29 6mg 6mg 6 years - - - - - - 
Patient 30 1mg NA 4 years - - - - - - 
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INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF BENZHEXOL, BIPERIDINE AND ORPHENADRINE AND 
DURATION OF THERAPY AS PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS (CONTINUED) 
 
Patient 36 - - - - - - 75mg NA 2 years 
Patient 38 - - - - - - 150mg NA <1 year 
Patient 39 - - - 3mg NA 2 years INA** 300mg INA 
(*NA – Not applicable; **INA – Information not available) 
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APPENDIX L: INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF SELEGILINE AND RASAGILINE AND DURATION OF 
THERAPY AS PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS 
 
Patients Selegiline Rasagiline 
Initial Current Duration Initial Current Duration 
Patient 11 - - - 3mg NA* <1year 
Patient 15 - - - 1mg NA <1 year 
Patient 16 
- - - 
1mg 1mg 2 years 
Patient 17 INA** NA 1 year 
- - - 
(*NA – Not applicable; **INA – Information not available) 
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APPENDIX M: INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF ENTACAPONE AND DURATION OF THERAPY AS 
PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS 
 
Patients Entacapone 
Initial Current Duration 
Patient 20 600mg NA* 1 year 
Patient 21 400mg 800mg 4 years 
(*NA – Not applicable) 
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APPENDIX N: INITIAL AND CURRENT PRESCRIBED DAILY DOSES OF AMANTADINE AND DURATION OF THERAPY AS 
PRESCRIBED TO PARKINSON’S PATIENTS BY NEUROLOGISTS 
 
Patients Amantadine 
Initial Current Duration 
Patient 1 200mg 200mg INA** 
Patient 2 INA 300mg INA 
Patient 15 200mg 200mg 1 year 
Patient 25 100mg NA* <1 year 
Patient 26 300mg NA <1 year 
Patient 38 400mg NA INA 
Patient 42 300mg 300mg 2 years 
Patient 43 300mg NA INA 
(*NA – Not applicable; **INA – Information not available) 
 
